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ABSTRACT OF THE DISSERTATION 
4-HYDROXY ESTRADIOL-INDUCED OXIDANT-MEDIATED SIGNALING IS 
INVOLVED IN THE DEVELOPMENT OF BREAST CANCER 
by 
 
Victor Onyishi Okoh 
 
Florida International University, 2011 
 
Miami, Florida 
 
Professor Deodutta Roy, Major Professor 
 
Breast cancer is a disease associated with excess exposures to estrogens. While the mode 
of cancer causation is unknown, others have shown that oxidative stress induced by 
prolonged exposure to estrogens mediates renal, liver, endometrial and mammary 
tumorigenesis though the mechanism(s) underling this process is unknown. In this study, 
we show that 4-hydroxyl 17β-estradiol (4-OHE2), a catechol metabolite of estrogen, 
induces mammary tumorigenesis in a redox dependent manner. We found that the 
mechanism of tumorigenesis involves redox activations of nuclear respiratory factor-1 
(NRF1); a transcriptions factor associated with regulation of mitochondria biogenesis and 
oxidative phosphorylation (OXPHOS), as well as mediation of cell survival and growth 
of cells during periods of oxidative stress. Key findings from our study are as follows: (i) 
Prolonged treatments of normal mammary epithelial cells with 4-OHE2, increased the 
formation of intracellular reactive oxygen species (ROS). (ii) Estrogen-induced ROS 
activates redox sensitive transcription factors NRF1. (iii) 4-OHE2 through activation of 
serine-threonine kinase and histone acetyl transferase, phosphorylates and acetylate 
NRF1 respectively. (iv) Redox mediated epigenetic modifications of NRF1 facilitates 
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mammary tumorigenesis and invasive phenotypes of breast cancer cells via modulations 
of genes involved in proliferation, growth and metastasis of exposed cells. (v) Animal 
engraftment of transformed clones formed invasive tumors. (vi) Treatment of cells or 
tumors with biological or chemical antioxidants, as well as silencing of NRF1 
expressions, prevented 4-OHE2 induced mammary tumorigenesis and invasive 
phenotypes of MCF-10A cells. Based on these observations, we hypothesize that 4-
OHE2 induced ROS epigenetically activate NRF1 through its phosphorylation and 
acylation. This, in turn, through NRF1-mediated transcriptional activation of the cell 
cycle genes, controls 4-OHE2 induced cell transformation and tumorigenesis.  
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CHAPTER I 
 
INTRODUCTION 
Estrogens are complete breast carcinogens in experimental models as they are capable of 
initiating and triggering growth and selection, resulting in palpable malignancy (1-3). 
Both epidemiological and animal studies indicate that estrogens are a known risk factor 
for breast cancer (1,3). However, the mechanisms by which estrogen initiate or stimulate 
the progression of cancer remain the subject of a long-standing controversy, because we 
have been not able to resolve whether estrogen or their metabolites are procarcinogenic. 
  
We have previously shown that estrogen-induced tumor formation is decreased in 
animals exposed to inhibitors of estrogen metabolism or to hormonally potent estrogens 
with decreased metabolic conversion to catechol metabolites compared to E2 (2). 
Moreover, we have shown that chronic treatment of the hamsters with vitamin C reduced 
the incidence of E2-induced renal carcinogenesis by ~50% (2). Since vitamin C has no 
antiestrogenic activity, its strong inhibitory effect on estrogen-induced tumorigenesis may 
largely be derived from its protective effect against the oxidative damage caused by the 
estrogens and its metabolites. Most of the recent studies show that hydroxyestrogens and 
methoxy derivatives represent the majority of either urinary or intratumor estrogens in 
human breast cancer patients, whereas they are relatively scarce in urine or mammary 
glands of healthy women (4). These studies showed that 4-OH-E2 is elevated in breast 
tumors as compared to normal mammary tissues which implicates its role in breast cancer 
and strongly suggest the involvement of estrogen metabolites in the initiation and/or 
promotion steps of breast carcinogenesis. 
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Recent studies indicate that mammary tumors can develop despite a lack of a functional 
ER α [2]. Although tamoxifen and other antiestrogens are considered to prevent cancer 
through competition for the ER, other mechanisms cannot be ruled out as these 
compounds also block metabolism and redox cycling of estrogen, and are free radical 
scavengers (5). The 4-OH-E2 induces an estrogenic response in the uterus of ER null 
mice, and this response is not inhibited by ICI182780 (6). These findings suggest that, in 
addition, to nuclear ER-mediated genomic signaling pathways, non-genomic pathway(s) 
are involved in the estrogen-dependent growth of preneoplastic and neoplastic cells. We 
believe that to produce cell transformation both genomic and non-genomic actions of 
estrogen are required and these two complementary mechanisms through which estrogens 
produce transformed phenotype of cells. Formation of estrogen-DNA adducts in 
mammary tissues have been shown by combined LS-MS-MS and LC-nano ES tandem 
mass spectrometry (7). In addition, 4-hydroxycatechol estrogen conjugates with 
glutathione or its hydrolytic products (cysteine and N-acetylcysteine) have been detected 
in mammary tissues from ERKO/Wnt-1 mice (8). Although this type of DNA adduction 
may play a role in the generation of mutations, it appears to be a late event. In our recent 
studies, estrogen-induced a rapid increase of intracellular ROS formation in MCF-7 cells 
(9). Based on our preliminary study showing 4-OH-E2-induced ROS formation in 
MCF10A cells, the accumulation of 4-OH-E2 in estrogen target organ of the cancer will 
result in increased formation of ROS in the target cells. In addition, 4-OH-E2 is also 
strongly active at the estrogen receptor (10,11), which would add to the growth 
stimulation of the ER-positive cells. Our preliminary data revealed that 4-OH-E2 may 
also activate an additional signal transduction pathway that is different from the classical 
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ER•signaling pathway. The contribution of this signal transduction system to breast 
carcinogenesis is the subject of the proposed study. 
 
In pursuing mitochondrial regulators of cell cycle progression, we discovered that 
intracellular ROS levels increase as cells progress through G1 and into S phase upon E2 
exposure (11). High ROS levels induce oxidative damage and arrests cells in G0/G1. 
However, low physiologic ROS levels are utilized by cells for cell-to-cell communication 
and in proliferation. Inhibition of estrogen-induced ROS by antioxidants prevents early 
G1 gene expression. We now know that the delicate intracellular interplay between 
oxidizing and reducing equivalents allows ROS to function as second messengers in the 
control of cell proliferation and cell transformation (11,12). Our preliminary study 
showed that MCF-10A cells treated with 4-OH-E2 rapidly produce ROS, which is 
preceded by an increase in the level of Ca2+. The accumulation of 4-OH-E2 as recently 
reported in the human breast tissue in cancer subjects (9) will allow increased formation 
of ROS and Ca2+ in the target organ of cancer in a sensitive subpopulation. Our 
preliminary study showed that the overexpression of catalase and MnSOD prevented 4-
OH-E2-induced anchorage-independent growth of MCF-10A cells. These studies data 
indicate that 4-OH-E2-induced cell transformation may be mediated, in part, by ROS and 
Ca2+ signal transduction pathways that are different from the classical nuclear ER 
genomic signaling pathway. Therefore, how 4-OH-E2, through ROS signalings, produces 
malignant phenotype is an issue of fundamental importance to this proposal. 
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Recently, an NRF1 and CREB pair has been identified as a key regulator of the 
transcriptional program of the cell cycle in human cells because thes pair of transcription 
factors showed a significant co-occurrence rate on promoters of cell cycle regulated 
genes (13). NRF1 appears to play an important role as a regulator of cell cycle genes 
because NRF1 binding site has been identified by comparing genome-wide locations on 
genes involved in DNA replication, mitosis, and cytokinesis (14,15). Some of the genes 
which contain NRF1 binding sites on their promoters included Cdc2, Cdc25C, PCNA, 
and cyclin B1. In addition to NRF1’s role in controlling mitochondrial biogenesis-related 
genes, these observations are consistent with a role for NRF1 in regulating genes 
involved in growth and development. The expression of early G1 genes, c-myc, c-fos, c-
jun, cyclin D1, and NRF1 are regulated by ROS (2,16). The mRNAs of some of these 
genes are induced by estrogen-induced ROS and hydrogen peroxide as well as other 
inducers of oxidative stress (2,11). Based on these studies, we have proposed that 4-OH-
E2-induced ROS through activating the transcription factor NRF1 leads to the induction 
of cell cycle genes that contain the binding site(s) for this transcription factor in their 
promoters. This, in turn, supports the growth of anchorage-dependent and -independent 
cells. 
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CHAPTER II 
HYPOTHESIS, SPECIFIC AIMS, AND RELEVANCE OF FINDINGS 
 
Hypothesis 
 
We hypothesize that 4-hydroxy estradiol (4-OH-E2), a catechol metabolite of 17β 
estradiol (E2)-induced ROS epigenetically activate NRF1 through its phosphorylation 
and acylation. This, in turn, through NRF1 mediated transcriptional activation of cell 
cycle genes, controls 4-OH-E2-induced cell transformation and tumorigenesis.  
 
 
Specific Aim 1:  To determine whether estrogen-induced RO/NS are involved in 
estrogen-induced in vivo growth of malignant breast epithelial cells. To achieve this aim, 
we would determine whether: a overexpresion of mt superoxide dismutase (SOD) or 
catalase that detoxify ROS; or co-treatment with the chemical antioxidant scavengers, N-
acetylcysteine and ebselen, prevents estrogen-induced cell transformation and in vivo 
growth of malignant breast epithelial cells. b: Whether Knockdown of mitochondrial 
biogenesis through silencing of mtTFA will lead to attenuations of RO/NS production 
and whether reduced ROS production prevents estrogen-induced cell transformation and 
in vivo growth of malignant breast epithelial cells.  
 
Specific Aims 2: To determine that 4-OH-E2-induced ROS through activation of NRF1 
signaling transform normal breast epithelial cells to malignant cells. To accomplish these 
goals, we will determine whether the transformation of normal breast epithelial cells by 
4-OH-E2 is prevented by: a) the overexpression of ROS modifiers catalase and MnSOD, 
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b) silencing of NRF1. Cell transformation will be assessed by determining colony 
efficiency, colony size, ductulogenic capacity, and invasiveness. We will also determine 
whether silencing of NRF1 and overexpression of MnSOD or catalase  prevent  4-OH-
E2-induced  tumor formation in three-dimensional culture mimicking in vivo 
environment. The findings of this aim will reveal a new paradigm by showing that the 
carcinogenic activity of 4-OH-E2 requires NRF1. 
 
Specific Aim 3: To determine whether 4-OH-E2 induced ROS through stimulating redox 
sensitive AKT kinase and histone acetyltransferase of CREB binding protein associated 
factor (P/CAF), respectively, control phosphorylation and acylation of the NRF1. The 4-
OH-E2-induced epigenetic changes in turn activate NRF1. To test the postulate of this 
aim, we will determine that: i) NRF1 stability and transactivation are regulated by 4-OH-
E2-induced ROS. This mechanism involves NRF1 phosphorylation by AKT kinase and 
NRF1 acylation by the histone acetyltransferase CREB binding protein-associated factor 
(P/CAF), respectively; and (ii) the 4-OH-E2-induced epigenetic changes have an additive 
or synergistic effect on NRF1 activation. We will determine whether NRF1 transctivating 
ability is modulated by controlling its phosphorylation and/or acylation; and (iii) 
transcriptional activation of cell cycle genes and cell cycle progression are prevented by 
silencing ofAKT, P/CAF, or NRF1. These observations will reveal the new paradigm of 
4-OH-E2-induced cell cycle regulation of anchorage-independent cells by NRF1 
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Relevance of findings 
 
This study addresses an important public health issue by studying whether 
phosphorylation and acetylation of NRF1 by 4-OH-E2-generated ROS promote 
malignant transformation of normal breast epithelial cells.  The proposed studies are 
highly innovative, since they tested the novel concept that oxidants participate in 4-OH-
E2-induced cellular transformation and tumorigenesis.  Understanding if aberrant 
activation of NRF1 signaling by 4-OH-E2-generated ROS contributes to development of 
E2-dependent breast tumors provides new insights into cancer predisposition.  Moreover, 
it provides a novel paradigm for understanding the molecular mechanisms underlying the 
carcinogenic effects of natural estrogen and other medicinal and environmental 
estrogenic agents.  This is a new line of research that may well set the stage for the design 
and development of new and more effective NRF1 signaling-based drugs or gene 
therapies for the prevention and treatment of breast cancer.   
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CHAPTER III 
LITERATURE REVIEW 
 
 
ESTROGEN-INDUCED REACTIVE OXYGEN SPECIES-MEDIATED SIGNALINGS 
CONTRIBUTE TO BREAST CANCER GROWTH 
Victor Okoh, Alok Deoraj, Deodutta Roy 
Department of Environmental and Occupational Health, Florida International University, 
Miami, FL 33199-0001 
(2010 –  Biophysica Biochmica Acta, Received 22 September 2010;  revised 12 October 
2010;  accepted 14 October 2010.  Available online 29 October 2010, 
doi:10.1016/j.bbcan.2010.10.005) 
 
ABSTRACT 
 
Elevated lifetime estrogen exposure is a major risk factor for breast cancer.  
Recent advances in the understanding of breast carcinogenesis clearly indicate that 
induction of estrogen receptor (ER) mediated signaling is not sufficient for the 
development of breast cancer. The underlying mechanisms of breast susceptibility to 
estrogen’s carcinogenic effect remain elusive. Physiologically achievable concentration 
of estrogen or estrogen metabolites has been shown to generate reactive oxygen species 
(ROS). Recent data indicates that these ROS can induce DNA synthesis, increased 
phosphorylation of kinases, and activation of transcription factors, e.g., AP-1, NRF1, 
E2F, NFkB and CREB of non genomic pathways which are responsive to both oxidants 
and estrogen. Estrogen-induced ROS by increasing genomic instability and by 
transducing signal through influencing redox sensitive transcription factors play 
important role (s) in cell transformation, cell cycle, migration and invasion of the breast 
cancer. The present review discusses emerging data in support of the role of estrogen 
induced ROS-mediated signaling pathways which may contribute in the development of 
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breast cancer. It is envisioned that estrogen induced ROS mediated signaling is a key 
complementary mechanism that drives the carcinogenesis process. ROS mediated 
signaling however occurs in the context of other estrogen induced processes such as ER-
mediated signaling and estrogen reactive metabolite-associated genotoxicity. Importantly, 
estrogen-induced ROS can function as independent irreversible modifiers of 
phosphatases and activate kinases to trigger the transcription factors of downstream target 
genes which participate in cancer progression. 
 
INTRODUCTION 
Estrogen is a class of 18-carbon steroid. There are a total of 9 estrogens in humans of 
which the three major ones are 17β-Estradiol (E2), Estrone (E1), Estriol (E3). These 
estrogens are synthesized primarily in the ovaries of premenopausal women. Other 
organs such as brain and adipose tissues also synthesize estrogens through aromatization 
of testosterone [1].  Estrogens are also synthesized in male species.  A relatively high 
concentration of estrogen is found in rete testis fluid and in testicular vein and lymph of 
rodents [2;3]. The level of estrogens in peripheral blood of men averages 69 pg/ml 
compared to 199 pg/ml in non-ovulating women [4]. E2 is the predominantly circulating 
and the most biologically active ovarian steroid. In addition to endogenous sources, the 
body burden of estrogen may increase from the intake of synthetic medicinal estrogens, 
such as 17α-ethinyl estradiol (used as oral contraceptive), mestranol, premarin (used in 
hormone replacement therapy), and diethylstilbestrol (used in the treatment of highly 
advanced breast and prostate cancers). Physiological estrogens are essential for the 
growth and maintenance of various reproductive and non-reproductive organs in the body 
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where they elicit different growth responses in tissues depending on the cell-type, type of 
estrogen receptor (ER) present, dose and timing of exposure.  
 
Elevated lifetime estrogen exposure has been shown to be a major risk factor for cancer 
in hormone-dependent organs, particularly breast and endometrium [5-9]. This may help 
explain the observation that breast cancer risk increases in the women who experience 
early menarche (onset of menstruation) and late menopause whereas breast cancer risk is 
reduced in the women who experience late menarche and early menopause [10;11]. A 
cohort study by the European Prospective Investigation into Cancer and Nutrition found 
that excess serum estrogens are associated with incidence of breast cancer in 
premenopausal women [12]. Similarly, estrogen replacement therapy in post menopausal 
women has been demonstrated to be associated with breast, cervical, and endometrial 
carcinoma [13]. In experimental models, estrogens are established breast carcinogens, as 
they are capable of initiating and triggering growth and selection to generate palpable 
malignancy [14-18].  These findings led the International Agency for Research on Cancer  
and National Toxicology Program to categorize estrogens as human carcinogens [19;20].  
Post menopausal women exhibit the highest breast cancer incidence when serum 
estrogens are at their lowest level [6]. In contrast, the estrogen levels in mammary tissues 
are similar in pre and post menopausal women [21]. In addition, post-menopausal breast 
cancer patients have significantly higher estrogen levels in breast tissues than non disease 
pre or post menopausal women [22]. This finding indicates that site-specific estrogen 
synthesis or estrogen load may be the major source associated with breast carcinogenesis 
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and growth of breast cancer cells. However, the underlying mechanisms of breast cell 
susceptibility to estrogen’s carcinogenic effect remain elusive. 
 
The signaling pathway plays a critical role in mammary gland development. This 
pathway has also been shown to be essential in promoting growth of estrogen receptor 
positive (ER+) breast cancer cells. Whether this pathway alone is sufficient to induce 
breast carcinogenesis is still unresolved. Mammary tumors can develop in mice lacking 
functional ER alpha (ERα) [15;23]. Likewise, E2 and its catechol metabolite, 4-hydroxy 
estradiol (4-OH-E2) can induce an estrogenic response in the uterus of ERα null mice, 
where an antiestrogen (ICI182780) fails to inhibit such response [24]. Though tamoxifen 
(TAM) and other antiestrogens inhibit breast cancer growth through their actions at the 
ER, these antiestrogens also inhibit growth of cancer cells that are estrogen receptor 
negative [25-27]. In addition, estrogen undergoes oxidative metabolism and generates 
ROS which is implicated in carcinogenic conversion and growth of cancer cells [9;18]. 
TAM on the other hand can block estrogen metabolism and acts as a ROS scavenger [14]. 
These findings therefore suggest that other mechanism(s) independent of ER status exist 
that mediate estrogen induced cellsignaling leading to malignant transformation and 
growth of mammary epithelial cells. One such mechanism being investigated by us is the 
role of estrogen induced mitochondria ROS in mammary carcinogenesis. Using 
physiologically achievable estrogen concentrations corresponding to the estrogenic 
menstrual peak, we showed that estrogen induces rapid formation of mitochondrial ROS 
in MCF-7 cells [28]. Other reports support our observation that estrogen-induced ROS 
production relies on mitochondria, which are the main source of ROS in the epithelial 
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cell [29]. Some of the same mitogenic pathways that are sensitive to ROS levels are 
regulated by carcinogenic levels of estrogen. We have recently shown that inhibitors of 
mitochondrial ROS production prevent E2-induced expression of cell cycle genes 
containing nuclear respiratory factor-1 (NRF1) binding sites (e.g., cyclin B1, PCNA, and 
PRC1), decrease E2-induced NRF1 expression, and delay growth [30].  Together these 
studies indicate that in addition to ER mediated signaling, E2 through ROS signaling can 
support initiation and progression of breast cancer by alternative pathways.  
 
In this review, we discuss a novel concept that estrogen-induced ROS can produce 
genotoxic effects as well as support the development of estrogen-dependent breast 
tumors. This envisioned ROS mediated mechanism most likely contributes to the process 
that drives carcinogenesis, while this mechanism seems to occur in the context of other 
ER-mediated signaling and estrogen reactive metabolite-associated genotoxicity. To 
highlight the ROS mediated carcinogenesis mechanism, first, estrogen metabolism and 
redox cycling of hydroxylated estrogens leading to the generation of genotoxic estrogen 
metabolites is briefly discussed. Then, we elaborate on the role of mitochondria in 
estrogen-induced generation of oxidants and emerging data on how estrogen-induced 
ROS modifies redox-sensitive signal transduction pathways that contribute in the cell 
transformation, cell growth and cancer progression. 
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GENERATION OF GENOTOXIC METABOLITES OF ESTROGEN AS A 
POTENTIAL MECHANISM OF BREAST CARCINOGENICITY 
 
Cells are protected from estrogen-mediated mitogenicity and genotoxicity through 
conjugation of parent estrogens to sulfate and glucuronide moieties. Estrogen metabolism 
and generation of genotoxic estrogen metabolites are summarized in Figure 1 and have 
been previously reviewed extensively [9;31-33], therefore we have limited our discussion 
in this area.  Endogenous and synthetic estrogens, i.e. E1, E2, E3, 17 α ethinyl estradiol 
(EE2) and equilenin (Eq) are converted  into catechol estrogens through aromatic 
hydroxylation by specific cytochrome P450 isoforms/peroxidase enzymes [9;34]. The 
catechol estrogens are inactivated by methylation, catalyzed by catechol 
methyltransferases, as well as by glucuronidation and sulfation, catalyzed by 
glucuronosyltransferases and sulfotransferases, respectively [35]. Oxidation of the 
catechol estrogens moieties gives rise to estrogen semi-quinones and quinines, i.e., 
estrogen-2,3-semi-quinone and estrogen-3,4-semi-quinone [36;37]. Catechol estrogens, 
particularly 4-OH-E2, via nonenzymatic autoxidation, may undergo redox cycling to 
produce reactive semiquinone and quinone intermediates with concomitant production of 
ROS. However, this redox reaction of catechol estrogens is enhanced in the presence of 
Cu2+ or Fe 3+ and by enzymatic catalysis by cytochrome P450 oxidases or peroxidases, 
which is accompanied with an increased generation of ROS. Catecholestrogens can 
reduce Cu2+ or Fe 3+ ions to Cu+ or Fe2+. The Cu+ or Fe2+ ions in turn, may reduce organic 
or inorganic peroxides, which are capable of initiating lipid peroxidation in the presence 
of oxygen. Both iron and copper are now recognized as  major transition metals that may 
facilitate the formation of ROS through redox cycling of catechol compounds as well as 
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by the Fenton reaction [38]. Estrogen quinones are conjugated with glutathione both in 
vivo and in vitro [37;39] by glutathione transferases [40]. 4-Hydroxylated estrogen 
metabolites or the diethylstilbestrol metabolite diethylstilbestrol-4, 4-quinone in a 
microsomal cytochrome P450 activation system, induce 8-hydroxylation of guanine bases 
of DNA. In addition to oxidant-induced damage to DNA, estrogens generate lipid 
peroxidation and oxygen radical-mediated oxidation of amino acid residues of proteins to 
carbonyl-containing moieties. The oxidant-induced oxidative DNA damage in estrogen-
target tissue has been taken as evidence for the generation of oxygen radicals by 
metabolic redox cycling of catecholestrogens or diethylstilbestrol (DES) and for their 
participation in the induction of estrogen-induced cancer in animals or humans. Catechol 
estrogen semiquinone/quinone can also directly react with DNA to form adducts [31]. 
These adducts can either be stable DNA adducts that remain in DNA or can form 
depurinating adducts that destabilizes DNA’s glycosyl bond [41]. DNA adduct formation 
and depurination at critical sites such as tumor suppressors or oncogenes can lead to 
mutations which have been postulated to be the initiator of breast cancer [41]. Rodent 
studies demonstrate that E2 induces tumors in those tissues only where E2 is 
predominantly converted to 4-OH-E2 by 4-hydroxylase enzyme [42;43].  We have 
previously shown that E2-induced tumor formation is decreased in animals exposed to 
inhibitors of estrogen metabolism [17;18] or to hormonally potent estrogens undergoing 
reduced metabolic conversion to catechol metabolites [44].  The rate of 4-OH-E2 
formation is also shown to be 4-fold higher than that of 2-OH-E2 in human mammary 
fibroadenomas and adenocarcinomas [45]. The 4-OH-E2  are the most prevalent estrogen 
metabolite in breast tumor tissues and have a significantly higher circulating level in 
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women with breast cancer [46]. Hydroxyestrogen and methoxy estrogen derivatives 
account for the majority of urinary or intra-tumor estrogens in human breast cancer 
patients but they are relatively scarce in the urine or mammary glands of healthy women 
[16].  Oxidative cellular damage such as 8-hydroxylation of guanine bases of DNA and 
lipid peroxidation have also been demonstrated in human breast and indicate the in vivo 
pro-oxidant effects of the estrogen and catecholestrogen metabolites formed in this tissue 
(reviewed in [9;31]). For example, elevated 4-OH-E2 levels in breast tumors and in 
women with breast cancer compared to normal mammary tissues implicate 4-OH-E2 in 
breast cancer and it strongly suggests that 4-OH-E2 metabolite participates in 
development of breast carcinogenesis [47]. Our recent studies showed that E2 or 4-OH-E2 
elicited transformed phenotypes in ERα negative MCF-10A cells through ROS-sensitive 
signal transduction pathways [48-51].  When exposed to E2, 4-OH-E2, 4-
hydroxyequilenin, equilenin or its catechol metabolite, similar transformation in MCF-
10F and MCF-10A were observed by other researchers [52;53]. Although neither 2-OH-
E2 nor 2-OH-E1 is carcinogenic in vitro or in vivo [42;54;55], both 2-OH-E2 and 2-OH-E1 
are capable of producing ROS and undergo metabolic redox cycling like 4-OH-E2. The 
lack of carcinogenicity of 2-hydroxylated estrogen metabolites in vivo may be due to 
their rapid inactivation by catechol-O-methyltransferase (COMT)-mediated O-
methylation [55-57], rapid clearance [58], and weak estrogenic hormonal activity 
(compared with 4-OH-E2) [59].  It may also be due to 2-MeO-E2, the major product of 
COMT-mediated O-methylation of 2-OH-E2 that possesses unique anti-tumorigenic 
activity.  These studies support the concept that E2 and mainly its metabolite 4-OH-E2 are 
carcinogenic in breast epithelial cells. 
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ESTROGEN RECEPTOR MEDIATED CARCINOGENIC ACTIONS 
 
The conventional paradigm of estrogen carcinogenic action is based on binding to ERα/β, 
which has been extensively reviewed; therefore, we limited our discussion in this area. 
Estrogen binding to its receptors, ERα and ERβ, initiates gene transcriptions by binding to 
estrogen response elements (ERE) of genes involved in cell growth. Therefore, increases in 
estrogen activity or exogenous estrogenic exposure may lead to increased cell proliferation 
[60]. It is speculated that rapidly proliferating cells are error prone due to the less time 
accorded for DNA proof reading and repairs. Errors incorporated into critical genes such as 
oncogenes and/or tumor suppressors may likely lead to mutations and neoplastic growth. 
Nevertheless, the classical concept of estrogen receptor mediated actions in cancer does not 
address the fact that the majority of normal mammary epithelial cells that transform into 
cancerous cells are ER negative (ER-) but are growth factor receptor positive (GFR+) [61;62]. 
On the other hand, about 7%-15% of normal mammary epithelial cells are ER positive (ER+) 
but lack growth factor receptors (GFR-) [63]. The predominant ER+ cells in normal mammary 
tissues are the stromal cells. Estrogen induced proliferative responses of normal ER- mammary 
epithelial cells may be mediated by the induction of GFR+ stromal cells [64]. Interestingly, the 
majority of breast cancer cells in vivo are  ER+ but GFR- and do proliferate upon estrogen 
exposure [65]. These observations therefore implie that ER positive phenotypic expressions 
observed in majority of breast cancer cells may be manifestation of malignant transformation. 
 
Furthermore, discrepancies between the binding affinity of various estrogens to ER and 
their potency both in vitro and in vivo have been reported (Figure 2). For example, 17α-
estradiol has a very weak affinity for ER compared to that of  DES and 17 α-
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ethinylestradiol; but its ability to stimulate the growth of Leydig cells and other cells is 
equivalent to that of DES [66]. Similarly, the receptor binding affinity of 4-OH-E2  is 
50% that of DES or E2, but its ability to stimulate cell growth in the mouse uterus is 
greater than either of these compounds [67]. In Noble rats, E1 is more potent than E2 in 
producing growth of mammary tissues [68;69]. In addition, estrogen-induced tumor 
formation is decreased in animals exposed to inhibitors of estrogen metabolism [17;18] or 
to hormonally potent estrogens with decreased metabolic conversion to catechol 
metabolites [44] compared to E2. The ectopic expression of Wnt-1, a proto-oncogene in 
mice induced mammary hyperplasia and tumorigenesis in the absence of ERα in female 
and male mice [15;23]. All these studies indicate that estrogen induced cellular responses 
including carcinogenicity and growth of cancer cell are verycomplex and the 
conventional paradigm as described above cannot explain all observed discrepancies.  
 
ESTROGEN, MITOCHONDRIA, AND ROS GENERATION  
 
Both natural and synthetic estrogenic compounds containing a phenolic structure possess 
pro-oxidant and/or antioxidant activities. A balance of pro- and antioxidant effects of 
estrogens depends on the nature (structure) of the estrogen and on its concentrations. 
Under physiological conditions, the parent estrogen and the metabolic profile of estrogen 
metabolites in a specific tissue or fluid determine its pro- or antioxidant activities. In 
additionto the above-described metabolic redox cycling of hydroxylated estrogens 
producing ROS, we present here the evidence supporting the role of mitochondria in 
estrogen-induced generation of oxidants.  
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Estrogen and mitochondria: Mitochondria are an integral component of steroidogenesis. 
Key enzymes of estrogen biosynthesis (3 β-hydroxysteroid dehydrogenase and 
aromatase) have been identified in the mitochondria of ovarian tumor epithelial cells 
[70].  Exogenously added estrogen is preferentially and rapidly(> 50% within a few 
minutes) transported  to mitochondria [71]. How estrogen functions in the mitochondria 
remains unclear; however, presence of ERα and ERβ in mitochondria indicates a 
potential role of estrogen in the regulation of mitochondrial genome transcription [72-74]. 
In the human mitochondrial genome, partial or ERE ½ sites in the D-loop region, CO II, 
tRNA-met, 12 S rRNA, 7 S rRNA, URF1, and URF5 were identified.  We recently 
reported that mitochondria are a major target of estrogen within the cell [28;75]. Estrogen 
can also affect mitochondria at the protein level.  Estrogen and ER agonists have been 
shown to inhibit mitochondrial respiratory complexes I, II, III, IV, and mitochondrial 
ATP synthase (F0F1-ATPase) [76;77], but most of these studies used cytotoxic dose of 
estrogen and any physiologic responses by mitochondria were probably overlooked. 
Mitochondrial proteins are encoded in the mitochondria and nuclear genomes. 
Mitochondrial transcription factor A (mtTFA), which controls mtDNA copy number, is 
essential for mitochondrial biogenesis [78]. When translocated into the mitochondria, 
mtTFA initiates transcription and replication of the mt genome.  Translation is initiated 
by mitochondrial translation initiation factor 2 (MTIF2), which is encoded by the mt 
genome and contains a consensus binding site for ER. The tissue-specific coactivators of 
steroid receptors (including ER), such as peroxisome proliferator–activated receptor-
coactivator-1 (PGC-1), and the PGC-1-related proteins, PRC and PERC, coactivate the 
expression of mtTFA [79-82]. Both transcriptional activators nuclear respiratory factor 1 
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and 2 (NRF1 and 2) and coactivators (PGC-1, PRC) act as important mediators in the 
maintenance and proliferation of mitochondria [83].  Steroid hormones, androgens and 
thyroxin, can induce changes in mitochndrial genome-derived mRNA and rRNA by 
increasing mtTFA mRNA expression from the nuclear genome [84].  At the post-
translational level, an interaction between mtTFA and P53 has been shown to control 
mitochondrial biogenesis [85], and P53 interacts with ER [86].  Estradiol increased 
phosphorylation of a 76-kDa protein in the mitochondrial fraction of the rat corpus 
luteum [87].  This report, together with the presence of protein kinases within 
mitochondria, further suggests that estrogens regulate mitochondrial physiology at the 
post-translational level [77]. 
 
Mitochondria and generation of estrogen induced ROS: Several enzymatic systems and 
organelles produce ROS, such as NADPH oxidases at the plasma membrane, nitric oxide 
synthases, xanthine oxidase, peroxisomes at endoplasmic reticulum (cytochromes P450) 
and mitochondria. Mitochondria however, are the largest source of ROS in epithelial 
cells. Over 90% of oxygen is consumed by mitochondria, and up to 4% of the oxygen in 
the mitochondria is utilized to produce RO/NS.  The respiratory chain produces 
superoxide radicals (O2-.). The major source of H2O2 in cells arises from the dismutation 
of O2.- (2O2.- + 2H+ =H2O2 + O2). At physiologic pH, non-enzymatic dismutation is rapid 
(~105 mol-1 sec-1), but dismutation is markedly accelerated by the superoxide dismutases 
(SOD; > 109 mol-1 sec-1).  H2O2 freely diffuses through cellular membrane and is a 
precursor of OH-. Mitochondrial nitric oxide synthase (NOS) produces nitric oxide (NO.), 
which combines with O2-. to generate peroxinitrite (ONOO-). All these RO/NS may cause 
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mitochondrial and cellular damage if present in excess (Figure 3). The physiologic 
production of RO/NS by mitochondria can have profound effects on initiation of 
preneoplastic foci and its promotion as well as tumor cell growth both in vivo and in vitro 
(Figure 3). Multiple non-mitochondrion and mitochondrion-dependent defense system 
regulate intracellular RO/NS formation and maintain an appropriate redox environment 
[88]. Glutathione, a tripeptide thiol (cysteine-glutamine-glycine), and thioredoxin (Trx), a 
small protein that has two cysteines in its active site, are responsible for much of the 
antioxidant defense of cells but are also likely mediators of oxidative signaling. These 
thiols are used as substrates for glutathione peroxidases, Trx peroxidases 
(peroxiredoxins) [75;89], and glutathione-S-transferases, enzymes that regulate the steady 
state concentration of hydroperoxides (ROOH) including H2O2, and also used as 
electrophiles, such as 4-hydroxy-2,3-nonenal (4HNE), which is a lipid peroxidation 
product. 
 
Earlier studies failed to identify that physiologic concentrations of estrogen stimulate 
mitochondrial ROS generation.That is why possibly cytotoxic doses of estrogen and 
isolated mitochondria were used. We and others have shown that mitochondria are 
significant targets of estrogen [28;30]. Recently, we reported that physiological 
concentrations of E2 stimulate a rapid production of intracellular ROS in epithelial cells 
which depends on cell adhesion, the cytoskeleton, and integrins [28]. In our studies of E2-
induced ROS generation in MCF-7 and other cells, hydroxylated estrogen metabolites or 
adducts immediately after addition of E2 were not detected which rules out the possibility 
of ROS generation by redox cycling of hydroxylated estrogens. These events occur 
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earlier than ER-mediated genomic actions. E2-induced ROS production does not depend 
on the presence of ER on breast cancer cells as ER- cell line MDA-MB 468 produced 
ROS equal to or more than that of ER+ MCF7, T47D, and ZR75 cell lines [28].  
   
The ROS molecules, H2O2 and NO, also stimulate mitochondrial biogenesis, a process 
that depends on the flow of molecules into and out of the organelle [90;91]. It has been 
shown recently that oxidative stress causes an increase in mitochondrial mass in human 
lung cells. However, the molecular mechanism underlying the increase in mitochondrial 
mass and mtDNA is still unclear. Furthermore, the mitochondrial mass of mtDNA-less 
cells was also significantly increased by exposure to low concentrations of H2O2, 
suggesting that the increase in mitochondrial mass in replicating cells may result from an 
increase in ROS production. Thus, the delayed production of estrogen-induced ROS may 
occur via this mechanism, whereas the transient estrogen-induced increase in ROS may 
result from estrogen activation of the mtTFA complex leading to increased oxidative 
phosphorylation.  
 
 
ESTROGEN-INDUCED ROS-MEDIATED OXIDATIVE DNA DAMAGES  
 
Estrogen-induced oxidative DNA damage through ROS has been extensively reviewed 
[9;31-33], therefore we have limited our discussion in this area here. 8- Hydroxy-guanine 
(8-OHdG), an indicator of oxidative DNA damage, causes G->T and A->C substitutions 
in DNA templates. It has been shown that breast carcinoma DNA contains dramatically 
higher concentrations of base modifications, such as 8-hydroxy-guanine, 2,6-diamino-4-
hydroxy-5-formamidopyrimidine, and 8-hydroxyadenine [92-94]. An elevated level 
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(3.35-fold higher) of 8-OHdG was observed in ER+ when compared with ER- malignant 
tissues. 8-OHdG level in ER+ MCF-7 cell line was significantly higher (9.3-fold higher) 
than ER- MDA-MB 231 cell line [93]. There was a higher level of 8-OHdG in the DNA 
of early-stage cancer tissue than that of later-stage cancer tissue, which suggests that ROS 
may play an important role in the early phase of carcinogenesis. The urinary 8-OHdG 
level (1,827 +/- 1,500 pmol/kg/day) in 18 women with gynecologic cancer  has been 
shown to be  significantly higher  than in 10 women  (747 +/- 425 pmol/kg/day) without 
carcinoma [94]. Gene mutation induced by ROS has been observed in C-Ha-ras-1 and 
p53 [95;96]. Recently, it has been shown that methylation alone induced C:G-->T:A 
transitions in the p53 gene, whereas nitric oxide treatment produced more C:G-->A:T  
transversions at CpG sites and, thus, increased mutational yields.  Alterations in the 
genome of breast cells is likely produced by oxidative attack of ROS generated by 
estrogen-induced oxidative stress in combination with receptor-mediated proliferation of 
oxidatively damaged cells. This view is supported by the findings of DNA damage 
induced in vitro or in vivo by estrogen-induced ROS, 4-OH-E2 and  both natural and 
synthetic estrogens in the target organs of cancer [31;32]. Catecholestrogen through 
redox cycling produce free radicals that generate various forms of free radical-induced 
DNA damage [31;32]. Cotreatment with an inhibitor of IL-1β and TNF-α, pentoxifylline, 
inhibited stilbene estrogen-induced increase in myeloperoxidase activities, 8-OHdG 
formation, mutations in the genome and prevented the estrogen induced testicular and 
uterine pre-neoplastic lesions [9]. Estrogen by stimulating nitric oxide synthase (NOS) 
and the subsequent generation of NO could affect methylation and expression of genes 
[97-99]. Thus, ROS/NO induced by estrogen may produce both gene mutations and gene 
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silencing, which, in turn, can predispose an individual to the development of cancer. 
Therefore, estrogen-induced ROS may play multiple roles in tumor initiation and 
progression. Compelling evidence for the transforming capacity of ROS is the finding 
that overexpression of Mox1 (the catalytic subunit of NADPH oxidase) induces 
superoxide generation and transforms NIH 3T3 cells. Furthermore, Mox1-transfected 
cells produce aggressive tumors in athymic mice similar in size to those produced by 
Ras-transformed NIH 3T3 cells [100], illustrating the critical role of this ROS regulator 
in vivo. These results are consistent with the concept that generation of genetic alterations 
is required for the initiation and progression of estrogen-induced tumors. 
 
ESTROGEN-INDUCED ROS MEDIATED REDOX SIGNALINGS 
 
ROS fulfill the characteristics of a second messenger since they are short-lived (rapidly 
generated and degraded), produced in response to a stimulus, highly diffusible (e.g., 
H2O2), and they are ubiquitously present in most cell types. In this section, we review the 
ROS-mediated signaling pathways which contribute to initiation, promotion and 
progression of estrogen-dependent breast tumors. Signaling proteins, including protein 
tyrosine phosphatases and several transcription factors, that contain critical cysteines are 
sensitive to redox changes and thus are potential targets of modifications by ROS (Figure 
4). A common feature of redox signaling appears to be the oxidative modification of 
critical cysteines in protein phosphatases that act on protein kinases. Kinases in turn 
activate redox sensitive transcription factors that influence the expression of genes 
involved in cell transformation, cell growth, and cancer progression.  
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Regulation of phosphatases by estrogen-induced ROS: ROS reversibly regulate cysteine-
based phosphatases, which include protein tyrosine phosphatases (PTPs), dual-specificity 
phosphatases (such as, Cdc25s), low-molecular-weight PTPs, and the lipid phosphatase, 
PTEN. Oxidation of PTPs can be reversed by thiol compounds, once the catalytic 
cysteine forms a disulfide bond with an N-terminal cysteine. This disulfide bond can 
originate from same site cysteines, as is the case with low molecular weight PTPS, from 
“distant” cysteines such as with PTEN and Cdc25, or from a bond between the PTP and a 
thiol, such as with PTP1B. The important step of the disulfide bond blocks the oxidation 
of the thiolate to Cys-SOH by the connection to another thiolate. Oxidation and 
phosphorylation have the potential of influencing each other in the signaling of PTPs and 
protein tyrosine kinase (PTKs). We have used Cdc25 as a major focus of this section to 
describe the redox regulation of phosphatase by estrogen-induced ROS. The Cdc25s, 
dual-specificity tyrosine phosphatases, possess the necessary elements to function 
directly in redox control of the cell cycle. Three homologues of Cdc25s exist in humans:  
Cdc25s A, B, and C. All contain a nucleophilic catalytic cysteine within a conserved 
motif that enables these enzymes to dephosphorylate phosphoproteins. The first 
suggestion that Cdc25 phosphatases act as potential redox controllers of the cell cycle 
was made more than 10 years ago by Mori laboratory which showed the direct 
involvement of ROS in the two-cell block of the mouse embryo [101]. Embryo 
development past the two-cell stage occurred when they injected the ROS modifiers SOD 
or Trx in vitro. Trx was shown to act through the phosphorylation state of Cdc2 kinase 
because the injection of Trx led to dephosphorylation and activation of the Cdc2 kinase 
during M-phase of the second cleavage. Other studies suggested that the oxidative stress 
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generated in human cells in response to UV or IR exposure degrades Cdc25s- A through 
its phosphorylation on serine-123 by check point kinase (chk) [102;103]. This leads to its 
ubiquitylation and its proteolytic degradation. In contrast, Finkel’s laboratory has shown 
that  Cdc25C undergoes rapid non proteasomal degradation in response to H2O2 treatment 
in HeLa cells [104]. This response is due to a decreased half-life for Cdc25C as a result 
of disulfide linkage formation between its active-site and backdoor cysteines. Cdc25C’s 
response to H2O2 treatment does not depend on the Chk pathway, suggesting a direct 
interaction between ROS and Cdc25C. The active-site cysteines of the Cdc25's are highly 
susceptible to oxidation [105]. The rate of thiolate conversion to the sulfenic acid by 
H2O2 for Cdc25B is 15-fold and 400-fold faster than that for the protein tyrosine 
phosphatase PTP1B and the cellular reductant glutathione, respectively [105]. Cdc25A 
(69M-1S-1) and Cdc25C (120M-1S-1), with highly homologous catalytic domains to 
Cdc25B (~60% identity), are only slightly less reactive than Cdc25B (164M-1S-1). The 
sulfhydryl group on cysteine residues can be oxidized to form a disulfide bond (Cys-
SSR), sulfenic acid (Cys-SOH), sulfinic acid (Cys-SO2H) or sulfonic acid (Cys-SO3H); 
the two latter being quite stable while disulfide bonds and protein sulfenic are relatively 
reactive and are often considered as the mediators in redox signaling. The active-site 
cysteine is protected by rapid intramolecular disulfide formation with back-door cysteines 
in wild-type enzymes and these intramolecular disulfides can then be rapidly and 
effectively reduced by Trx/TrxR2 but not glutathione [105]. Finkel and his associates fail 
to show oxidation of Cdc25A, because they used very a high concentration of H2O2 
[106]. 
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Rudolph’s laboratory has shown that the oxidation of Cdc25’s catalytic site cysteine 
residues decrease its activity via the formation of an intramolecular disulfide bond. In 
addition, the catalytic cys430 formed a disulfide bond with the invariant cys384 in some 
crystals suggesting that Cdc25 may be self inhibited during oxidative stress. The 
nucleophilic catalytic cysteines of phosphatases are known to be highly susceptible to 
oxidation, a property that permits redox regulation of this enzyme family. Recent studies 
have shown that O2.- is a more efficient regulator of PTP1B than H2O2, with a calculated 
rate constant in vitro (~3 x 102 M-1sec-1) about eight times faster than for H2O2 [107]. 
Nevertheless, one can argue that the reaction rate would be more than 100 times faster 
with H2O2 than with O2.- in cells, considering that the steady state concentration of H2O2 
in the cytosol is approximately 103 times more than the concentration of O2.- [108]. As 
described above, H2O2 exposure oxidized –SH group of Cdc25A faster than that of 
PTP1B [105;109]. Besides the widely believed concept that chk-mediated 
phosphorylation leads to Cdc25 proteosome-dependent degradation; its activity appears 
to be regulated by oxidation in the same way as oxidation regulates PTP1B activity.  
 
A rapid decrease in Cdc25A activity was shown when MCF-7 cells were exposed to 
physiological concentrations of estrogen [51]. A similar decrease in Cdc25A activity was 
observed in H2O2 treated HeLa cells [110]. Further examination revealed a lower level of 
Cdc25A –SH residues in the estrogen treated group compared to the vehicle control [51]. 
In addition, cotreatment with antioxidants prevented the oxidation of –SH residues in 
estrogen treated cells [51] . These findings suggest that estrogen-induced ROS 
oxidatively inactivates Cdc25A. A recent study showed that the oxidation of the Cdc25 
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active cysteine site leads to enzyme inactivation [111;112]. We and others have also 
identified an estrogen mediated protein interaction between Cdc25A and ERK in MCF-7 
and hepatoma cells respectively when treated with Cdc25A inhibitor Cpd [113]. 
Independent of ERα/ß, estrogen activates the MAPK pathway via ROS -dependent 
inactivation of Cdc25A. An increase in Cdc25A mRNA has been reported after 6 hrs of 
E2 treatment and an increased synthesis of Cdc25A protein was detected from 10 to 12 
hrs after E2 treatment [114;115]. The level of Cdc25A protein did not change 
immediately after E2 exposure, however, an increased in the level of its protein as early 
as 3 hrs after E2 exposure was detected. This observation suggests that E2 treatment 
increases Cdc25A stability. We further looked for any post-translational modification 
from E2-exposure because full enzymatic activity of Cdc25A requires phosphorylation at 
multiple Ser and Thr residues in the amino-terminal of the protein. In contrast to UV or 
IR effects on Cdc25A in cells, we observed a rapid decrease in serine phosphorylation of 
Cdc25A in response to physiological concentrations of estrogen which paralleled the 
decrease in phosphatase activity. A similar decrease in the serine phosphorylation of 
Cdc25A and its activity was observed in response to the exposure of cells with H2O2. 
Cdc25A is also phosphorylated at tyrosine residues, and in contrast to serine 
phosphorylation, tyrosine phosphorylation of Cdc25A was enhanced in cells treated with 
estrogen or H2O2. Others have also shown that  lower oxidant concentration increase the 
rate of tyrosine phosphorylation by tyrosine phosphatase [116]. These studies did not 
examine the oxidation of active site cysteines nor did they explain how tyrosine 
phosphorylation occurred and how tyrosine phosphorylation inactivated phosphatase 
activity. ROS activated ERK enhanced tyrosine phosphorylation of Cdc25A in E2-treated 
30 
 
MCF-7 cells protects Cdc25A from degradation [117]. Tyrosine phosphorylation of 
increased the half-life and accumulation of Cdc25A which may contribute to Cdc25A -
stimulated Cdk2 activity.  
 
Besides the Cdc25, some of the other phophatases, such as, MKP3, PTEN, PTP1B1, 
PTP2A, and PP5 [118-120] are  responsive to ROS and regulate estrogen-mediated 
signaling. For example, the activity of Ser/Thr protein phosphatase 5 (PP5) is responsive 
to oxidative stress and estrogen. Elevated levels of PP5 protein found in human breast 
cancer have been linked to the progression of human breast cancer [121]. ERK-specific 
phosphatase MKP3 is another ROS responsive phosphatse that may influence 
phosphorylation at Ser118 of ERα by regulation of pERK1/2 MAPK. Antioxidant 
treatment by increasing MKP3 phosphatase activity blocked tamoxifen resistance [122]. 
These phophatases are reversibly regulated by ROS. These oxidatively modified 
phophatases act on their corresponding kinases based on their temporal and spatial 
localization in the cells.  
 
Activation of kinases by estrogen-induced  ROS: 
We describe below some of the kinases which may be influenced by estrogen-induced 
ROS signaling via redox regulation of phosphatases.  
Structural changes to PTPs, as well as 
serine/threonine and phospholipid phosphatases, are induced by ROS, and the altered 
protein conformation leads to signaling cascade upregulation. Included in these cascades 
are src/Abl kinase-dependent, MAPK-dependent, and PI3 kinase-dependent pathways, 
leading to activation of AP-1, NF-kB, NRF1, and other redox-regulated transcription 
factors.  
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A-Raf: The mitochondrial localization of protein kinases A-Raf, PKCδ, and PKCЄ is 
evidence that this subcellular compartment harbors redox sensors [123;124].  The role of 
the protein kinase A-Raf in the mitochondria is not clear, but A-Raf mRNA is highly 
expressed in normal murine tissue [125].  In HeLa cells, epidermal growth factor (EGF) 
rapidly and transiently activates A-Raf, which in turn phosphorylates the MAP kinase 
activator MEK1  [125].  Interestingly, E2 can stimulate the phosphorylation of A-Raf and 
it appears to participate in cell cycle progression in ER+ MCF-7 cells [126].  Thus, it 
appears that mitochondrial oxidants may modulate estrogen-induced cell proliferation via 
A-Raf pathway. In addition to A-Raf, other redox sensitive proteins associated with 
mitochondria, PKCδ and PKCζ, have been demonstrated to activate the Raf/MEK/ERK 
pathway or directly activate MAPKs, respectively [124;127].  As zinc finger domains of 
Raf and PKC are targets of oxidative stimuli and Raf and PKC are localized in 
mitochondria, estrogen-induced ROS may activate A-Raf and/or PKC via the MEK/ERK 
pathway. Signaling pathways involving JNK and p38 MAPK are very responsive to 
redox regulation. JNKs have been studied primarily in the context of stress responses and 
apoptosis; however, accumulating evidence indicates that the JNK pathway also 
contributes to proliferative responses. For example, JNK1-/- mouse embryonic fibroblasts 
(MEFs), as well as JNK1-JNK2-/ MEFs, proliferate more slowly than do wild-type MEFs 
and reach a lower saturation density, establishing that JNK is required for normal MEF 
proliferation [128].  A role for JNK in cancer development is supported by recent studies. 
It has been shown that skin tumorigenesis is suppressed in JNK2-deficient mice [129], 
and expression of an inactive variant of the JNK substrate c-Jun in immortalized 
fibroblasts expressing v-Src and v-Fos reduces tumorigenicity in nude mice [130]. The 
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oxidative enhancement of Src-family tyrosine kinases and certain PKC isoforms as well 
as the dissociation of the JNK/GSTp and ASK1/Trx complexes may together contribute 
to the redox sensitivity of these pathways. These and other data suggest that signaling 
through the A-Raf/JNK pathway is very responsive to redox regulation and mediates 
oncogenic signals and supports cell proliferation in the absence of stress.  
 
 ERK: In addition to the ability of E2 to promote ER-dependent gene transcription, it 
rapidly activates ERK-1 and ERK-2 [130-134]. The activation mechanism by which this 
rapid signaling event occurs is unclear. The activation is extremely fast and it is believed 
that they are initiated at the plasma membrane and do not involve ER-mediated gene 
transcription. Several investigators have concluded that estrogen-induced MAPK 
activation is promoted by membrane bound ERα or ERß [135-137]. There are no known 
functional motifs within the structure of the ER that can promote second messenger 
signaling [138]. Most of the studies investigating rapid MAPK activation by estrogen 
have employed estrogen responsive cells including MCF-7 breast cancer cells [133;139], 
osteosarcoma cells [140], and neuroblastoma cells [141]; yet these studies have not 
directly addressed the roles of ERα and ERß in promoting estrogen -induced ERK 
activation. There are reports which show no correlation between ERα/ß expression 
patterns and the activation of ERK-1/-2 in estrogen treated breast cancer cell lines. Both 
estrogen and the pure antiestrogen ICI182780 activate ERK-1/-2 in human SKBR3 breast 
carcinoma cells, which lack ERα /ß protein and m RNA [131]. Other researchers have 
suggested that a membrane-associated ER-like G protein is responsible for nongenomic 
estrogen signaling [142-144]. They showed evidence that cellular expression of the 
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orphan receptor, GPR30, is sufficient for estrogen-induced activation of ERK-1/-2. Based 
on these observations, it is not clear which membrane protein or how the membrane 
proteins (ER or GPR30) activate ERK signaling in estrogen exposed normal or cancer 
cells. 
 
In many cells, extracellular H2O2 alone activates ERK-1/-2. As discussed previously, 
studies have shown that estrogen exposure rapidly activates ERK and our work indicates 
that both estrogen and H2O2 rapidly inactivate Cdc25A and activate the ERKs in MCF-7 
cells. Inactivation of Cdc25A by its inhibitor Cpd5 results in the activation of EGFR 
tyrosine kinase and more recently was shown to activate ERK-1/2 in hepatoma cells 
[113]. Both EGFR and ERK have been shown to form protein complexes with  Cdc25A 
in hepatoma cells [145]. Since ERK can interact with and phosphorylate EGFR, Cdc25A-
ERK interaction could be responsible for EGFR activation. Moreover, napthoquinone 
based inhibitors inactivate Cdc25A by covalently binding to cysteine residues at the 
active sites of Cdc25A [146]. Thus, it is possible that ERK may be activated by inhibiting 
its association with Cdc25A or inactivating Cdc25A through its redox regulation by 
estrogen-induced ROS.  
 
 AKT: AKT (also called PKB) is a serine-threonine protein kinase. It is a downstream 
target of PI3-kinase. AKT binds to the products of PI3-kinase. AKT affects numerous 
downstream targets either directly or indirectly, including the pro-apoptotic proteins Bad 
and Caspase 9, the growth-inhibitory proteins glycogen synthase kinase-3β, the forkhead 
transcription factors, the kinase IKKα, and the kinase mTOR [147;148]. AKT has 
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recently been identified to control NRF1 activity [149]. Several investigators have 
concluded that estrogen-induced AKT activation is promoted by membrane bound ERα 
or ERβ [150;151]. There are no known functional motifs within the structure of the ER 
that can promote second messenger signaling. There are reports which show no 
correlation between ERα/β expression patterns and the activation of AKT-1/-2 in 
estrogen treated breast cancer cell lines. 17α-estradiol, through an ER independent 
mechanism, activates PI3K-AKT signaling [152]. Recently Lee et.al., [151] reported that 
up-regulation of PI3K/AKT signaling by E2 is mediated through activation of ERα, but 
not ERβ. In ovarian cancer cells, 4-OH-E2 induces AKT phosphorylation while 2-OH-E2 
did not [153].Our study showed that 4-OH-E2 increased AKT poshphorylation in ERα 
lacking MCF-10 cells. Based on these observations, it is not clear which membrane 
protein and/or how the membrane proteins activate AKT in estrogen exposed normal 
cells. AKT activity depends on its phosphorylation, which is positively regulated by PI3K 
and negatively regulated by a class of protein phosphatases (PPs) [154]. AKT can be 
activated by both E2 and H2O2 [118;149-151]. ROS reversibly regulate cysteine-based 
phosphatases [119]. There are indirect evidences indicating that AKT associates with 
Cdc25. For example, AKT phosphorylates Cdc25s [155]. AKT activation suppresses 
Cdc25 inhibitor napthoquinone- and methylating agent temozolomide –induced G2 arrest 
and cell death [156;157]. A recent study indicate that Cdc25A interacted with AKT 
[158]. The reversible inactivation of Cdc25A or PTEN by estrogen-induced ROS appears 
to be a potential key player in the activation of AKT. 
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Activation of redox sensitive transcription factors by estrogen-induced oxidants 
signaling
 
: A significant number of transcription factors, including estrogen receptor, are 
redox sensitive. Some of these transcription factors contain critical cysteine residues that 
can be affected by ROS. As described above, signaling pathways are targeted by ROS, 
which result in the activation of kinases through inactivation of redox sensitive 
phosphatases. The active kinases, in turn, regulate phosphorylation of transcription 
factors. Regulation of AP-1, NF-kB, and CREB by both estrogen and ROS is widely 
accepted and their redox regulation by ROS has been discussed [9;118]. We have focused 
our discussion mainly on NRF1 in this section. 
ER: A large class of DNA-binding proteins such as the glucocorticoid receptor (GR), ER, 
and early growth response factor-1 (egr-1), contain zinc finger domains [159], which 
consist of at least two zinc-coordinated thiolates.  Oxidation of a zinc finger converts 
cysteine thiol groups to disulfide releasing zinc from the protein and resulting in a change 
in protein conformation that may affect protein function. Interestingly, oxidative stress 
has been reported to modulate ERα and ERβ expression in various cell lines.  In human 
breast cancer cells MCF-7 and T-47D, exposure to 2.5µM of H2O2 increased the protein 
level of ERα while having a minimal effect on ERβ [160].  Endogenous oxidative stress 
induced by PMA (100 ng/ml) in the macrophage cell line, J774A1 also increased the 
expression of ERα [75] and it was found that Ras mitogenic activity is, in part, 
superoxide dependent.  A recent study showed that at least 75 genes out of 891 
estrogen/ER-regulated genes were responsive to oxidants and ERα silencing. The 
oxidant-sensitive subset of estrogen/ER-responsive breast cancer genes are linked to cell 
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growth and invasion pathways. Findings of this study suggest that oxidant sensitive 
signaling pathways contribute to the development of an aggressive subset of ER+ breast 
cancers [161]. Although protein kinases are known to participate in phosphorylation 
signal cascades, they may also participate in redox signaling networks due to these zinc 
finger domains, e.g., ROS can activate PKC that triggers the release of zinc ions 
[162;163].  Another protein kinase, c-Raf, known to participate in the MAPK signal 
cascade was also demonstrated to be redox-activated at the zinc finger domain [162;164].  
As zinc-finger domains within these kinases have been reported to act as oxidant sensors, 
a mode of cross-communication appears to exist between redox and phosphorylation 
networks. Like serine-thereonine phosphatases as discussed above, ROS can inhibit some 
of the protein tyrosine phosphatases by reversible oxidation of their cysteine residues and 
enhance protein kinases, such as Src, c-Jun amino-terminal kinase (JAK), Ras, PKC, and 
MAPK [21]. These kinases are involved in modulating ER signaling [165;166]. Thus, 
ROS-mediated signaling represents another means by which ER function can be 
modulated by oxidants, and may be responsible for the clinical phenotype of ER breast 
cancer. Rapid effects of estrogen have been demonstrated to mediate the DNA binding 
activity and phosphorylation of transcription factors.  For instance, a 10 nM estradiol 
treatment of rat adipocytes doubles AP-1 DNA binding in 15 min [167].  In addition, 
CREB protein is phosphorylated rapidly by estradiol (10nM) treatment within 15 min. 
Given that estradiol can stimulate mitochondrial ROS generation and that the 
transcription factors AP-1, NF-kB, and CREB are targets of oxidative stimuli [167;168], 
it is possible that estrogen-specific effects at the level of the mitochondria can activate 
these transcription factors by above-descibed signal transduction pathways.  
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Mitochondrial generation of ROS leading to the activation of transcription factors AP-1, 
NF-kB, and CREB has downstream consequences for apoptosis, cell cycle progression, 
cell transformation, cell migration and cell invasion.  
 
AP-1 and  CREB: Growth factors and TPAactivate AP-1-dependent transcriptional 
activation and evidence is accumulating that ROS and 4-Hydroxy-2-nonenal (4HNE) 
increase the DNA binding activity of AP-1 [169-174]. The initial increase is not 
dependent upon protein synthesis and probably involves post–translational modifications 
of previously existing AP-1 complexes; however, increased synthesis of Fos and Jun also 
occurs rapidly upon stimulation [175]. Jun transcription is controlled by TRE and MEF2 
sites while Fos transcription requires SRE and CRE sites that are regulated by all three 
MAPK cascades [176]. Binding of AP-1 to DNA can occur without phosphorylation, but 
increased binding and transcriptional activation are both signaled by phosphorylation of 
Fos and Jun [177]. Several transcription factors, including c-Fos and Elk-1 are 
phosphorylated by ERK1/2. The JNK and p38MAPK are more strongly activated by 
stress signals and their activation occurs through similar phosphorylation cascades. The 
c-Jun family of transcription factors are specifically phosphorylated by the JNK at Ser 63 
and Ser 73 in a two-step process that requires binding to the delta subdomain prior to 
efficient phosphorylation at the NH2 -terminal activation domain[178]. JNK also binds 
and phosphorylates the Elk-1 and ATF-2 transcription factors [179;180]. The 
phosphorylation of Jun at the N-terminus by JNK not only is required for transcriptional 
activation [181;182] but also seems to protect Jun against degradation by ubiquitination 
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[183]. This results in an increase in the half-life and accumulation of Jun that may 
contribute to the JNK-stimulated AP-1 transcriptional activity.  
 
In addition to phosphorylation, the AP-1 complex is regulated by redox mechanisms. Fos 
and Jun have a single conserved cysteine residue located in the basic region of DNA–
binding domains that must be reduced for DNA binding activity [184]. The transcription 
factor AP-1 is strongly responsive to redox regulation. The exact nature of the redox 
change is not clearly identified. Recent in vitro data indicate that reversible S-
glutathiolation of the conserved cysteine may be involved [185]. Others suggest that the 
reversible redox regulation of AP-1 is mediated by Trx and the nuclear protein Ref1, 
which both increase AP-1 binding activity [186;187]. Direct association between Trx and 
Ref-1 has been reported [188]. Recently we have demonstrated the evidence for the 
involvement of redox signaling with estrogen-induced cell proliferation [28;75]. 
Physiological concentrations of E2 stimulate a rapid production of intracellular ROS 
which lead to the phosphorylation of c-jun and CREB. Although direct ER transcription 
factor effects are required to promote DNA synthesis, our recent data showed that MCF-7 
cell growth and cyclin D1 expression are suppressed by antioxidants and mitochondrial 
blockers. This observation supports our novel finding that nongenomic estrogen-induced 
mitochondrial ROS modulate the early stage of cell cycle progression [28].  It has 
become evident that regulation of the cellular redox environment is critical for estrogen-
mediated signaling. Thus, ROS may regulate AP-1 activity through several targets. ROS 
can modulate effector molecules such ERK and the c-fos/c-jun heterodimer (AP-1); and 
these effector molecules are known to participate in growth signal transduction [28;30]. It 
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is possible that JNK pathway may be involved in the AP-1 binding and transcriptional 
activation induced by mitochondrial oxidants produced upon exposure to estrogen. 
Although the ERK pathway has been shown to be involved in AP-1 activation by other 
agonists, we think that it may not participate in this case, based on the inability of H2O2 
alone to stimulate the ERK pathway in MCF-7 cells [189]. JNK is activated by stress 
stimuli through an activation module that may include the MAP3K apoptosis-signal 
regulating kinase (ASK-1) [85].Interestingly, recent data suggest that ASK-1 is activated 
by ROS either through Trx oxidation [190] or through dimerization [191]. Thus, ROS can 
either activate the JNK module or induce the formation of 4HNE, which may directly 
activate JNK [173]. 
  
The expression of early G1 genes, c-myc, c-fos, c-jun, cyclin D1, and NRF1 are regulated 
by ROS [192;193]. The mRNAs of some of these genes are induced by estrogen-induced 
ROS and H2O2 as well as other inducers of oxidative stress [114;130;192;194]. As 
described above c-Fos and c-Jun comprise part of the transcription factors AP-1; and AP-
1 binding activates the expression of down-stream target genes. In this regard, the 
induction of c-Fos, c-Jun and cyclin D1 is an ideal paradigm for studying the role of early 
response genes in response to oxidative stress-induced by estrogen. The mRNAs of c-Fos 
and c-Jun are induced by estrogen and also by relatively small amounts of H2O2, 
superoxide, NO, and other inducers of oxidative stress [114;192]. The earliest known 
growth-regulatory gene activated by E2 is c-Myc. Increased transcription of myc, as 
measured by accumulation of mRNA, occurs within 30 min, and peak protein levels are 
observed within 1–3 h of treatment with E2 of MCF-7 cells [114]. Recent studies indicate 
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that Myc protein is stabilized by E2, up to 12 h after its addition, well past the decline in 
mRNA levels. Myc expression elicits active cyclin E-Cdk2 and S-phase entry in growth-
arrested MCF-7 cells. Although Myc is clearly implicated in E2 action, it was not found 
in a genetic screen for E2-responsive genes in MCF-7 cells. Myc is induced by exposure 
to ROS [114]. Cyclin D1 is a well-defined target of E2 action in MCF-7 cells, and in 
rodent breast epithelial tissue, ovary and uterine endometrium. In MCF-7 cells, addition 
of E2 to G0/G1-arrested cells results in a two- to three-fold induction of cyclin D1 mRNA 
within 1-3 h and a three- to five-fold increase in synthesis and steady-state levels of 
cyclin D1 protein within 3-6 h. Given that cyclin D1-knockout mice are fertile, the 
physiologic relevance of ER as a target of cyclin D1 is uncertain. Cyclin D has a half 
ERE. Planas-Silva et. al., demonstrated that E2 transiently upregulates synthesis of c-Fos 
and c-Jun in MCF-7 cells, but not in hER-transfected HaCa T nontransformed human 
keratinocytes [195]. Earlier studies indicated, however, that E2 increases AP-1 activity 
without increased synthesis of c-Jun or c-Fos and without the synthesis of any new 
proteins. Foster and Wimalasena demonstrated that ligand-activated ER is fully active at 
8–10 h after E2 treatment [114]. The products of at least two E2 target genes, c-Myc and 
cyclin D1, can independently promote G1/S transition in MCF-7 cells and activate cyclin 
E–Cdk2 coincident with formation of high molecular mass cyclin E–Cdk2–p130 
complexes depleted in p21CIP1 and p27KIP1. The expression of c-fos and c-myc did not 
depend on the presence of growth factors, suggesting that integrins alone through ROS 
could regulate the Go/G1 transition. Furthermore, integrin clustering in the absence of 
cell spreading was sufficient to induce expression of early genes (jun B and ras) involved 
in the Go/G1 transition and were able to trigger G1/S transition through modulating 
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cyclin D1 expression [196;197]. Integrins, through ROS, control the expression of these 
cell cycle genes, and it is now obvious that cell adhesion and integrin ligation are 
obligatory processes for regulation of cdks and cyclins. JNK and p38 also have been 
shown to cooperate with ERK in pp60(v-src)-induced cyclin D1 expression in breast 
cancer cells [114]. However, an unresolved issue regarding E2-mediated signaling is 
whether E2 receptors themselves actually initiate signal that can intervene in the Go/G1 
and G1/S transitions. The expression of early G1 genes, c-myc, c-fos, c-jun , cyclin D1 
are regulated by ROS [192]. Low and intermediate levels of RO/NS regulate cellular 
signaling and play an important role in normal cell proliferation [9;196]. Constant 
activation of AP-1 transcription factor appears to be one functional role of elevated ROS 
levels during tumor progression [198]. Based on these data, estrogen-induced ROS may 
control the expression of genes involved in cell cycle progression. 
 
NF-kB: Activation of NF-kB is another well-studied model of redox regulation. The 
oxidation of a conserved cysteine residue in the DNA-binding region adjacent to the 
leucine zipper in AP-1 abolishes its binding to DNA [185]. The DNA binding activity of 
AP-1 is restored by Trx and the nuclear signaling protein redox factor-1 (Ref-1) [188] 
and enhanced by transient overexpression of Trx in vivo. Compared with NF-kB, AP-1 is 
less sensitive to oxidative inhibition by glutathione disulfide in vitro but more sensitive to 
oxidized Trx. Thus, in intact cells, the elevation of intracellular oxidized glutathione 
(GSSG) levels by inhibition of glutathione reductase inhibits selectively the DNA-
binding activity of NF-kB and not that of AP-1 [199]. The protein NF-kB is regulated by 
its interactions with the inhibitory co-factor, which sequesters NF-kB to the cytoplasm.  
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AKT is known to phosphorylate an upstream kinase, IKKβ, which stimulates the 
degradation of Ik-B [130].  As AKT can participate in the activation of IKKβ, it may be 
possible for estrogen-induced mitochondrial ROS to stimulate the transcription activity of 
NF-kB via the AKT pathway.   
 
 NRF1
 
: The human alpha-palindromic nuclear respiratory factor -1 binding protein 
(NRF1) is a 503 amino acid (aa) transcription factor [200;201], located on chromosome 
7q32.2 [202] and codes for 68 kDa nuclear proteins [200;203]. Several compounds that 
induce cellular oxidative stress have been shown to increase NRF1 expression and 
increase in mitochondria proliferation. For example, the bacterial lipopolysaccharide and 
tertiary butyl hydroperoxide have both been demonstrated to induce cellular oxidative 
stress which upregulates NRF1 expression and mitochondria biogenesis in rat liver cells 
[149;193]. Likewise, rat liver cells overexpressing NRF1 have been shown to induce 
ROS production and increase in mitochondria proliferation [149]. Similarly, exposures of 
human lung fibroblast cell line, MRC-5, with H2O2 at concentrations of 90-360 µM 
induced increases in mtDNA and mitochondria biogenesis in exposed cells [204]. The 
role of oxidative stress and NRF1 expression were further corroborated by works done by 
Miranda et. al., which revealed that HeLa cells depleted of mtDNA were under oxidative 
stress which induced expression of NRF1 and mitochondrial biogenesis [205]. Lastly, 
estrogen exposure has been reported to increase NRF1 overexpression which increased 
mitochondria biogenesis in MCF-7 malignant mammary epithelial cells, and human 
bronchial epithelial cells from female patients [206;207]. 
43 
 
Oxidants modulate NRF1 expression and mitochondria biogenesis; antioxidants 
conversely inhibit intracellular ROS and NRF1 expressions. For example, oral 
administration of vitamin C has been demonstrated to inhibit NRF1 expressions with 
reduction in mitochondria biogenesis and diminished endurance training capacity [208]. 
In addition, catalase overexpressions have been shown to reduce NRF1 expressions and 
mitochondria content in heart muscles of aged mice which attenuated age related diseases 
observed in mice [209]. These studies imply that cellular oxidative status modulates 
NRF1 expression. Activated NRF1 expressions in response to ROS can lead to enhanced 
mitochondria biogenesis and increased bioenergetics, as well as regulation of genes 
involved in apoptosis and cell cycle progression.  
 
NRF1 expression in MCF-7 (or any ER+ cell types) may not be entirely due to cell’s ER 
status. Estrogens concentration of 10 nM has been reported to induce oxidative stress in 
MCF-7 cells [210;211]. In a similar manner, the pro-oxidative compound sodium 
butyrate [212;213] has also been shown to induce NRF1 expression in MCF-7 cells 
[214]. Sodium butyrate lacks estrogenic property. In addition, oxidative stress has been 
reported to induce NRF1 expressions in ER- breast cancer cell line such as MDA-MB-
468 as well as in ER- human bone osteosarcoma (U2OS) cells [215]. Likewise, SERMs 
such as TAM, RAL and Fulvestrant which are also pro-oxidant upon chronic exposures 
[216], also increase NRF1 expressions in SERM resistant MCF-7 cells [217]. These 
studies suggest that estrogen inductions of NRF1 in estrogen responsive breast cancer 
cells are not exclusive to ER status. It implies that perhaps estrogen induced oxidants also 
mediate NRF1 expressions in breast cancer cells irrespective of ER status. This point is 
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important when considering mechanisms by which estrogen induce mammary 
carcinogenesis and growth of breast cancer cells.  
 
This observation is supported by several findings. For example it has been reported that 
exposures of rat cardiomyocytes and liver cells to sublethal levels of pro-oxidative 
compounds such as LPS or t-BOOH induced oxidative stress, NRF1 expressions, 
mitochondria biogenesis, and promoted cell’s survival and growth [193;218]. Conversely, 
silencing of complex II, one of the primary genes regulated by NRF1, inhibited 
OXPHOS, ROS production and augmented cell growth [219]. In similar manner, 
exogenous addition of oxidants to hepatoma cells depleted of mitochondria induced 
NRF1 expressions and cell proliferation [149]. These findings imply that oxidant induced 
NRF1 regulation promotes cell growth by coupling mitochondria bioenergetic with cell 
proliferation. This is further supported by findings in our laboratory that chronic 
exposures of non-tumorigenic, ER- mammary cells (MCF-10A) with 100 ng/ml estradiol 
or its catechol derivatives, 4-OH-E2 but not 2-OH-E2, induced oxidative stress, mammary 
transformations as well as up-regulations of NRF1. However silencing of NRF1 inhibited 
estrogen induced oxidative stress and inhibition of cell’s transformation [49;50]. Similar 
observations were also reported in pre-malignant primary fibroblast cells. In these cell 
lines, it was observed that NRF1 and other mitochondria genes were among the 
transcription factors over-expressed during malignant transformation [220].  However in 
this study, high NRF1 expressions were likewise linked to oxidative stress and energy 
demand by proliferating cells. These studies imply that for cells to survive in elevated 
oxidative environment, they must be able to up-regulate NRF1 expression, which in turn 
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increases mitochondria biosynthesis and OXPHOS. However, it is counterintuitive to up-
regulate pro-oxidative mechanisms during periods of oxidative stress. It is therefore 
speculated that high ROS levels serve other purposes such as clonal selection of 
neoplastic cells, and induction of apoptosis in non-neoplastic cells [221;222]. Similar 
mechanism might be in play during estrogen induced mammary carcinogenesis. In 
population of initiated cells, oxidative stress and NRF1 expression may serve to provide a 
pro-tumorigenic selective environment as well as the energy necessary for these cells to 
proliferate and grow, irrespective of ER status.  
 
Though estrogens have been reported to modulate NRF1 expressions via E2/ER binding 
to ERE on NRF1 promoter regions in a number of cell lines [206;207], we demonstrated 
that prolonged treatment of MCF-7 cells with estrogen also induced NRF1 expression, 
increased cell proliferation and colony formation in soft agar assays (Okoh et al, 
unpublished data). Interestingly, the silencing of NRF1 or pretreatment of cells with NAC 
significantly reduced NRF1 expression and inhibited estrogen induced cell proliferation 
and anchorage independent growth (Okoh et al, unpublished data). Conversely, 
overexpression of NRF1 in the same cell line increased cell proliferation independently 
of estrogen action. These findings from our laboratory therefore imply that NRF1 
expression observed in MCF-7 cells treated with estrogen is redox based as antioxidants 
abolish NRF1 expressions. It also suggests that redox expressions of NRF1 due to 
estrogen exposure may contribute to breast cancer cell growth independent of E2/ER/ERE 
mechanisms. If this is the case, it can be surmised that estrogen induced ROS contributes 
in part to growth of malignant cells in a manner unrelated to ER activations. This 
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assertion may therefore explain why oxidative stress is positively correlated with 
tumorigenesis [223;224], aggressive breast cancer phenotypes [225], and therapeutic 
resistance of breast cancer patients [226]. 
 
ROLE OF ESTROGEN-INDUCED REDOX SIGNALING IN THE DEVELOPMENT 
OF BREAST CANCER  
 
ROS affects generation of new phenotypes of cells during the development of breast 
cancer through its influence on the regulation of protein kinases and signal transduction 
pathways. Here we describe how estrogen-induced ROS may contribute in the generation 
of different cell phenotypes required for the development of breast cancer. 
 
Estrogen-induced ROS as potential mediator of cell transformation and generators of 
human breast cancer stem cells: A delicate intracellular interplay between oxidizing and 
reducing equivalents  allows ROS to function as second messengers in the control of cell 
proliferation and cell transformation [227;228]. Many studies implicate ROS in cell 
transformation and in the uncontrolled growth potential of tumor cells [224;229-233]. We 
also find that estrogen stimulates the growth of TM3 and HEK 293 cells in an ER-
independent manner [9;30]. In another study estradiol-induced kidney tumor incidence in 
Syrian hamsters treated with antioxidants was effectively reduced by ebselen, sodium 2-
mercaptoethanesulfonate (Mesna, a cytoprotective thiol-containing agent), NAC and 
vitamin-C administration [17;18].  Also, cotreatment with pentoxifylline, an inhibitor of 
IL-1β and Tumor necrosis factor (TNFα) synthesis, prevents estrogen-induced testicular 
and uterine cancers [9]. Superoxide dismutases (SODs) are the first and the most 
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important line of antioxidant enzyme defense against ROS and particularly superoxide 
(O2-) radical. Overexpression of the enzyme responsible for mitochondrial superoxide 
detoxification, manganese superoxide dismutase (MnSOD), inhibits the malignant 
phenotype [234-236]. MnSOD knockout mice exhibit increased oxidative DNA damage 
[237]. Soini et al.,2001 reported that MnSOD expression is less frequent in the tumor 
cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast 
epithelial cells. Several epidemiologic studies have shown an increased risk of breast 
cancer in the MnSOD Ala-Val polymorphic populations [238;239]. In a recent study it 
was shown  that genetic polymorphism in the MnSOD gene may be associated with 
increased risk of breast cancer among Chinese women with high levels of oxidative stress 
or low intake of antioxidants [240]. Studies also show that there is no positive relation 
between genetic variation in MnSOD and breast cancer [241]. Our preliminary study 
showed that MCF-10A cells treated with 4-OH-E2 rapidly produce ROS, which is 
preceded by an increase in the level of Ca2+. The accumulation of 4-OH-E2 as recently 
reported in the human breast tissue in cancer subjects [46;242] will allow increased ROS 
and Ca2+ levels in the target organ of cancer in a sensitive subpopulation. Later, 
overexpression of catalase and MnSOD prevented 4-OH-E2-induced anchorage-
independent growth of MCF-10A cells. These data together indicate that 4-OH-E2-
induced cell transformation may be mediated, in part, by ROS signal transduction 
pathways that are different from the classical nuclear ER genomic signaling pathway 
(Fig. 4).  
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Estrogen-induced ROS as mediators of cell cycle progression: 
 
As shown in Figure 3, high 
ROS levels induce oxidative damage and arrests cells in G0/G1. However, low 
physiologic ROS levels are utilized by cells for cell-to-cell communication and in 
proliferation [28]. The rapid stimulation of intracellular ROS by PDGF, EGF, and NGF 
suggests that this underlying mechanism of cell growth may be shared by other growth 
factors or mitogens, including estrogen  [243]. Exogenous addition of low concentrations 
of H2O2 and/or O2.- has been demonstrated to stimulate cell growth in a variety of cell 
types including fibroblasts and prostate cancer cells [159]. Although these phenomena 
have been overshadowed by studies concentrating on the role of ROS in the pathology of 
various diseases and apoptosis, they suggest that outcomes other than apoptosis may be 
coupled to the signaling event represented by the estrogen-induced generation of ROS. 
Cell cycle progression is regulated by an intricate web of signaling pathways mostly 
requiring growth factor stimulation and ultimately involving cyclins, cyclin-dependent 
kinases (cdks), and cell cycle inhibitors. Constant activation of redox sensitive 
transcription factors appears to be one functional role of elevated ROS levels during 
tumor progression [198]. The results of our more recent studies show that ebselen (a 
substance with glutathione peroxidase-like activity), and inhibitors of mitochondrial 
replication and protein synthesis prevent estrogen-induced G1 to S transition. Low and 
intermediate levels of ROS regulate cellular signaling and play an important role in 
normal cell proliferation [196]. These data suggest that redox signaling supports cell 
proliferation in the presence of estrogen-induced ROS.  
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Several lines of indirect evidence support a role for mitochondrial oxidants in estrogen-
induced cell proliferation. Isoforms of Trx, Trx-2 and thioredoxin reductase (TrxR2), 
which regenerates the reductant form of Trx, have been detected in mitochondria 
[89;244].  Dominant-negative inhibition of TrxR2 causes an increase in H2O2 
accumulation, which activates cell proliferation [245] and increased expression of  cell 
cycle genes involved in the G1 and S phases of the cell cycle [244-247].  In vitro 
treatments of primary human endometrial stromal cells with estrogen at different 
concentrations (10nM-100nM) result in an increase in Trx protein and mRNA expression 
which implicates Trx in cell growth and differentiation of estrogen responsive tissue 
[247]. Alterations in the cellular redox status due to increased expression of TrxR2 have 
been suggested to play a role in the growth of hepatocellular carcinomas [248]. Whether 
estrogen can specifically increase the expression or activity of Trx2 and/or TrxR2 is not 
known, but these findings suggest that estrogen may modulate signal transduction of 
mitochondrial derived ROS via the thioredoxin system. Indirect evidence is also provided 
by the overexpression of the MnSOD enzyme responsible for mitochondrial ROS 
detoxification, which inhibits breast tumor growth [235].  As H2O2 is a highly diffusible 
signaling molecule and both MnSOD and NOS are modulated by estrogen [249;250], it is 
plausible that estrogen-induced ROS signaling at the level of mitochondria contributes to 
cell proliferation.  
 
Many of the genes associated with high-risk breast tumors appeared to be involved in 
cell-cycle regulation, including Cdc2 and PRC1 [251]. Integrins through ROS control the 
expression of cell cycle genes; and cell adhesion and integrin ligation are obligatory 
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processes for regulation of cdks and cyclins [182-184]. Recently, an NRF1 and CREB 
pair has been identified as a key regulator of the transcriptional program of the cell cycle 
in human cells because this pair of transcription factors show a significant co-occurrence 
rate on promoters of cell cycle regulated genes [252;253]. NRF1 appears to play an 
important role as a regulator of cell cycle genes because NRF1 binding site has been 
identified by comparing genome-wide locations on genes involved in DNA replication, 
mitosis, and cytokinesis. Some of the genes which contain NRF1 binding sites on their 
promoters include Cdc2 [254], guanine-nucleotide exchange factor, RCC1, DNA 
polymerase-α, ornithine decarboxylase, GADD153, growth-arrest and DNA-damage-
inducible protein153 [252]. Mammary carcinogenesis is characterized by an increased 
expression of NRF1, which may be linked, with increased energy demand by rapidly 
proliferating cells [255;256]. However, NRF1’s role in mammary carcinogenesis may be 
more than mere energy modulators. NRF1 has been reported to be over-expressed in a 
number of malignant tissues including breast cancer tissues where its levels are higher in 
disease regions compared to adjacent normal regions suggesting that NRF1 may play a 
role in mammary carcinogenesis [256]. For example microarray study of genes expressed 
during mammary tumorigenesis in MMTV-neu mouse model reveals that NRF1 were 
among the transcription factors over-expressed in tumor tissues compared to adjacent 
normal tissue [257]. Similarly, another microarray analysis of NRF1 expression in human 
tissues reveals that while normal mammary tissue had more NRF1 expression than most 
normal tissues analyzed, (except for lung tissues), the levels of this transcription factor 
were highest in breast cancer tissues compared to other cancer types [256]. Lastly, NRF1 
is amongst a few sets of transcription factors whose overexpression is correlated with 
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progression of mammary carcinogenesis [255]. While these findings were attributable to 
increased energy demand, other evidence exist that suggest that these transcription factors 
may directly or indirectly regulate genes involved in cell proliferation in manners 
unrelated to mitochondria biogenesis. Whether NRF1’s role in these malignant cells is 
indicative of metabolically active cells or whether it also regulates growth related genes 
that promotes malignancy is yet to be investigated. NRF1 may also play major roles in 
modulating cell proliferation in a manner not related to mitochondria biogenesis.  
 
NRF1 regulates many other genes that may be involved in the development of breast 
cancer than that described above. For instance, there is a striking overlap in target genes 
between E2F4 and NRF1 [252;255]. E2Fs are target of both estrogen and oxidative stress 
[258;259]. There is a functional interaction of E2Fs with other transcription factors, such 
as FOXO1, hypoxia-inducible factor 1 (HIF-1), nuclear factor B (NFB), and peroxisome 
proliferator-activated receptor (PPAR), including NRF1, during oxidative responses in 
cells. NRF1 has been reported to transcriptionally regulate the expression of E2F1 [260] 
and E2F6 [215] genes. Both genes belong to E2F family of transcription factors which 
functions in cell cycle controls. While E2F1 is generally considered as a transcription 
factor activator and E2F6 as a transcription factor repressor, the coordinated activities of 
these genes are essential in regulating cell cycle control and to have a major role during 
carcinogenic process [261]. Overexpression of E2F1 in mammalian cells has been 
reported to induce neoplastic transformation of rat embryo fibroblasts, induce colony 
formation in soft agar assay and induce tumor in nude mice [262;263]. Conversely, 
under-expression of these same genes has likewise been shown to induce broad range of 
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mice tumors as well [264;265]. This seemingly contradictory observation of E2F1 
expressions highlights the tight regulations NRF1 must undertake to keep E2F1 gene 
expression at ‘normal’ physiological levels. E2F6 is a member of the E2F family of 
transcription factor involved in regulation of cell proliferation and differentiation via 
target genes involved in DNA replication, DNA repair, cell cycle control and apoptosis 
[261;266;267]. E2F6 expressions in cells induces growth by inhibiting cell’s exit from 
the S phase, and delays re-entry into the cell cycle in quiescent cells [268;269]. Growth 
arrested cells due to delayed cell cycle could accumulate pre-malignant genetic lesions 
and cell transformations potentials as DNA repairs and proof reading also ceases during 
quiescence.  
 
Findings that the proliferative growth of breast cancer cells exposed to estrogens activate 
E2F1 expressions an ER independent manner provide further support to the above 
concept [270]. Of interest in this study is the finding that overexpression of ER in ER - 
breast cancer cells (MDA-MB-231) did not induce cell proliferation upon estrogen 
treatment even though E2F1 was mildly activated [270]. Similarly, it  was shown in ER+ 
ZR-75 cells that ER/Sp1/NFY interactions are  not necessary for estrogen-induced 
transactivation [259]. These findings indicate that ER status is not the sole determinant of 
breast cancer progression and growth due to estrogen exposures. It should be noted also 
that another study with similar conditions had observed that MCF-7 cells exposed to 
estrogen increased NRF1 and mitochondrial expressions via ER activation [206]. Both of 
these in vitro studies with MCF-7 cells may therefore serve to elucidate the mechanism 
by which estrogen induces growth of breast cancer cells, i.e. estrogens induced oxidants 
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mediate NRF1 expression which may regulate E2F1 expression and promote breast 
cancer cell growth.   
 
Other than binding to promoter regions of target genes involved in mitochondria 
biogenesis and OXPHOS, NRF1 also modulates genes involved in mitochondria 
regulations. For example,  Nrf-2 (NFE2L2), a redox sensitive gene known to regulate 
antioxidants responses, has been reported to bind to antioxidant response elements on 
NRF1 promoter region to regulate ROS production as well as induction of antioxidant 
responses in cardiomyocytes overexpressing heme oxygenase (HO)-1 [271]. Likewise, 
cMyc overexpressions and induction of apoptosis in NIH 3T3 cells depleted of serum is 
also reported to be mediated by NRF1 activations [272]. Hormones such as Thyroid 
hormone (T3) and estrogens (E2) have also been reported to upregulate NRF1 expressions 
and mitochondria biogenesis through binding to responsive elements in NRF1 promoter 
regions [273;274]. NRF1 has also been reported to transcriptionally regulate expression 
of myocyte enhancer factor 2A (MEF2A) which is a muscle specific gene [275]. MEF2A 
is a DNA-binding transcription factor that activates muscle-specific, growth factor-
induced, and stress-induced genes such as the cytochrome c oxidase (COX) subunits 6A 
(COX6A). Interestingly, MEF2A also functions in skeletal and cardiac muscle 
development as well as in neuronal cell differentiation and survival. They also play 
diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK 
signaling pathway in muscle cells [276]. Dysregulation of MEF2A is implicated in 
Chinese patients with coronary artery disease [277;278] and in hepatocellular carcinoma 
[279].Our recent study showed that co-exposure of inhibitors of mitochondria shown to 
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control mitochondrial oxidant production prevents E2-induced expression of cell cycle 
genes, cyclin B1, PCNA, and PRC1 containing NRF1 binding sites, and caused loss of 
NRF1 expression and growth delay. The E2-induced stimulation of the expression of 
NRF1 and these cell cycle genes, and growth were restored by removing exogenous 
mitochondrial inhibitors that diminished oxidant exposure indicating that oxidative stress 
stimulates these cell cycle genes in part via NRF1 activation. Cyclin D1 has recently been 
reported to inhibit NRF1 expression which leads to reduced mitochondria biogenesis in 
mouse embryo fibroblasts (MEFs) [280]. Overexpression of cyclin D1 is usually 
associated with cancer cell growth [281]. While it is counter intuitive that rapidly 
proliferating cell such as MEF would inhibit mitochondria biogenesis which is a major 
source of energy production, proliferating cells do generate excess ROS because they are 
metabolically active. Excess cellular ROS are known to have adverse effects of cell’s fate 
ranging from apoptosis to growth retardation [228]. Therefore it is plausible that cyclin 
D1 expression that drives cell cycle progression could also function to reduce 
mitochondria activity during periods of excess ROS.  Hence the inhibition of NRF1 
expression by cyclin D1 may be a negative feedback mechanism that protects the cell 
from harmful effect of mitochondrial derived ROS. This assertion is supported by the fact 
that cyclin D1 expression is likewise upregulated by mitogenic E2 [282;283] as well as by 
ROS [284].  
 
Estrogen-induced ROS as a mediators of breast cancer progression: E2F1 is over-
expressed in breast tumors when compared with normal mammary tissue, and that 
patients with high E2F1-expressing tumors have significantly reduced disease-free status 
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and overall survival compared with patients with low-expressing E2F1 tumors [285-289]. 
It should be also noted that NRF1 expressions are positively correlated with oxidative 
stress and progressions of mouse or human mammary carcinogenesis [255-257]. E2F6 on 
the other hand are transcription factor repressors and function mainly in growth inhibition 
[261;268]. Interestingly, one of the target gene of E2F6 is the breast cancer gene BRCA1 
[290]. BRCA1 regulates cell cycle progression, apoptosis, and DNA repair, and loss of 
BRCA1 expression is linked to cell proliferation and transformation [291]. While BRCA1 
overexpression has been reported to confer therapeutic resistance,  BRCA1 deficiency 
confers sensitivity to oxidative stress [292]. In addition, BRCA1 mutations are associated 
with breast cancer progression [290]. Therefore, NRF1 dysregulation of E2F6 can lead to 
BRCA1 dysfunctions with adverse consequences ranging from apoptotic cell death to 
malignant transformation of breast epithelial cells.   
 
In addition to regulation of E2F family of transcription factors, NRF1 is also known to 
regulate genes that favor breast growth and metastasis. For example NRF1 tightly 
regulates the expression of calpain proteases in normal cells [293]. Overexpression of this 
protolytic enzyme mediates tumorigenesis, metastasis and angiogenesis in breast cancer 
and other cancer types [294;295]. NRF1 also regulates expression of integrin-associated 
protein [296]. Integrins are essential for a cell’s adhesion during normal development. 
Dysregulation of intergrin has been shown to promote carcinogenesis in mammary cells 
as well as other cells types [297]. Lastly, NRF1 has also been reported to regulate 
proliferation and growth of breast cancer in response to estrogen via activations of p115, 
membrane tethering protein involved in mammary development  [298]. 
56 
 
The DNA binding domain of redox sensitive NRF1 protein has been found in the 
regulatory regions of over 600 human genes [254]. Interestingly, while NRF1 expression 
is usually associated with modulating energy demand in proliferating cells, it is equally 
expressed in quiescence cells albeit by different mechanisms [254]. NRF1 is ubiquitously 
expressed in skeletal muscles, heart muscle, brown adipose fat, kidney and liver cells, 
and all cells with high energy demand [82;299;300]. NRF1 has been implicated in 
regulating genes unrelated to mitochondria biogenesis as well. For example, NRF1 
transcriptionally regulates expression of CXCR4, a co-receptor for human 
immunodeficiency virus infection [301], GluR2, a neural subunit that controls Ca2+ 
permeability of AMPA receptors [302], CD155, a human polio virus receptor that 
functions in cell adhesion [201], the X gene of hepatitis B virus (HPV) which functions in 
HBV replication in vivo [303], integrin-associated protein which plays  significant role in 
neurite outgrowth [296], GalNAc-T3 genes that function in glycosylation of mucin 
proteins in epithelial derived tumors [214], fragile X mental retardation 1 (FMR1) genes 
[304], and visinin-like protein-1 (VSNL1), a neuronal Ca2+ sensor protein [305] whose 
dysregulation is implicated in Alzheimer disease and schizophrenia [306], as well as 
cancer promotion and metastasis [307] .   
 
These findings suggest that redox sensitive NRF1 directly or indirectly participates in the 
processes that favor tumorigenic conversion and aberrant cell growth either by 
modulating energy demand and/or modulating expressions of genes involved in cell cycle 
controls. While NRF1’s actions on these genes are associated with normal physiological 
function, their dysregulation may lead to increased apoptosis or cell growth. In situations 
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where NRF1 expressions or functions are dysregulated by estrogen or estrogen induced 
oxidative stress, downstream genes likewise can be modulated and manifest adverse 
effects on cell’s fate. These effects may range from induction of apoptosis, to malignant 
transformation and growth of cancer cells. In mammary cells where aberrant cell growth 
or apoptosis that have been pre-initiated during estrogen metabolism and are under 
oxidative stress, oxidant induced NRF1 expression could further enhance excess growth 
in subsets of initiated cells.  
 
Estrogen induced ROS, NRF1 and therapeutic resistance: Redox sensitive NRF1 may 
play an important role in therapeutic resistance of breast cancer cells. Drug resistance of a 
number of cancer cells are characterized by oxidative stress and metastasis  
[224;308;309]. Tumors contain a subset of cells that both self renew and give rise to 
differentiated progeny. The self renewal properties of these cells are the real driving force 
behind tumor growth, metastasis and recurrence as they are responsible for tumor escape 
from conventional therapies resulting in disease relapse. Oxidative stress induces 
apoptosis in a number of cells but in drug resistant cancer cell, the opposite is true; 
oxidative stress facilitates malignant growth and metastasis of breast cancer cells by 
activating MMPs such as collagenases (MMP-2) and inhibiting antiproteases such as 
tissue inhibitory metalloproteases TIMP [310;311]. Interestingly high mitochondria 
content and oxidative stress are not only associated with breast cancer risk, they are also 
reported to be positively correlated with stages of cancer and therapeutic resistance 
[308;312;313]. Whether excess NRF1 expression mediates chemoresistance and 
malignant growth of cancer cells or whether increased oxidative state observed in cancer 
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cells are the manifestation of metabolically active cells is unknown. For example, 
treatment of several cancer cells lines with natural or synthetic flavonoids have been 
shown to restore chemo-sensitivity of these cells to cancer drugs [314;315]. Similarly, 
antioxidants have also been demonstrated to improve efficacies of chemo and radio-
therapies in several types of human cancers [316-320]. While some epidemiological 
studies confirm the effectiveness of antioxidant supplementation [321], many studies see 
no effect [322]. Similarly several in vitro and in vivo studies have shown that 
antioxidants can improve drug efficacies [323]. Antioxidants when enhance the anti 
cancer drug effects in vitro and in animal models, implies that lowering cancer redox 
status may be pertinent to its therapeutic response. If that is the case, then NRF1 
modulation of cellular redox status via mitochondria regulation may be central in oxidant 
mediated chemoresistance and malignant growth of cancer cells.  
 
The MDR1 gene (multidrug resistance gene 1) is a membrane glycoprotein that functions 
in effluxing drugs from within cells in a number of malignant cell types [324]. This gene 
is expressed in 42% of breast cancer cases and  patients with tumors expressing MDR1 
gene are three times more likely to experience chemotherapy failures than patients whose 
tumors were MDR1 negative [325]. TAM, one of the most popular drugs used to treat 
breast cancer and which have a high failure rate after prolong usage has been reported to 
up regulate MDR1 gene expression in breast cancer cells [326]. TAM exposures have 
been shown to increase NRF1 expression in MCF-7 breast cancer cells as well [327]. 
Interestingly, NRF1 is a transcriptional regulator of MDR1 gene expression in resistant 
oral cancer cells and in acute lymphoblastic leukemia (ALL) [328;329]. This could be a 
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mechanism that integrates drug induced oxidative stress, NRF1 expression and 
chemotherapeutic resistance in a number of cancers including breast cancer. While 
evidence of such association has not been reported in drug resistant human breast cancer 
cases, the rationales for such investigations are merited. There are indications that NRF1 
expression may correlate with different stages of breast cancer causing possible 
therapeutic failures [255;330].  
 
SUMMARY 
Until recently, it has been argued that hydroxylated metabolites of estrogen (catechol 
estrogens) participate in redox cycling in the endoplasmic reticula of cells and during this 
redox cycling of hyroxylated estrogens, ROS are generated. These redox reactions may 
occur in vivo, if free hydroxylated metabolites are in close proximity of activating 
enzymes within the target cells. Studies recently showed that estrogens or estrogen 
metabolites directly acting on mitochondria of epithelial or immune cells generate ROS. 
Based on the dose and time of induction, the ROS, seem to play dual functions in 
epithelial cells. While higher doses of ROS induce oxidative damage in the genome of 
cells leading to cell apoptosis, exposure of low levels of ROS produce genomic instability 
as well as transduce signals for cell growth, cell transformation and cell invasion. This 
view is consistent with findings that (i) estrogen-induced ROS can lead to increased 
phosphorylation of kinases, such as ERK, AKT, with this effect being attributed to the 
redox regulation of redox-sensitive phosphatses. Some of the nongenomic pathways by 
which estrogen activates MAPK and AKT pathways can be explained based on estrogen-
induced ROS transducing signal to their respective specific phosphatses. (ii) The 
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transcription factors AP-1, NRF1, E2F, NFkB and CREB are responsive to both oxidants 
and estrogen. It is possible that estrogen-induced ROS transduce signals to the nucleus 
for the activation of transcription factors such as AP-1, CREB, E2F, NF-kB, and NRF1 to 
regulate their downstream target genes involved in cell transformation, cell cycle, 
migration and invasion (Figure 4). (iii) There is growing evidence that estrogen-induced 
regulation of breast cancer cell cycle is coupled to rates of cellular metabolism, ROS 
levels and mitochondrial mass. (iv) Inhibition of cell transformation, growth of breast 
cancer cells and tumor formation by overexpression of ROS detoxifying genes and co-
treatment with antioxidants supports the role of ROS in estrogen-dependent breast cancer. 
(v) Estrogen-induced ROS by increasing genomic instability and by transducing signal 
through influencing redox sensitive transcription factors contribute to initiation as well as 
progression of breast cancer. It is envisioned that this is an important mechanism that 
drives the carcinogenesis process, but that it occurs in the context of other processes such 
as ER-mediated signaling and estrogen reactive metabolite-associated genotoxicity under 
investigations that may also contribute to the process. Taken together, estrogen-induced 
ROS mediated redox signaling seems to be complementary to the process of ER mediated 
cell transformation, growth and carcinogenesis. On the other hand, estrogen-induced 
ROS can function as independently reversible modifiers of phosphatases and activate 
kinases to trigger the transcription factors of target genes which participate in cancer 
progression. Further elaboration however, points to a convergence of both ER mediated 
signaling and E2 induced ROS signaling effects on the transcription factors which 
possibly act in synergy and contribute to the growth and cancer progression. 
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FIGURES AND LEGENDS 
 
 
Figure 1. Scheme showing metabolism of estrogen and redox cycling of its metabolites. 
CE = Catechol estrogen, SQ = Semi quinone, Q = Quinone, Q-SG = Quinone-glutathione 
conjugate. 
 
 
 
Figure 2. Estrogen induced cellular responses including carcinogenicity and growth of 
cancer cell  do not   correlate with the binding affinity of various estrogens to estrogen 
receptor (ER) and their potency both in vitro and in vivo  
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Figure 3. Dual Roles of ROS: High ROS levels induce oxidative damage and produce 
cell death, where as  low physiologic ROS levels facilitate cell-to-cell communication 
and cell proliferation 
 
 
Figure 4. Mechanism of ROS signaling in coordinated   inactivation of phosphatases and  
activation of kinases leading to  estrogen-mediated  changes in the expression  of genes 
involved in growth, apoptosis, transformation or invasion of cells 
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CHAPTER IV 
 
REACTIVE OXYGEN SPECIES CAUSES NEOPLASTIC  TRANSFORMATION 
AND XENOGRAFT GROWTH OF 4-HYDROXY ESTRADIOL-TRANSFORMED 
MAMMARY EPITHELIAL CELLS VIA TRANSDUCTION OF REDOX SIGNALS 
TO PI3K/AKT PATHWAY 
        
  Victor O. Okoh, Deodutta Roy 
Department of Environmental and Occupational Health, Florida International University, 
Miami, FL 33199-0001 
 
  
ABSTRACT  
Unopposed free estrogen (estrogen without progesterone) is a major risk factor for breast 
tumors. The mechanism by which estrogen is involved in the development of malignant 
breast lesions is not clear. We found that reactive oxygen species (ROS)- induced by 
repeated exposures to 4-hydroxy-estradiol, a predominant catechol metabolite of 17 β-
estradiol, caused transformation of immortalized human mammary epithelial cells. This 
was evident from inhibition of growth of tumors by overexpression of catalase as well as 
co-treatment with ebselen. Assessment of 4-hydroxy-estradiol transformed clones in 2-D 
and 3-D cell cultures showed that they formed spheroid structures in various matrices as 
well acquired invasive properties.  During 4-OH-E2-mediated malignant transformation 
process increased AKT phosphorylation through PI3K activation was observed. This 
PI3K-mediated phosphorylation of AKT in 4-OH-E2-induced malignant cells was 
inhibited by ROS modifiers as well as by silencing of AKT expression. RNA interference 
of AKT markedly inhibited 4-OH-E2-induced in vitro tumor formation. Among the genes 
being significantly up-regulated during the 4-OH-E2-mediated malignant transformation 
process well known proliferating cell nuclear antigen (PCNA) as well as the cell cycle 
genes cyclinB1 and Cdc25c9 were identified. The expression of these genes was 
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inhibited by ROS modifiers as well as by silencing of AKT expression and NRF1, a 
transcription factor that controls mitochondrial biogenesis (a major source of ROS). 
These studies demonstrate that: (i) 4-hyroxy-estradiol is one of the main estrogen 
metabolites that induce mammary tumorigenesis and (ii) ROS-mediated redox signaling 
leading to the activation of PI3K/AKT signaling plays an important role in 4-hydroxy-
estradiol-induced malignant phenotype of breast epithelial cells. In conclusion, ROS are 
important signaling molecules in the development of estrogen-induced malignant breast 
lesions that may be useful as therapeutic targets for prevention and treatment of breast 
cancer. 
 
INTRODUCTION 
 
Elevated lifetime estrogen exposure is a well-known major risk factor for breast cancer. 
A large body of epidemiological and experimental evidence points to a role for estrogen 
in the etiology of human breast cancer (1-9).  In experimental models, estrogens are 
complete breast carcinogens, as they are capable of initiating and triggering growth and 
selection to generate palpable malignancy (8-14).  However, the signaling mechanisms 
by which estrogen contributes in the initiation of breast cancer remain the subject of a 
long-standing controversy.  This is due, in part, to the inability to resolve whether 
estrogen or estrogen metabolites are procarcinogenic. 17β-estradiol (E2) is metabolized 
to 2- and 4-hydroxy-estradiols by cytochrome p450s.  We have previously shown that 
E2-induced renal tumor formation is decreased in animals exposed to inhibitors of 
estrogen metabolism or to hormonally potent estrogens undergoing reduced metabolic 
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conversion to catechol metabolites compared to E2 (10-12, 15). Russo and others have 
shown that E2 or 4-OH-E2 transform normal ERα negative breast epithelial MCF-10F 
cells (17-20). 17ß-estradiol-induced transformed MCF10F cells formed tumors in SCID 
mice.  4-OH-E2 is twice as capable of producing anchorage-independent growth as E2 in 
MCF10F cells (18,20). In contrast, neither 2-OH-E2 nor 2-OH-E1 are carcinogenic in 
vitro or in vivo (15). Similar results have been reported in MCF-10A cells exposed to 17 
beta-estradiol, equilenin or its catechol metabolite, 4-hydroxyequilenin (21,22). Recently, 
Parks et al (2009) demonstrated that treatment of MCF-10A cells with 4-OHE2 induced 
in vitro transformation of cells (23).  However, these studies in MCF-10A failed to show 
in vivo tumorigenicity, invasiveness or display other salient neoplastic properties.  In the 
present study we have established that repeated exposure of 4-OH-E2 to MCF-10A 
produced tumors both in vitro and in vivo.  
 
Induction of estrogen receptor (ER) upon estrogen exposure is not sufficient for the 
development of breast cancer. Recent studies indicate that mammary tumors can develop 
in the absence of a functional ERα (24).  Although tamoxifen and other antiestrogens are 
thought to prevent cancer through their actions at the ER, other mechanisms cannot be 
ruled out as these compounds also block metabolism and redox cycling of estrogen and 
are free radical scavengers (25).  4-OH-E2 induces an estrogenic response in the uterus of 
ERα null mice, and this response is not inhibited by the antiestrogen ICI182780 (26).  
These findings suggest that estrogen-dependent growth of cells is regulated not only by 
nuclear ER-mediated genomic signaling pathways, but also by non-ER pathway(s).  We 
believe that genomic and non-genomic actions of estrogen produce complementary 
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effects that are required for cellular transformation. Physiologically achievable 
concentrations of estrogen or estrogen metabolites directly acting on mitochondria of 
mammary epithelial or immune cells generate reactive oxygen species (ROS) (27). We 
previously showed that 17-β estradiol (E2)-induced DNA synthesis in breast cancer 
MCF-7 cells depends on mitochondrial oxidant signaling (28). In this study, we have 
extended our efforts on understanding how an E2 metabolite, 4-OH-E2 produces 
malignant phenotype through ROS signaling.  We investigated whether the susceptibility 
of normal breast epithelial MCF-10A cells to neoplastic transformation by estrogens 
depends on ROS-mediated redox signalings. We present here for the first time that 
oxidants induced by E2 and 4-OH-E2 but not 2-OH-E2 exposures mediate in vitro 
transformation of MCF-10A cells. 4-OH-E2 transformed cells are not only tumorigenic in 
mice but also display invasive properties as well as proliferate independent of growth 
factors.  Co-treatments of 4-OH-E2 transformed cells with biological or chemical ROS 
scavengers, or silencing of Akt1 prevented tumorigenic conversion of MCF-10A cells. 
We propose a mechanism of tumorigenic conversion that involves oxidant-mediated 
activation of redox sensitive PI3K/AKT signaling.  
 
MATERIALS AND METHODS 
 
Reagents 
17β-Estradiol (E2), 2-hydroxyestradiol (2-OH-E2), 4-hydroxyestradiol (4-OH-E2), 
Ebselen, N-acetyl-cysteine (NAC), and dimethylsulfoxide (DMSO) were all purchased 
from Sigma (St Louis, MO, USA). All antibodies; PI3K (p110), phospho PI3K (p85), 
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phospho-AKT (ser 473) and total AKT antibodies were purchased from Cell Signaling 
Technology Inc. (Boston, MA). All tissue cultures reagents were purchased from 
Invitrogen Corporation (CA) unless otherwise specified.  
 
Culture of MCF-10A cells and Adenovirus gene transfer 
Human mammary epithelial cells (MCF-10A) were obtained from American Type 
Culture Collection (ATCC) and were routinely cultured in phenol red-free DMEM-F12 
media (1:1) supplemented with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin (10 
μg/ml), epidermal growth factor (20 ng/ml), 100 ng/ml cholera toxin and penicillin-
streptomycin (100 μg/ml each) and incubated at 37°C in a humidified atmosphere 
containing 5% CO2. The cell culture media, serum, antibiotics, and growth supplements 
except cholera toxin (Calbiochem, La Jolla, CA) were purchased from Invitrogen Corp 
CA). For experimental purposes, culture media were changed to starvation media (serum 
free media + antibiotics) and allowed to incubate for 48 hrs prior to commencement of 
most experiments, unless otherwise indicated. Serum deprivation synchronizes cells in 
the G0/G1 phase of the cell cycle.  
 
The Adenovirus-CMV (empty vector), Adenovirus-MnSOD (AdCMVMnSOD), and 
Adenovirus-Catalase (AdCMVCat) constructs were purchased from ViraQuest, Inc. 
(North Liberty, IA, USA).  The adenovirus constructs used were replication-defective, 
E1- and E3-deleted recombinant adenovirus (29). Inserted into the E1 region of the 
adenovirus genome was either the human MnSOD or catalase gene, both of which are 
driven by a cytomegalovirus promoter. Cells were seeded in plates at 15%-70% 
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confluence. The following day, cells were infected with adenoviruses over-expressing 
MnSOD or catalase or vector at 100 MOI in serum free media. Control cells were treated 
with 100 MOI of the adenovirus-CMV construct. This viral load was determined to 
achieve greater than 50% growth arrests of MCF-10A cells without significant cell death 
for the duration of experiment.  Infected cells were cultured for 48 hrs after which cells 
were used for experiments. 
 
Akt1 RNAi transfections  
Pre-designed and verified human shRNA for Akt1 and corresponding null vectors were 
purchased from OriGene (OriGene Technologies, Inc. Rockville, MD). Transfections of 
cells were carried out in a sub-confluent cell population using FuGENE 6 (Roche) 
transfection reagents according to the manufacturer's protocol. Briefly, MCF10A cells 
were seeded in 6 well plates with growth factor supplemented media (SM) overnight. 
Post seeding, cells were transfected with 2 µl of Fugene-6 (Roche) preincubated for 
20 min at room temperature with 0.5 µg plasmid RNAi or its null controls (sham). Forty 
eight hrs post transfection, media were changed to serum-free (starvation media) media 
and incubated for an additional 48 hrs, after which cells were used for various 
experiments. Transfection efficiencies ranged between 60-80% as quantified by 
decreased protein expression levels.  
 
Cell viability assay 
CellTiter-Fluor™ Cell Viability kit was purchased from the Promega Corporation and 
used according to manufacturer’s instructions. Briefly, cells were seeded in 96 well plate 
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at a density of 1.0x104 cells/well, serum starved for 48 hrs and treated with estrogens or 
ROS modifiers. At the end of treatment procedure, substrate reagents (GF-AFC) were 
mixed with substrate buffer and dispensed into wells. This assay measures protease 
activity in live cells as opposed to MTT or MTS assay kits that measure formation of 
formazon crystals by mitochondrial enzymes. Plates were read on a fluorescence plate 
reader at 380–400 nm excitation and 505 nm emission and data is expressed as mean of 
three experiments +/- SD. 
 
Cell transformation 
The cell transformation was carried out by a modified protocol of Russo’s group (18). 
Briefly, MCF-10A cells were seeded at 30% density in a 10 cm dish. After 24 hrs of  
seeding, media were replaced with stavation media and allowed to culture for 48 hrs, and 
then cells were subjected to two treatment cycles with E2 or its catechol metabolites. A 
treatment cycle includes a 48 hr starvation period, 48 hr treatment period (100 ng/ml of 
either E2, 2-OHE2, and 4-OHE2), and 48 hr recovery period in growth media containing 
10% horse serum (HS) and no growth supplements. At the end of two treatment cycles, 
cells that would be used for immunoprecipitation and Western blot analysis were treated 
for an additional 30 mins with estrogens, lysed with RIPA buffer, immunoprecipitated 
and processed for western analysis. For anchorage independent growth assay 5000 
cells/well were used for colony formation assays in soft agar. 
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Anchorage independent growth 
Anchorage independent growth, an indicator of neoplastic transformation of cells, was 
assessed as previously described by Zhou et al (30). Briefly, base support agar were made 
fresh by diluting 1.0% molten agarose mixed with 1:1 2x culture media (2x DMEM/F12 
media, 20% HS, 2x Penicillin-Streptomycin and 200 pg/ml estrogens) to a final 0.5%. 
Molten agar was left at 42 oC in a water bath until dispensed at 200 ul/well in 48 well 
plates, then allowed to solidify for 4 hrs at room temperature. Top agarose overlay was 
made fresh by mixing 0.7% molten agarose with 2x culture media containing appropriate 
5000 cells/well, then gently overlaid over base agar. Cells were incubated for a minimum 
of 21 days in a 37°C incubator with 5% CO2.  Cultures were fed every week with top 
agar layer and colony formation was assumed when cell masses were 100 micron or 
greater as measured on a Nikon TE2000U inverted microscope (Nikon Corp., USA) with 
Metamorph software (Universal Imaging, USA). Images were acquired by using an 
Olympus C-5060 digital camera attached to the Nikon TE2000U inverted microscope 
with a 4x objective. Four wells were enumerated for each group and data expressed as 
mean of five wells +/- SD. 
 
Invasion and ductulogenic assays 
In order to determine invasiveness of transformed cells, several colonies were aseptically 
picked, dissociated with trypsin and cultured for 20-30 passages in a low growth factor 
media (DMEM F12, 5% FCS, 4 ng/ml EGF, 2.0 ng/ml insulin, 100 ng/ml hydrocortisone, 
1x Penicillin-Streptomycin) and eventually DMEM/F12 with 5% HS media, and 1x 
Penicillin-Streptomycin. Cells (5.0 x 103 cells/ml) for invasion assays were seeded over 
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8 μm pore transwell filter insert (Transwell, Coastar Cambridge, MA) precoated with 
Matrigel (Collaborative Research, Bedford, MA). Chemoattractants used were reduced 
growth factor supplemented media or media with 10% FBS media positive control cells 
MDA MB 231. Matrix invasion was allowed for 16 hrs at 37 °C in a CO2 incubator. The 
non-invaded cells inside chambers were wiped off with a cotton swab, and the filters 
were fixed, stained by Diff Quick (Sigma, St. Louis, MO), cut out and mounted onto 
glass slides. The total number of cells that crossed the membrane were counted under a 
light microscope, enumerated and expressed as fold increase compared to parent cell line. 
The experiments were repeated five times and results are expressed as the mean ±S.D. 
 
For ductulogenesis, 1.0x103 cells/ml of transformed cells (p121 and screened from 3x 
Matrigel), MDA MB 231 and  parental MCF-10A cells were mixed with collagen 
(Collagen Co., Palo Alto, CA, USA) and seeded in chamber slides precoated also with 
collagen. Cells were incubated for three weeks with bi-weekly feeding with 5% HS 
media. To confirm spheroid formation from collagen matrix, we diluted HuBiogel, a 
human matrix mimetic (VIVO Biosciences Inc.), 1:3 with media and coated 0.22 micron 
pore transwell filter inserts for 6 hrs at 37 oC incubator. Cells (1.0 x 103) were seeded into 
each insert and chemoattractant media (DMEM/F12, 5% HS, 1x Penicillin-Streptomycin) 
were added at bottom of insert. Cells were cultured for 14 days with media changed twice 
weekly. Images were acquired with a Olympus C-5060 digital camera under an inverted 
microscope with 4x objective as described above. 
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Chemical antioxidant treatments  
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also 
removes both H2O2 and peroxynitrite) or NAC (a precursor of glutathione and scavenger 
of ROS) (31, 32) varies according to the experiments design. For all experiments, 40 μM 
Ebselen and 1.0 mM NAC were used for cell treatments. For example, in DCF assays, 
antioxidants were pre-loaded onto cells for 2-4 hrs before ROS measurement commences. 
For BrdU assays, cells were cultured with the chemical antioxidants throughout the 
experimental procedure. For transformation regimen, antioxidants were applied to cells 
each time cells were treated with estrogens. For anchorage independent growth assays, 
antioxidants were added to soft agar matrix media and during weekly feeding of colonies.   
 
Measurement of reactive oxygen species (ROS) 
Cellular ROS were measured on a 96 well plate reader and confocal fluorescence 
microscopy as previously described by Felty et al (27). Briefly MCF-10A cells were 
seeded at a concentration of 1.0 × 104 cells per well in black 96-well flat bottom plates 
(ThermoFisher Scientific Inc. USA) and allowed to adhere overnight. Post seeding, cells 
were serum starved for 48 hrs after which they were pretreated for 4 hrs with chemical 
antioxidants Ebselen or NAC (Sigma USA) diluted in Hank's balanced salt solution 
(HBSS) followed by incubation with 10 µM 2',7'-dichlorofluorescin diacetate (DCFH-
DA) (Invitrogen Corp) for 20 min. Cells were rinsed with HBSS followed by various 
estrogen treatments as described in the figure legends. DCFH-DA is a non-fluorescent 
cell-permeable compound, which is acted upon by endogenous esterase that removes the 
acetate groups generating DCFH. In the presence of intracellular ROS, DCFH is rapidly 
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oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF). The oxidative products 
were measured with a Tecan Genios 96 well microplate reader using 485 and 535 nm as 
excitation and emission filters respectively or fluorescence images were acquired on a 
Nikon TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1 
laser scanning confocal microscope system (Nikon Corp., USA). The built-in Nikon EZ-
C1 software was used for confocal image acquisition and analyses.  DCFH-DA stock 
solutions were diluted at a 1:1 ratio with Pluronic F-127 (20% w/v). Data are expressed 
as mean of three experiments +/- SD. 
 
Immunoprecipitation and Western Blot Analysis 
After the respective treatments, cells were rinsed twice with ice cold phosphate buffered 
saline (PBS), harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% 
Nonidet P-40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors 
(Roche). Samples were diluted to 500 µg of protein in 1 ml of lysis buffer, and pre-
cleared for 1 hr at 4 °C with 10 µl of 1:1 slurry of protein A-agarose beads (Invitrogen 
Corp) in lysis buffer. After a brief centrifugation to remove pre-cleared beads, 2 µg of 
desired capture antibodies were added to each supernatant and incubated on a rocking 
platform at 4 °C overnight and captured proteins were precipitated with 40 µl of protein 
A-agarose beads for 2 hr. The beads were washed five times with lysis buffer and 
resuspended in 40 μL sample loading buffer, subjected to electrophoresis and electro-
blotted onto a PVDF nylon membrane. Primary antibodies used for Western blots were  
diluted 1:1000 in phosphate buffered saline Tween-20, PBST  and horseradish 
peroxidase-conjugated secondary antibodies were diluted 1:50,000 in PBST. Blots were 
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treated with ECL reagents (Amersham Biotech), and proteins were detected by 
autoradiography. Band intensity was quantified with Bio-Rad Gel Doc Imaging System. 
 
Immunofluorescence labeling  
MCF-10A cells were seeded and treated in chamber slides as indicated in legends to the 
figures. Post treatment, cells were fixed with ice cold methanol for 15mins, and 
permeabilized with 0.5% Triton X-100 for 30 mins. Cells were blocked with 1% normal 
goat sera for 1 hr after which they were probed with antibodies diluted 1:500 for Akt and 
1:500 for phospho AKT. Alexa Fluor labeled secondary antibody directed against AKT 
antibody was diluted 1:1000. The confocal fluorescence images were scanned on a Nikon 
TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1 laser 
scanning confocal microscope system (Nikon Corp., USA). The z-series scanning was 
done at every 1 μm up to a z-depth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2 
Plan Fluor oil immersion objective. The built-in Nikon EZ-C1 software was used for 
confocal image acquisition and analyses.  
 
RESULTS 
 
Exposure of MCF-10A cells to 17β-estradiol (E2) and its metabolites produces a rapid 
increase in ROS levels: Before carrying out cell transformation, we characterized normal 
human mammary epithelial cells for their ability to produce ROS in response to 17 beta-
estradiol (E2) exposure. These cells respond to E2 in terms of producing ROS very 
similar to breast cancer cells. ROS production by E2 and its metabolites, 2-OH-E2 and 4-
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OH-E2 in normal human mammary epithelial MCF-10A cells was dose-dependent (Fig. 1 
A,B). 4-OH-E2 induced significantly more ROS in these cells compared to E2 and 2-
OHE2. The abilities of these estrogens to produce ROS were inhibited by overexpression 
of catalase or treatment with Ebselen or NAC (Fig. 1C). When MnSOD were over-
expressed in these cells, ROS levels increased significantly compared to cells treated with 
estrogen alone (Fig. 1C). We also measured the cellular protease activities to rule out the 
possibility that the differential ROS levels were not as a result of differential cell 
densities or viability. Our results indicate that 4-OH-E2 is the most effective in 
generating intracellular ROS in MCF-10A cells. Mitochondria may be the major source 
of estrogen induced intracellular ROS, because overexpression of MnSOD, a 
mitochondria superoxide dismutase that converts super oxides to hydrogen peroxide, 
increased the ROS content maximally. 
 
Exposure of MCF-10A cells to 17β-estradiol (E2) and its catechol metabolites induced 
dose-dependent colony formation: Both MCF-10F and MCF-10A cells are spontaneously 
immortalized, ER negative normal human breast epithelial cell lines that are non 
tumorigenic in vivo. We used the anchorage independent growth (AIG) assay to examine 
cell transforming ability of E2 by detecting AIG positive colony formation. E2 exposure 
to MCF-10A cells produced dose dependent increase in colony formation. We found that 
repeated treatments of MCF-10A cells with various doses of E2 or its catechol 
metabolites induced in vitro transformation of MCF-10A cells in a dose dependent 
manner (Fig 2). 4-OH-E2 is more potent in transforming normal mammary epithelial 
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cells compared to E2, while 2-OHE2 is a weakly transforming metabolite of MCF-10A 
cells (Fig 2).  
 
Clonogenic expansion and invasiveness of 4-OH-E2 transformed MCF-10A cells: Since 
4-OH-E2 induced the highest transforming frequency, we further examined whether 4-
OH-E2 induced colonies are clonogenic. We picked several colonies from each soft agar 
at the end of 21days and cultured them in media with 10% FBS (designated as a regular 
media -RM). Several of these clones did not survive beyond the 10th passage in RM. 
However, of the 5 that survived up to the 21st passage, we determined whether these cells 
have acquired anchorage independent growth properties, a hallmark for transformed cells 
and whether these clones also respond to estrogens. Cells were fed twice per week and 
cultured for 21days. Colonies were counted from quadruplicate wells, (± SD). One of our 
clones was highly clonogenic (P21) and responsive to E2. We labelled this clone as 
MCF-10T15 (Figure 3A).  Analysis of the invasive property of this clone MCF-10T15 by 
invasion assay showed that it is highly invasive (Fig. 3B). 
 
 3-D Spheroid formation of 4-OH-E2 transformed clone: To assess whether 4-OHE2 
transformed MCF-10A cells are neoplastic, we picked few colonies from anchorage 
independent growth assay and cultured them repeatedly in growth factor reduced media, 
then assessed cells periodically for their ability to form spheroid structures in collagen 
coated 0.22 μm transwell inserts, or in a rotary vessel using HuBiogel, a memetic of 
human stromal matrix. We found that over progressive passages, the clones in collagen 
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matrix assumed a more heterogeneous population with small masses (p0) as opposed to 
homogenous population with aggressive phenotype (p200) (Fig. 4).  
 
The tumorigenic conversion ability of 4-OH-E2-transformed MCF-10A cells was further 
investigated by 3-D culture using HuBiogelTM. For 3-D culture, anchorage-independent 
MCF-10A human mammary gland epithelial cells transformed by 4-OH-E2 treatment 
were mixed with 3D HuBiogelTM matrix containing DMEM-F12, seeded into 55 ml 
rotating-wall vessels and incubated at 37°C for 16 days. These conditions allow for the 
spontaneous formation of tissue-like spheroids (Fig 4).   
 
 Loss of ductulogenicity in 4-OH-E2 transformed cells: The ability to form ductile 
structures are characteristic of normal mammary epithelial in collagen matrix. Loss of 
this ability is a hallmark of transformed cells. Assessment of transformed cells in a 
collagen matrix indicates that these cells have indeed lost their ability to form ductile 
structures upon repeated treatment with 4-OHE2 (Fig 5A). This phenotypic change was 
evident right from p0 cell population and continued even at p121.  
 
Aggressive phenotype enrichment: Initial invasion assessment of fifteen colonies from 
soft agar assay indicates that three colonies have acquired the ability to invade Matrigel 
matrix. These clones were subsequently cultured in growth factor reduced media over 
several generations and assessed periodically for invasive phenotype. We observed that 
successive passage of these clones increased their ability to invade Matrigel matrix. One 
of the clones termed clone c (MCF-10Ac) had actually acquired invasion capability that 
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is about 30% that of MDA MB 231 cell line at passage (Fig 5B). The other clones had 
lesser invasive abilities compared to MCF-10Ac (data not shown).  
 
4-OH-E2 treatment causes epithelial to mesenchymal transition (EMT) in MCF10A cells: 
We found that the 4-OH-E2 transformed clones looked very different from WT both in 
morphology, size and time it takes to form a sheet upon seeding. Figs. 5C, 1,2 shows that 
transformed clones were bigger than their WT counterpart in monolayer culture just after 
seeding (3 hrs). In addition, transformed cells displayed an abnormal differentiation 
pattern and loss of cell polarity, all phenotypes of cancer cells (Fig. 5C 3,4). The majority 
of clones exhibited morphological changes that resembled epithelial to mesenchymal 
transition. As shown in Figure 8b, MCF10A cells showed highly organized cell-cell 
adhesion and cell contact, whereas 4-OH-E2 transformed-MCF10A cells had an 
elongated and refractive appearance with cell scattering and loss of cell-cell contacts. The 
cobblestone-like morphology of MCF10A cells at confluency was replaced in 4-OH-E2 
transformed-MCF10A cells by a spindle-like fibroblastic morphology. 
 
Inhibition of 4-OH-E2-induced cell transformation by ROS modifiers: In cells 
overexpressed with adenovirus construct containing  catalase and MnSOD that lowers 
oxidant production as well as in mtTFA silenced cells, E2 produced fewer colonies 
compared to E2 alone  (Fig 6). Treatment of cells with chemical ROS scavenger (Ebselen 
or NAC) significantly inhibited the abilities of E2 or 4-OHE2 to induce neoplastic 
transformation of MCF-10A cells as assessed by inability to form colonies and grow in 
soft agar assays (Fig 6).  This implies that oxidants induced by E2 and 4-OHE2 are 
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necessary for tumorigenic transformation of MCF-10A cells and when oxidant levels 
were scavenged by biological and chemical antioxidants, estrogen induced transformation 
of mammary cells was inhibited.  
The growth of the E2-induced transformed clone was highly responsive to E2 and was 
inhibited by Ebselen and N-acetyl cysteine. Antioxidants reduce E2-induced DNA 
synthesis in MCF-10A transformed cells (Figure 7). As shown in Figure 8, treatment with 
E2 produced spheroids (Left Upper Panel). Overexpression of catalase and Ebselen 
inhibited E2-induced tumor spheroid formation. Cells were labeled with CFSE using the 
Vybrant kit for checking viability. All spheroids showing the green fluorophore (Fig. 8 
Right Upper Panel) indicate that cells in tumor spheroids are alive.  
 
4-OHE2 induced ROS activates PI3K/AKT signaling pathway: Consequences of elevated 
ROS in cells are apoptotic cell death, quiescence or cell transformation and neoplastic 
growth (33,34) The signaling pathway associated with survival of cells under oxidative 
stress is attributed in part to activation of PI3K and AKT signaling pathways (34, 35). 
Therefore, we determined whether estrogen induced oxidants in normal mammary 
epithelial cells activate PI3K and AKT signaling pathways during neoplastic 
transformations of MCF-10A. We found  that repeated treatments of MCF-10A cells with 
E2 and 4-OHE2 increased phosphorylation of both PI3K and AKT in cells treated with 
regimen of estrogen which produced cell transformation (Fig 9). Phosphorylation of both 
PI3K and AKT was attenuated by co-treatment  with either biological or chemical ROS 
modifiers (Fig 5). The activation of PI3K and AKT activation by 4-OHE2 were about 
30% and 120% higher than E2 or 2-OHE2 respectively (Fig 10). Interestingly, we also 
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observed that silencing of Akt1 (Fig 11A), the downstream recipient of PI3K activation 
and Akt1 regulates proliferation and growth of mammalian cells significantly diminished 
4-OHE2 induced neoplastic transformations of MCF-10A cells (Fig 11B). These data 
support that intracellular ROS induced by 4-OHE2 may activate AKT signaling pathway 
which favors survival and proliferation of cells, both required for malignant 
transformation.  
 
4-OH-E2-induced ROS modulates cell cycle genes through a nongenomic, ER 
independent signaling pathway:  We investigated whether 4-OH-E2-induced ROS 
signaling is involved in the modulation of cell cycle genes in the conversion of  normal 
breast epithelial cells to malignant cells. Using a normal cell line (MCF-10A) that 
develop transformed clones in response to 4-OH-E2 or E2, the expression of cell cycle 
genes, cyclin D and pcna were measured by real time RT-PCR (Fig. 12). After exposure 
of 8h following two 48 hr treatments with 4-OH-E2; we observed an approximately 1.34-
, and 1.54- fold increase in the mRNA expression of pcna and cyclin D1. Overexpression 
of MnSOD and catalase as well as co-treatment with Ebselen and NAC markedly 
decreased 4-OH-E2 induced pcna and cyclin D1 expression compared to E2 treated cells.   
 
DISCUSSIONS 
Our results showed that E2 and its metabolite, 4-OH-E2, elicited transformed phenotypes 
in MCF-10A cells, which are estrogen receptor-α (ERα) negative.  Similar results have 
been reported in MCF-10A cells exposed to E2 or its catechol metabolite and 4-
hydroxyequilenin (21-23). Russo and others have shown that E2 or 4-OH-E2 transformed 
111 
 
MCF-10F cells were also ERα negative (17-20).  Our results are in agreement with 
previous studies that 4-OH-E2 is twice as carcinogenic as E2.
 
  In contrast, neither 2-OH-
E2 is carcinogenic in vitro or in vivo (15).  Interestingly, both 2-OH-E2 and 2-OH-E1 are 
capable of producing ROS and undergo metabolic redox cycling like 4-OH-E2.  The lack 
of carcinogenicity of 2-hydroxylated estrogen metabolites in vivo may be due to their 
rapid inactivation by COMT-mediated O-methylation, rapid clearance, and weak 
estrogenic hormonal activity as compared with 4-OH-E2 (10-12, 36,37).  Most 
importantly, it may be due to 2-MeO-E2, the major product of COMT-mediated O-
methylation of 2-OH-E2 that possesses unique anti-tumorigenic activity.  These studies 
support the concept that E2 and its main metabolite 4-OH-E2 are carcinogenic in breast 
epithelial cells.   
Recent studies indicate that mammary tumors can develop in the absence of a functional 
ERα (24).  Although tamoxifen and other antiestrogens are thought to prevent cancer 
through their actions at the ER, other mechanisms cannot be ruled out as these 
compounds also block metabolism and redox cycling of estrogen and are free radical 
scavengers (25).  4-OH-E2 induces an estrogenic response in the uterus of ERα null 
mice, and this response is not inhibited by the antiestrogen ICI182780 (26).  These 
findings suggest that estrogen-dependent growth of cells is regulated not only by nuclear 
ER-mediated genomic signaling pathways, but also by non-genomic pathway(s).  
Genomic and non-genomic actions of estrogen may produce complementary effects that 
are required for cellular transformation.  Estrogen is genotoxic, as seen by the presence of 
DNA adducts in mammary tissues from ERKO/Wnt-1 mice (38,39).  Although the 
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formation of DNA adducts may lead to gene mutation, this type of DNA damage appears 
to be a late event arising from E2 metabolism.  We have recently shown that estrogen 
induces rapid formation of ROS in MCF-7 cells (27,40). 4-OH-E2 has been implicated in 
transforming MCF-10A cells via ROS formation based on inhibition of anchorage 
independent growth of MCF-10A cells (23). This study did not show in vivo tumor 
formation of transformed cells. The main difference between of our work and previous 
reports is that our transformed clones are tumorigenic in mice and ROS modifiers. The 
overexpression of catalase that converts hydrogen peroxide to water and Ebselen, a 
gluthione peroxidase mimic,  inhibited cell transformation and tumor formation.  This is 
important because MCF-10A cells are easily transformed in an in vitro system, even by 
mild stress such as reduced growth factor media or hypoxic conditions (41).  
Both E2 and 4-OH-E2 treatment of MCF-10A cells, increased the formation of ROS as 
compared to untreated cells, whereas 2-OHE2 induced the minimum increase in ROS 
formation in MCF-10A cells. Over-expression of biological ROS modifiers and chemical 
scavengers of ROS prevented 4-OH-E2-induced anchorage independent growth of MCF-
10A cells. We observed similar results with 3-D culture of transformed cells using 
HuBiogel and xenograft tumor growth. These findings suggest that ROS induced by 
repeated exposures to 4-OH-E2, a predominant catechol metabolite of E2, cause 
transformation of immortalized human mammary epithelial cells with malignant growth 
in nude mice. Since 4-OH-E2 induces more ROS formation compared to E2 in MCF10A 
cells, the accumulation of 4-OH-E2 in the breast is expected to augment ROS formation 
here as well.  4-OH-E2 strongly binds to ER (42,43) and it takes longer to dissociate from 
the ER than E2 (44).  The greater ROS production, ER action, and breast tissue 
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accumulation of 4-OH-E2 compared to E2 may account for its greater carcinogenicity in 
MCF-10A cells.   
 
We and others have shown that mitochondria are significant targets of estrogen (27,40). 
Recently, we reported that physiological concentrations of E2 stimulate a rapid 
production of intracellular ROS in epithelial cells which depends on cell adhesion, the 
cytoskeleton, and integrins (27,40). These events occur earlier than ER-mediated 
genomic actions. E2-induced ROS production does not depend on the presence of ER on 
breast cancer cells as ER-cell lines MDA-MB 468 produced ROS equal to or more than 
that of ER+ MCF7, T47D, and ZR75cell lines (27).  
 
It has been wrongly concluded by Parks et al (23) that redox cycling of catechol estrogen 
is the source of ROS. Catechol estrogens, particularly 4-OH-E2, via nonenzymatic 
autoxidation, may undergo redox cycling to produce reactive semiquinone and quinone 
intermediates with concomitant production of ROS (10-12). However, this redox reaction 
of catechol estrogens is enhanced in the presence of Cu2+ or Fe3+ ions and by enzymatic 
catalysis by cytochrome P450 oxidases or peroxidases, which is accompanied with an 
increased generation of ROS. Furthermore, Parks et al (23) implied the contribution of 
redox cycling of catechol estrogen generating ROS based on indirect evidence using a 
non-specific inhibitor of cytochromes P450, SKF525A and dicumarol, an inhibitor of 
quinine reductase. Dicumarol can also inhibit mitochondrial diaphorase, which is 
involved in reduction of Coenzyme Q10 in the mitochondria (45). Similarly, SKF-525A 
inhibits mitochondrial oxidative metabolism in intact cells and isolated mitochondria 
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(46). Lower ROS formation observed in the presence of SKF525A and dicumarol may be 
as a result of inhibition of the mitochondrial electron transport chain. Increased ROS 
formation is observed within 30 seconds of E2 treatment (40). Due to the speed of ROS 
production as observed in our study, it is unlikely that redox cycling of 4-OHE2 is the 
source of these oxidants. Furthermore, in our studies of E2-induced ROS generation in 
MCF-7 and other cells, hydroxylated estrogen metabolites or adducts immediately after 
addition of E2 were not detected which also rules out the possibility of ROS generation 
by redox cycling of hydroxylated estrogens. 
 
Little is known about the potential direct involvement of ROS signaling in breast cancer 
development. However, we and others have recently discovered that estrogen-induced 
oxidative bursts occur exclusively in perinuclear regions. This surge in ROS production 
may target inducible promoters, signaling transcription-initiation complex assembly and 
subsequently, driving estrogen-induced gene expression (28). While studying 
mitochondrial regulators of cell cycle progression, we discovered that E2-induced G1 to 
S phase transition is associated with an increase in intracellular ROS levels (28).  These 
findings strongly support the idea that both E2-induced ROS and ER activity are required 
for breast cancer cell proliferation (28).  When produced at high levels, ROS levels 
induce oxidative damage and G0/G1 arrest.  However, when present at physiologic 
levels, ROS mediate essential cellular functions such as cell-to-cell communication and 
proliferation.  For example, estrogen-generated ROS mediate early G1 gene expression, 
as seen by the ability of antioxidants to block this effect (28).  We now know that the 
delicate intracellular interplay between oxidizing and reducing equivalents allows ROS to 
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function as second messengers in signaling pathways controlling cellular proliferation 
and transformation (47,48).  Recent studies implicate a role for ROS in cell 
transformation and several lines of indirect evidence support a role for ROS in the 
development of breast cancer (49,50),  We recently found that, in Syrian hamsters, 
estradiol-induced kidney tumor formation was reduced by the antioxidants N-
acetylcysteine, vitamin C, sodium 2-mercaptoethanesulfonate (cytoprotective thiol-
containing agent), and Ebselen (51,52).  Consistent with this finding, estrogen-induced 
testicular and uterine cancers are prevented by pentoxifylline, a compound with 
antioxidant effects stemming from its ability to block synthesis of the inflammatory 
mediators, IL-1β and TNFα (49).  Overexpression of manganese superoxide dismutase 
(MnSOD), the mitochondrial enzyme responsible for superoxide detoxification, blocks 
the appearance of malignant phenotypes (53), and the loss of this enzyme partly 
contributes to malignant phenotypes (54,55).  Not surprisingly, MnSOD knockout mice 
exhibit increased oxidative DNA damage (56).  MnSOD expression is less frequently 
found in tumor cells of invasive breast carcinomas than in non-neoplastic breast epithelial 
cells (57).  Several epidemiological studies have shown that MnSOD polymorphic 
populations have an increased risk of breast cancer (59-60).  The recent findings that 4-
OH-E2 accumulates in the breast tissue of cancer subjects (61-63) and predominant 4-
hydroxylation of E2 occurs in the target organs of cancers (64-66) suggest that the target 
organ of cancer would be particularly sensitive to 4-OH-E2-induced ROS formation.  In 
our studies, overexpression of catalase and antioxidants (N-acetyl cysteine and Ebselen) 
prevented 4-OH-E2-induced anchorage independent growth of MCF-10A cells. These 
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results indicate that 4-OH-E2-induced cell transformation may be mediated, in part, by 
redox-sensitive signal transduction pathways.    
 
Both AKT and ERK are redox sensitive kinases.  Thus, 4-OH-E2-generated ROS may 
activate ERK or AKT, which could then directly phosphorylate and activate transcription 
factors controlling cell cycle, cell migration or cell invasion genes. Several investigators 
have concluded that estrogen-induced AKT activation is promoted by membrane bound 
ERα or ERβ (67,68). There are no known functional motifs within the structure of the ER 
that can promote second messenger signaling. There are reports which show no 
correlation between ERα/β expression patterns and the activation of AKT-1/-2 in 
estrogen treated breast cancer cell lines. 17α-estradiol, through an ER independent 
mechanism, activates PI3K-AKT signaling (69). Recently, Lee et.al. (67) reported that 
up-regulation of PI3K/AKT signaling by E2 is mediated through activation of ERα, but 
not ERβ. In ovarian cancer cells, 4-OH-E2 induces AKT phosphorylation while 2-OH-E2 
did not (70). Our study showed that 4-OH-E2 increased AKT poshphorylation in ERα 
lacking MCF-10 cells, while 2-OH-E2 did not increase AKT phosphorylation.  The PI3K 
inhibitor, LY294002, and ROS modifiers blocked 4-OH-E2-induced AKT 
phosphorylation. AKT activity depends on its phosphorylation, which is positively 
regulated by PI3K and negatively regulated by a class of protein phosphatases (PPs) (71). 
AKT can be activated by both E2 and H2O2 (67-73).  ROS reversibly regulate cysteine-
based phosphatases (reviewed in 47). The ability of E2 and H2O2 to activate AKT may be 
attributable to inactivation of cysteine-based phosphatases by ROS (47, 67-73).  The 
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reversible inactivation of phosphatases, such CDC25A and PTEN, by estrogen-induced 
ROS may be a key component of AKT activation (47,72).   
 
The PI3K/Akt signaling pathway seems ubiquitous to carcinogenic conversions (74-76). 
Oxidant mediated hyperactivation of AKT can phosphorylate and inhibit pro-apoptotic 
proteins such as BAD and  caspase 9 while phosphorylating and activating pro-growth 
transcription factors such as ASK1 and GSK3. The outcome of this hyperactivation could 
therefore be cells surviving and proliferating in a high oxidative state. If these cells have 
been initiated by acquisition of pre-tumorigenic lesions by 4-OHE2 metabolism, oxidant 
mediated growth of these cells could be the basis for malignant transformation of 
mammary cells. The loss of PTEN activity, hyperactivation of PI3K/AKT signaling 
pathway, excess estrogen exposure and oxidative stress have been implicated in breast 
carcinogenesis (47).  In this study, we also observed that PI3K/AKT signaling proteins 
were hyperactivated in MCF-10A cells treated repeatedly with estradiol and 4-OHE2 
though the activations of 4-OHE2 were more than those of E2 and 2-OHE2 respectively. 
Importantly, chemical and biological antioxidant mitigated PI3K/AKT activations and 
inhibited estrogen induced mammary tumorigenesis. To rule out the possibility that 
antioxidant regulation of PI3K/AKT activations are not related to estrogen induced 
mammary tumorigenesis, we silenced AKT1 expression, the AKT isoform implicated in 
survival, growth and tumorigenesis of cells including mammary cells (74-76). We found 
that silencing of this gene prevented estrogen’s ability to transform MCF-10A cells. 
These data indicates that estrogen induced redox activation of PI3K/AKT signaling 
pathway is essential for mammary tumorigenesis.  
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A substantial number of experimental and epidemiological studies support an important 
role for AKT in tumorigenesis. PI3-kinase and AKT act as oncogenic determinants in 
several human cancers. AKT genes are amplified or overexpressed in gastric, ovarian, 
breast, pancreatic, and prostate cancers (77,78). AKT1 levels are higher in a panel of 
human breast carcinoma cell lines than in breast epithelial cells, particularly those with 
higher HER2 expression. AKT1 activity is increased by either E2 or IGF-I in estrogen-
dependent MCF-7 cells, and both factors act synergistically to increase AKT1 activity 
and promote cell proliferation (79). Transgenic mice expressing AIB1 (ER co-activator) 
in the mammary gland develop mammary hyperplasia and mammary carcinomas. 
Increased activation of the PI3K/AKT pathway is implicated in the development of 
mammary carcinoma in AIBI mice (80). AKT activation amplifies the proliferation 
induced by cyclin D1 or HPV E7 during morphogenesis and cooperates with these 
oncoproteins to promote proliferation and morphogenesis in the absence of growth factors 
(81). H-ras transformation of MCF-10A cells results in upregulation of MAP kinase and 
PI3-kinase signals (82). Similarly benzo(a)pyrene quinone is reported to induce 
anchorage-independent growth of MCF-10A cells which depends on the activation of 
PI3K/AKT activation (83). Chronic activation of AKT2 leads to an increase of the events 
associated with tumorigenesis (84). Most importantly, AKT activation disrupts mammary 
acinar architecture and enhances proliferation in an mTOR-dependent manner (80). Our 
study showed that the exposure of 4-OH-E2 or E2 to normal human breast epithelial 
MCF-10A cells produced transformed phenotypes. These cells show increased AKT and 
increased cell number in the absence of EGF or insulin. The 4-OH-E2-induced cell 
proliferation was attenuated by the antioxidant N-acetylcysteine. Overexpression of 
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catalase and MnSOD also reduced the extent of 4-OH-E2-dependent increased cell 
growth and AKT activation. Taken together, these data indicate that 4-OH-E2-induced 
ROS activates the AKT pathway in MCF-10A cells to support the growth of cells in 
growth factor deficient conditions. 
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FIGURES AND LEGENDS 
 
 
 
Fig. 1. 17β-estradiol and its catechol metabolites induce ROS production in MCF-10A 
cells in a dose dependent manner. Cells were seeded at 1.0 × 104 cells per well. 24 hrs 
post seeding, cells were serum starved for 48 hrs in DMEM/F12 (1:1) with 1x penstrep. 
For the groups that were treated with NAC or ebselen, these cells were pre-treated with 
1.0 mM NAC, pH 7.0 or 40 µM ebselen for 4 hrs before DCF assay. For the groups that 
were treated with catalase or manganese super dismutase (MnSOD), these cells were 
infected with adenovirus over-expressing these ROS modifiers at moi 100 for 48 hrs prior 
to seeding for DCF assay. At end of starvation and antioxidant treatments, cells were 
preloaded with 10 µM 2',7'-dichlorofluorescin diacetate (DCFH-DA) diluted in Hanks 
Balance Saline Solution (HBSS), and incubated for 20 mins in 37oC incubator. Post DCF 
treatment, cells were washed with HBSS and treated with various concentrations of 
estrogens diluted in HBSS and fluorescence emission read on Tecan Genios microplate 
reader using 485 and 535 nm as excitation and emission filters respectively. Fluorescence 
129 
 
images were acquired on confocal microscopy. To determine whether observed ROS 
modification by estrogens or antioxidant were due to differential cell density or viability, 
duplicates plates were seeded and treated with ROS modifiers as described above, then 
challenged with 100 ng/ml 4-OHE2. Instead of loading DCF, cells were treated with 
CellTiter-Fluor™ as described by manufacturer. This reagent measures protease activity 
as an indication of cell viability. Plates were read on fluorescence plate reader at 400nm 
excitation and 505nm emission and data expressed as mean of three-five experiments +/- 
SE. (A) Histogram of fluorescence emitted by the oxidation of DCFH-DA by estrogens 
and read on Tecan plate reader in 5 min. Data is expressed as mean of +/- SE of five 
experiments. (*) Indicates significantly different from control (DMSO) groups while (#) 
indicates significant different from 4-OHE2, (P<0.05). (B) Confocal images of cells 
preloaded with 1.0 μM DCF and treated with 100 pg/ml of various estrogens, and 
fluorescence image acquired 5 min after treatment. (I) DMSO, (II) E2, (III) 4-OHE2, (IV) 
2-OHE2. (C) Histogram of ROS modulation by 4-OHE2 versus viable cells. (**) 
Indicates significantly different from control (DMSO) groups while (#) indicates 
significant different from 4-OHE2, (P<0.05) 
 
 
 
Fig. 2. E2 and 4-OHE2, but not 2-OHE2 transforms MCF-10A cells in a dose dependent 
manner. MCF-10A cells were seeded at sub-confluence and serum deprived for 48 hrs 
after which they were exposed to various doses of E2 or its catechol metabolites for two 
treatment cycles of 48 hrs each, interspersed with 48 hrs recovery period. (I) DMSO, (II-
III) 5.0 and 50.0 μg/ml BaP as positive controls respectively. We used estrogen 
concentrations of 0.1, 10.0 and 100.0 ng/ml respectively for transformation experiments; 
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IV-VI) E2; VII-IX) 4-OHE2 and X-XII) 2-OHE2 treatments.  Fig 2B) Fold differences in 
colony formations were compared to colonies from 0.1ng/ml estrogen treatments. Data 
expressed as mean of four wells +/- SD. (**) Indicates significantly different from control 
0.1 ng/ml groups while (#) indicates significant different from 100.0 ng/ml 4-OHE2 
treated group, (P<0.05) 
 
  
 
 
 
Fig. 3. Clonogenic expansion and invasiveness of 4-OH-E2 transformed MCF-10A cells: 
A. For colonogenic expansion analysis, we picked several colonies from each soft agar at 
the end of 21days and cultured them in media with 10% FBS, designated regular media 
(RM). Several of these clones did not passage beyond 10th passage in RM. However, of 
the 5 that survived up to the 21st passage, we seeded these cells at 50 k cells/well in soft 
agar to determine whether these cells have acquired anchorage independent growth 
properties, a hallmark for transformed cells and whether these clones also respond to 
100pg/ml estrogens. Cells were fed twice per week and cultured for 21days. Colonies 
were counted from quadruplicate wells, (± SD). B. To assess invasive properties of the 
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clones derived from 4-OH-E2 induced MCF-10A transformed cells, we seeded 10K 
MCF-10T15 cells, a clone from MCF-10A transformation in  BD BioCoat™ Matrigel™ 
Invasion Chambers. We also seeded these cells in glass chamber as we previously found 
that MCF-10A cells don’t attach very well to glass in the first 16-24hrs. For the invasion 
assay (a), the chemotractant is either growth supplemented media ( SM) or media with 
only 10% FBS (RM). 
 
 
Fig. 4. Spheriod Formation in Collagen and HuBiogel  
 Single colony from anchorage independent growth were aseptically picked at end of 21st  
day of culture. Clones were grown in growth factor reduced media (DMEM F12, 5% 
FCS, 4 ng/ml EGF, 2.0 ng/ml insulin, 100 ng/ml hydrocortisone, 1x penstrep) for 40-60 
generations, then in growth factor depleted media (DMEM F12, 5% FCS, 1x penstrep) 
onward. Clones were routinely assessed on collagen and HuBiogel for phenotypic 
evolutions. p0 indicates transformed cells prior to colony assay, p44-p200 are phenotypes 
of clone over several passages. Images were acquired with hand held Nikon digital 
camera over an inverted microscope with 20x objective.  
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Fig.5. Phenotypic Assessment of Transformed Cells  
 Clones from p121 cells were assessed for ductulogenesis, seeding phenotype and 
invasiveness. A) Ductulogenic assay on collagen matrix. B) Invasive characteristics of 
clone compared to MDA-MB 231 on matrigel 16 hrs post seeding. Data normalized to 
MDA-MB, +/- SD. Histogram of invaded cells expressed as mean invaded cells per field.  
C 1-II) Phenotypic assessment of clone versus wild type - 3 hrs post seeding and  III-IV) 
24 hrs post seeding. 
 
 
Fig . 6. ROS Scavengers Attenuates Cell Transformation. To determine whether ROS 
scavenger attenuates in vitro transformations of MCF-10A cells, we infected cells with 
adenovirus over-expressing catalase or MnSOD at moi 100. Post infections, cells were 
subjected to transformation regimen. For group that were treated with chemical 
modifiers, this group were treated continuously with 40.0 uM ebselen throughout 
transformation period except during recovery times. At end of transformations 
procedures, cells were seeded for soft agar colony formation at 7.5 x 104 cells/well in 48 
well plate. Assays were fed weekly for 3 weeks. Colonies formed in 4 wells were 
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enumerated and scored as mean +/- SD. Images were captured with Nikon digital camera 
over in inverted microscope with 4x objective. Fig 3A:  (I) DMSO, (II) 4-OHE2, (III) 
catalase infected cells, (IV) Catalase+4-OHE2, (V) MnSOD infected cells,  (VI) MnSOD 
infection+4OHE2, (VII) Ebselen treated cells (VIII) Ebselen treated cells + 4-OHE2. Fig 
3B:  Number of colonies per well. Data are means +/- SD of five plates.  (**) Indicates 
significantly different from control (DMSO) groups while (*) indicates significant 
different from 4-OHE2, (P<0.05) 
 
 
 
Figure 7. The growth of E2-induced transformed clone was inhibited by both 
antioxidants, ebselen and N-acetyl cysteine. Cells were grown in 96-well plates for 2 
days in 10% FBS DMEM/F12 and serum starved 2 days prior to addition of E2 for 18 h-
48 h unless specified otherwise. Bromodeoxy uridine (BrdU) incorporation assay was 
used to measure DNA synthesis as indicator of apoptosis in transformed cells. 
Antioxidants ebselen, NAC, and catalase were pretreated for 2 h prior to the addition of 
E2. Colorimetric BrdUrd incorporation was measured at 450 nm with a plate reader. 
Results are expressed as mean OD ± SD of three separate experiments with control set as 
100% DNA synthesis. (**) Indicates treatment significantly different from control. (*) 
Indicates treatment significantly different from E2. (P<0.05) 
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Figure 8. E2-induced 3-D tumor spheroid formation was inhibited by ROS modifiers. 
Spheroids were grown in a rotary vessel using HuBiogel, a memetic of human stromal 
matrix in catalase over-expressing cells or ebselen treated cells. Cells were labeled with 
CFSE using the Vybrant kit for checking viability. All spheroids showing the green 
fluorophore (Right Upper Panel) indicate that cells in tumor spheroids are alive. 
 
 
 
Fig. 9. Estrogen and its metabolites differentially activates PI3K/Akt signaling pathway 
during mammary transformation. MCF-10A cells were seeded for transformation as 
described in methods. At the end of transformation process, cells were treated for 
additional 30 min with 100.0 ng/ml estrogens or its catechol metabolites. Cells were 
harvested and lysed with RIPA buffer and PI3K and Akt proteins were 
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immunoprecipitated with respective antibodies and fractionated on 12% SDS-PAGE 
electrophoresis gel. Proteins were blotted onto PVDF membrane. Membrane were then 
probed with (A) p85 (p-PI3K) and p110 subunits of PI3K respectively. (B) 
Phosphorylated Akt (pAkt) and total Akt. Band intensity were quantified with Biorad 
GelDoc 2000 and normalized to vehicle. (**) Indicates that E2 and 4-OHE2 treatment 
group is significantly different from control (DMSO) groups while (*) indicates that other 
treatments groups are significantly different from 4-OHE2. (P<0.05). Results are 
expressed as mean fold change of three separate experiments. 
 
 
 
 
Fig. 10.  4-OHE2 Activation of PI3K/Akt Signaling Pathway is Abrogated by Chemical 
and Biological ROS Modifiers. MCF-10A were seeded and treated with Ebselen or NAC 
during transformation regimen, or pre-infected with adenovirus expressing Catalase or 
MnSOD, then subject to transformation regimen as described in methods. At the end of 
transformation process, cells were treated for additional 30 minutes with 100 ng/ml 4-
136 
 
OHE2. Cells were lysed with RIPA buffer and immunoprecipitated with PI3K and Akt 
antibodies respectively. IP products were fractionated on 12% SDS-PAGE 
electrophoresis gel. Proteins were blotted onto PVDF membrane. Membranes were then 
probed with phosphorylated PI3K (p-PI3K) and PI3K, or phosphorylated Akt (pAkt) and 
total Akt. Band intensity were quantified with Biorad GelDoc 2000 and normalized to 
vehicle. (A) Immunoblot of activated PI3K and its modulation by biological ROS 
modifiers at the end of transformation regimen. (B) Immunoblot of activated Akt and its 
modulation by biological ROS modifiers at the end of transformation regimen. (C)  
Immunoblot of activated PI3K and its modulation by chemical ROS modifiers at the end 
of transformation regimen. (D) Immunoblot of activated Akt and its modulation by 
chemical ROS modifiers at the end of transformation regimen. (**) Indicates that 4-
OHE2 treatment group is significantly different from control (DMSO) treatments groups 
while (*) indicates treatment is significantly different from 4-OHE2, (P<0.05). Results 
are expressed as mean fold change of three separate experiments. 
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Fig. 11. 4-OHE2 induced Activation of Akt1 Mediates MCF-10A Neoplastic 
Transformation . To ascertain whether Akt activations are involved during estrogen 
induced mammary transformation, cells were transfected with shRNA for Akt1 or it 
corresponding vector, and subsequently subjected to transformation regimen. After 
transformation process, cells were used for soft agar colony assay, or treated for 
additional 30 minutes then used for immunoblot. Cells were also seeded for 
immunofluorescence labeling with anti Akt antibodies for confocal microscopy. Panel A: 
I) DMSO, II) 4-OHE2, III) Sham Akt1 knockdown, IV) Sham Akt1 knockdown + 4-
OHE2, V) Akt1 knockdown, VI) Akt1 knockdown + 4-OHE2. (**) Indicates that 4-
OHE2 treatment group is significantly different from control (DMSO) groups while (*) 
indicates that other treatments groups are significantly different from 4-OHE2, (P<0.05). 
Panel B: Immunoblot of transformed cells expressing total Akt. Data is expressed as fold 
difference of 3 experiments, OD ± SD. (*) indicates treatment is significantly different 
from 4-OHE2, (P<0.05). Panel C: Immunofluorescence label of transformed cells 
expressing total Akt, I) sham kd + DMSO, II) Sham kd + 4-OHE2, III) Akt1 kd + 
DMSO, IV) Akt1 kd + 4-OHE2. 
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Fig. 12. 4-OHE2 induced up-regulation of cell cycle gene during neoplastic 
transformation of mammary cells is inhibited by ROS modulators  
MCF-10A cells were seeded for transformation as described in methods. At end of 
transformation period, cells were treated for additional 18 hours with vehicles or 
estrogens after which they were washed with cold PBS containing protease inhibitors. 
Cells were detached with trypsin and RNA isolated from 2.0 x106 cells, and 10ng RNA 
were used for qRT-PCR analysis of cell cycle genes primers on ABI Real time PCR 
machine. Data represents mean of 3 different experiments +/-SE, (P<0.05). (*) indicates 
treatment significantly different from DMSO while (**) indicates significant difference 
from 4-OHE2.  A) Fold change of PCNA transcript in 4-OHE2 transformed cells treated 
with ROS modulators, or transformed cells transfected with Akt1 RNAi. B) Fold change 
of cell cycle genes in 4-OHE2 transformed cells overexpressing catalase. 
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ABSTRACT 
 
We have shown earlier that chronic exposure to estrogen induces ROS production and 
promote growth and metastasis of breast cancer cells via ER related pathways.  Recently  
nuclear respiratory factor 1 (NRF1), a transcription factor, known to regulate cell’s redox 
status via mitochondria biogenesis has been implicated to play a role in breast 
carcinogenesis. In this study we demonstrate that estrogen induced ROS mediated 
signaling activates AKt activation which phosphorylates NRF1, a transcription factor, 
known to play a critical role in mitochondrial biogenesis.   This is the first report to 
demonstrate that exposure of MCF-7 cells to estradiol induced phosphorylation of AKt to 
activate NRF1. Activated NRF1 then modulates estrogen induced growth and invasion of 
MCF-7 cells in a redox dependent manner. Treatments of cells with ROS modulators or 
knockdown of NRF1 diminished NRF1 expression as well as estrogen induced growth of 
MCF-7 cells. These findings suggest that estrogen-induced redox signaling of NRF1 may 
be required for in vitro growth and metastasis of breast cancer cells. 
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INTRODUCTION 
 
Excess estrogen (also referred to as E2 or estrogen) exposure is associated with breast, 
endometrial and testicularovarian cancer [1-3]. Estrogens promote proliferation and 
growth of cancer cells by activation of estrogen receptors (ER) and non-ER activation 
pathways [1;2] While ER and regulatory gene altered by estrogen exposure may promote 
growth of breast cancer cells, recent evidence suggest that reactive oxygen species (ROS) 
may contribute in regulating survival, proliferation, growth and metastasis of  breast 
cancer [4-8].   
 
The role of ROS in breast cancer is not new. Both in vitro and in vivo studies have  
suggested that malignant breast cells compared to normal cells are under intrinsic 
oxidative pressures [9-12], which may correlate positively with excess estrogen exposure 
[13;14] and inefficient antioxidant systems [15]. These redox imbalances result in 
accumulations of oxidants, such as, hydrogen peroxide (H2O2) and hydroxyl ions (-OH ) 
[16;17]. These oxidants can have significant consequences on the fate of cancer cells 
ranging fromfrom apoptotic cell death, to proliferation, growth, metastasis and 
therapeutic resistance [18-21]. However, the mechanism (s) involved in oxidative stress 
and fate of breast cancer is complex and poorly understood. Several studies however 
suggest that impaired redox mechanism induces dysregulated phosphorylation and 
dephosphorylation of signaling proteins which activate or deactivate redox sensitive 
transcription factors [22]. NRF1 (nuclear respiratory factor-1/alpha-palindrome-binding 
protein) is one of the main transcription factors which are modulated in response to 
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oxidative stress. , NRF1 is a redox sensitive transcription factor known to regulate 
mitochondria biogenesis as well as oxidative phosphorylation (OXPHOS) [23;24]. 
OXPHOS is involved in the production of most of the mitochondria ROS. Dysregulated 
and increased OXPHOS activity may result in excess ROS production which can have 
deleterious effects onmtDNA integrity and ETC. [25].  Simultaneously, estrogens have 
been shown to induce increased NRF1 expressions,OXPHOS activity [26] and ROS 
production in mammary cancer cells [27]. Therefore, breast cancer tissues with 
significant  oxidative damages [5;14], possibly, are the source of  mitochondria derived 
oxidants via estrogen induced NRF1.  This may also explain why ER+ breast cancer have 
high  mitochondria copy numbers [28], exhibit significant mtDNA damages [29-31] and 
positively correlate with NRF1 expressions in higher grades [32;33]. .  
 
In contrast, sublethal levels of ROS induce NRF1 expression which regulates the 
mitochondria/DNA retrograde communication. If dysregulated, NRF1 can turn on genes 
involved in carcinogenesis and metastasis of cancer cells [34]. That is why antiestrogenic 
compounds such as raloxifene and tamoxifen likely fail upon prolong usage because 
these compounds act as pro-oxidant upon chronic exposures [44-47] as well as inducers 
of NRF1 [48].  
 
NRF1 is predominantly associated with mitochondria regulation in response to oxidative 
stress, genome wide in silico analysis however, revealed that this gene also regulates over 
400 genes involved in cell cycle progression, metabolism, DNA replication, and 
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transcriptional regulation [35], as well as genes involved in cell survival and growth [36], 
invasion and metastasis [37;38].  
 
In this study, we investigate whether estrogen-induced oxidants mediate in vitro growth 
and metastasis of malignant breast epithelial cells and the mechanisms involved. Our 
study revealed that estrogen induced NRF1 expression and its phosphorylation and 
dephosphorylation activated by redox dependent cellular signaling mediate proliferation, 
anchorage independent growth and metastasis of MCF-7 cells. Further, over-expression 
of biological ROS scavengers (MnSOD and Catalase) or treatments of cells with 
chemical antioxidant, (N-acetylcysteine (NAC) and ebselen), inhibited estrogen induced 
NRF1 expression and growth of malignant breast epithelial cells.  
 
MATERIALS AND METHODS 
 
Cell Line and Cell Culture 
Human mammary adenocarcinoma cell line (MCF-7) were obtained from American Type 
Culture Collection (ATCC) and were routinely cultured in phenol red-free DMEM/F12 
media with 10% (vol/vol) FBS, 1x penstrep. DMEM/F12 Media.  FBS and antibiotics 
were purchased from Invitrogen corp. For experiments , cells were seeded at 10-75% 
confluency depending on the experimental designs and incubated at 37°C in a humidified 
incubator containing 5% CO2and 85%  humidity. Cells were allowed to adhere for 24 hrs. 
after which culture medium were replaced with serum-free media (SFM) containing 
penicillin-streptomycin (100 μg/ml each) and cells were allowed to grow for 48 hrs. 
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Serum deprivation was used to synchronize cells in the G0/G1 phase of the cell cycle 
followed by treatments with estrogens or antioxidants, as described in the figure legends. 
 
Measurement of Reactive Oxygen Species (ROS) 
Cellular ROS were measured as previously described [27]. Briefly MCF-7 cells were 
seeded at a concentration of 1.0 × 104 cells per well in black 96-wells plate with clear flat 
bottom (ThermoFisher Scientific Inc. USA) and allowed to adhere overnight. Next day, 
cells were cultured in SFM for 48 hrs. They were then pretreated for 4 hrs with chemical 
antioxidants [ebselen and N-acetyl cysteine (NAC)] diluted in Hank's balanced salt 
solution (HBSS), followed by incubation with 10 µM 2',7'-dichlorofluorescin diacetate 
(DCFH-DA) (Invitrogen Corp.) for 20 min. Cells were rinsed with HBSS followed by 
various treatments with 100 pg/ml estrogens as described in the figure legends. DCFH-
DA is a non-fluorescent cell-permeable compound, which is acted upon by endogenous 
esterases that remove the acetate groups generating DCFH. In the presence of 
intracellular ROS, DCFH is rapidly oxidized to the highly fluorescent 2',7'-
dichlorofluorescein (DCF). The oxidative products is then measured with a Tecan Genios 
microplate reader using 485 and 535 nm as excitation and emission filters, respectively. 
DCFH-DA stock solutions were diluted at a 1:1 ratio with Pluronic F-127 (20% w/v).  
 
RNAi transfections  
Pre-designed and tetracycline inducible human shRNA for mitochondria transcription 
factor A (TFAM) and Akt1 shRNA with corresponding vectorcontrol were purchased 
from OriGene (OriGene Technologies, Inc. Rockville, MD). Pre-designed NRF1 siRNA 
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and corresponding scrambled constructs were purchased from Ambion (Applied 
Biosystems/Ambion, Austin, TX). Plasmid over-expressing NRF1 were custom made by 
OriGene (Rockville MD) and FLAG tagged DN-NRF1 is a kind gift from Dr. Liu. All 
purified plasmids were transfected into 35% confluent MCF-7 cells using FuGENE 6 
(Roche) transfection reagents according to the manufacturer's protocol. Transfection 
efficiencies for all plasmid were determined by protein expression levels which ranged 
from 50% to 80% reductions in respective gene expressionsThe concentration of 
plasmids used for transfections in all experiments was as recommended by Roche and 
were based on surface area of dishes used for each experiment. Post transfection, cells 
and their lysates were used for western blot analysis, BrdU, soft agar assays and invasion 
assays as described in subsequent sections.  
 
BrdU cell proliferation assay 
MCF-7 cells were seeded in 96-well plates at a density of 3,500 cells/well and incubated 
overnight. Cells were plated in quadruplicate for each experimental group. After 24 hrs of 
incubation cells were cultured in SFM  for 48 hrs. Cells cells were the treated with E2 
(100 pg/ml) in the presence or absence of antioxidants for 18 hrs. Cell proliferations were 
measured by colorimetric immunoassay of BrdU incorporation into the DNA using 
Roche BrdU cell labeling kits as recommended by manufactures (Roche Molecular 
Biochemical, Indianapolis, IN). Briefly, cells were pulsed with BrdU labeling reagent for 
3 hrs followed by fixation in FixDenat solution for 30 min at room temperature. 
Thereafter, cells were incubated with 1:100 dilution of anti- BrdU-POD for 1 h at room 
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temperature. Finally, the immunoreaction was detected by adding the substrate solution 
and the color developed was read at 370 nm with a Tecan Genios microplate reader. 
 
Adenovirus Transduction 
Adenoviruses over-expressing MnSOD (SOD), Catalase (Cata) or control  vectors were 
purchased from ViraQuest, Inc. (North Liberty, IA, USA).  MCF-7 cells were seeded into 
appropriate dishes at 15-70% confluence depending on the experimental design. Next 
day, cells were infected with Adenovirus over-expressing SOD, Catalase or vector at 
either moi 50 to 400 in SFM. Cells were cultured for 48 hrs after which they were used 
for various experiments.  
 
Chemical antioxidant treatments  
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also 
removes both H2O2 and peroxynitrite) and NAC (a precursor of glutathione and 
scavenger of ROS [49;50] differs according to the experiments to be performed. For 
example, in DCFH assays used to measure intracellular ROS in live cells, 40 µM  and 1.0 
mM ebselen and NAC respectively were pre-loaded onto cells  2-4 hrs before ROS 
measurement were commenced. For BrdU assays, cells were treated with 40 uM and 1.0 
mM ebselen and NAC respectively throughout the culture periods. For anchorage 
independent growth assays, antioxidants were mixed with cells and agar matrix before 
assay commenced, and added to media during bi-weekly feeding of colonies. For 
immunoprecipitations (IP) and western blot analysis, cells were exposed to a single 
treatment with these antioxidants during 48 hr culture in SFM  before western analysis. . 
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Cell viability assay 
CellTiter-Fluor™ Cell Viability kit were purchased from promega corporation and 
according to manufacturer’s instructions assay was conducted. Briefly, cells were seeded 
in 96 well plate at 1.0x104 cells/well, culyuired in SFM for 48 hrs post seeding, and 
treated accordingly with estrogens and antioxidants. At the end of the treatments , 
substrate reagent (GF-AFC) were mixed with substrate buffer and dispensed into well. 
This assay measures cell’s protease activities as quiescent and growth arrested cells are 
still viable even if mitochondria activities or oxidant levels are diminished. Plates were 
read on fluorescence plate reader at 380–400 nm excitations and 505 nm emissions. 
 
Western Blot Assays 
Cells for western blot analysis were seeded in T-75 flasks and grown to 70% confluence 
and manipulated according to experimental designs. Post treatments, cells were harvested 
in radioimmune precipitation buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet P-
40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors (Roche). 
Equal amounts of total cellular protein were mixed with loading buffer (25% glycerol, 
0.075% SDS, 1.25% 2-mercaptoethanol, 10% bromphenol blue, 3.13% stacking gel 
buffer) and fractionated by electrophoresis on 12%  polyacrylamide, 0.1% SDS resolving 
gels. Rainbow marker (Biorad USA) was used as the molecular weight standard. Proteins 
were transferred to PVDF Immobolin-P transfer membranes (Millipore) using transfer 
buffer [25 mM glycine, 25 mM ethanolamine, and 20% methanol]. The membranes were 
blocked one hour at RT with blocking buffer [1×phosphate buffered saline, 0.1% Tween-
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20 with 5% (w/v) nonfat dry milk (PBS-T)]. Blots were subsequently incubated for 2 hr 
at room temperature with various antibodies as indicated in legends.  
 
Immunoprecipitation  
For experiments to determine epigenetic modifications of NRF1, cells were seeded in T-
75 and grown to 70% confluence. Post treatments, cells were rinsed twice with PBS, 
harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet P-40, 0.1% 
SDS, 50 mM Tris) containing protease and phosphatase inhibitors (Roche). Whole cell 
lysates (WCL) were diluted to 500 µg of protein in 1 ml of  lysis buffer, and samples 
were pre-cleared for 1 hr at 4 °C with 40 µl of a 1:1 slurry of protein A-agarose beads 
(Invitrogen Corp) in lysis buffer and 1 µg of rabbit IgG. After a brief centrifugation to 
remove pre-cleared beads, 0.5 µg of anti-NRF1 antibody was added to each sample and 
incubated on a rocking platform at 4 °C overnight. Captured proteins were pulled down 
(precipitated??)  by the addition of 10 µl of protein A-agarose beads to each sample and 
the slurries were incubated on the rocking platform at 4 °C for 2hrs. The beads were then 
washed five times with lysis buffer and resuspended in 40 μL of 1×SDS electrophoresis 
sample buffer [50 mM Tris–HCl (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.1% 
bromophenol blue, and 10% glycerol], resolved on 12% SDS-PAGE electrophoresis and 
transferred onto a PVDF nylon blotting membrane. To determine whether serine residues 
of NRF1 are phosphorylated due to treatment, blot was probed with 1-5000 mouse 
monoclonal antibody against phosphoserine residue (Santa Cruz Biotech). To determine 
whether treatments induced modulations of NRF1 correlates with TFAM, one of its 
effector, WCL from same group were immunoprecipitated with rabbit anti mtTFA and 
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probed with mouse against mtTFA. All primary antibodies were diluted 1:1000 and 
detected after incubation with horseradish peroxidase(HRPO)-conjugated secondary 
antibody diluted 1:50,000 PBS-T. Blots were treated with ECL reagents (Amersham 
Biotech), and all proteins were detected by autoradiography. 
 
Anchorage independent Growth 
Anchorage-independent growth assays were performed as previously described [51]. 
Briefly, base support agar were made fresh by diluting 1.0% molten agarose mix with 1:1 
with 2x culture media (2x DMEM/F12 media, 20% HS, 2x Penstrep antibiotics and 200 
pg/ml estrogens) to a final of 0.5%. molten agar were maintained  at 42 oC water bath 
until dispensed at 200 l/well in 48 well plates, then allowed to solidify for 4 hrs at room 
temperature. Top agarose overlay were made fresh by mixing 0.7% molten low melting 
point (LMP) agarose with 2x culture media containing appropriate 5000 cells/well, then 
gently overlaid over preformed base agar. Cells were incubated for a minimum of 21 
days in 37°C incubator with 5% CO2.  Cultures in 48 well plate were fed once every 
week with 200 l of 0.5% melted agar in growth  media.  Colonies of separate cell 
aggregates at 100 M or greater in size, as measured with metamorph software (Nikon 
Corporation, USA) were counteds. Images were acquired by Olympus C-5060 digital 
camera under an inverted microscope with 4x objective.  
 
Invasion Assay 
The in vitro invasion assay was carried out to examine tumor cell invasiveness as 
described previously [52] with some modifications. Briefly, 24-well Transwell unit with 
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8 μm polycarbonate Nucleopore filters (Corning) were coated with 60 μL of 0.8 Matrigel. 
MCF-7 cells (1 × 105) transfected with plasmid overexpressing NRF1 or null were placed 
in the upper compartment, and the medium containing 10% fetal bovine serum was added 
to the lower compartment. For group treated with NAC, the chemical ROS modifier was 
added to media in the lower chamber to a concentration of 1.0 mM. The Transwell plates 
were incubated at 37°C for 48 and 72 hrs accordingly. Cells invaded to the lower surface 
of the membrane were stained with Giemsa staining and observed using light microscope. 
The invading cells were stained and counted per insert and photographed. Experiment 
were conducted in triplicates and repeated three times.   
 
Statistical analysis 
Results are expressed as mean ± S.D. Differences between means were evaluated by two-
tailed Student's t-test. ANOVA was used to determine differences between groups. 
 
RESULTS 
 
Estrogen induced ROS levels mediate proliferation and growth of MCF-7 cells in vitro 
 
Estrogens have been reported to modulate mitochondria ROS production in MCF-7 cells 
and other cell types [27;53]. These ROS are postulated by us and other [20;47;54;55] to 
mediate proliferation and growth of subsets of breast cancer cells. To test this hypothesis, 
biological ROS modulators (MnSOD and catalase) were oveerexpressed in MCF-7 cells , 
or cells were pretreated with chemical ROS modulators, 40 μM ebselen or 1.0 mM 
NAC). These cells were then challenged with 100 pg/ml estrogens. Data reveals that 
treatment of cells with estrogen alone increased ROS production and DNA synthesis 
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whereas treatment with catalase alone (moi 50) diminished ROS production and DNA 
synthesis. However, co-treatment of cells with catalase (moi 50) and estrogen 
significantly increased ROS level and DNA synthesis beyond catalase alone infected 
groups. Interestingly, similar trends were observed in MnSOD infected cells at moi 50 
though the magnitude in ROS production and DNA synthesis is significantly more than 
that observed in estrogen or catalase treated groups (Fig. 1A). Both chemical ROS 
modulators used in this experiment also diminished ROS production and DNA synthesis. 
However, when cells were infected with adenoviruses at moi of 200, catalase diminished 
estrogen induced ROS production and DNA synthesis while  MnSOD significantly 
increased ROS production and dramatically reduced DNA synthesis compared to cells 
treated with moi 50 (Fig 1B). To resolve the inverse correlation of MnSOD over-
expression at moi 200 and DNA synthesis, we infected cells with various viral loads of 
MnSOD expressing viruses; and as control, we also infected cells transfected with control 
adenovirus vectors at moi 50. Infected cells were then used for colony assay and 
monitored for anchorage independent growth for three weeks. We observed that low viral 
MnSOD load (moi 5-50) promoted increased number and size of colonies (Fig. 2B, C) 
whereas viral load higher than moi 50 induced diminished cell growth (Fig 2D-G). 
Adenovirus containing control vectors at moi 50 did not induce growth advantage over 
corresponding MnSOD expressing adenoviruses indicating that it’s the overexpressed 
MnSOD that is modulating cell growth. However, to ascertain whether the observed 
cancer growth retardation of MnSOD infection is higher than moi 50 is due to cell 
lethality, we stained single cell population from all virus infected groups (control, 
catalase and MnSOD) with trypan blue solution and found that over 70% of the cells 
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infected with virus up to moi 200 were viable whereas 90% of moi 400 and above 
infected cells were not viable after 21 days of cultures in soft agar assay (data not 
shown). Since moi 200 infected cells were viable up to 21 days, we chose this viral load 
for subsequent experiments. The effects of ROS modulators on estrogen induced growth 
of breast cancer were further evaluated byco-treatment of MCF-7 cells with estrogen and 
biological or chemical ROS modulator. It wasfound that these antioxidants significantly 
inhibited estrogen induced growth of MCF-7 cells in vitro (Fig 3).  
 
Estrogen induced oxidants activate Akt signaling pathway which contributes to in vitro 
growth of MCF-7 breast cancer cells 
 
The mechanisms by which estrogen induce cell proliferations and growth of estrogen 
responsive breast cancer cells are attributable to ER mediated process. It has been shown 
that  upon estrogen stimulations, cells secrete growth factors which activate receptor 
tyrosine kinases and initiation of complex signaling cascade of phosphorylation-
dephosphorylation reactions that  subsequently leads to cancer cell growth and metastasis 
[56]. One such signaling pathway activated by estrogen exposure that leads to survival 
and growth of MCF-7 cells is the PI3K/Akt signaling pathways [57;58]. Oxidants such as 
superoxides and hydrogen peroxides have likewise been reported to activate this 
signaling pathway which mediates survival and growth of exposed cells [18-20]. To 
determine whether E2 induced oxidants can activate PI3K/Akt signaling pathway and 
whether ROS scavengers or inhibitors of PI3K would mitigateAkt phosphorylation, 
MCF-7 cells were either infected with biological antioxidants, or pretreated with 
chemical ROS scavengers (ebselen, NAC) prior to estrogen treatments as described in 
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methods. Whole cell lysate were resvolved on 12% SDS-PAGE gel, and probed with 
appropriate antibodies. Data reveals that 100 pg/ml estrogen treatment induced Akt 
activation which were inhibited by chemical or biological antioxidants as well as by 
LY294002, an inhibitor of PI3K which regulates Akt activations (Fig 4). These findings 
support the hypothesis that oxidant (ROS) induced by estrogen exposures can activate 
Akt signaling proteins and activated Akt has been demonstrated to favor survival, 
proliferation and growth of cells during periods of oxidative stress [59;60].  
 
 
Estrogen induced Akt activation phosphorylates NRF1 which promotes growth of 
responsive cells 
 
Cellular responses to oxidants are mediated in part, by redox activation of NRF1 which 
regulates mitochondria biogenesis and cellular antioxidant responses [61;62]. NRF1 has 
been reported to be trans-activated by Akt phosphorylation of its serine/threonine residue  
in response to growth factors and oxidative stress  [62-64]. Trans-activated NRF1 are 
believed to mediate cellular responses to oxidative stress such as mitochondria 
biogenesis, restoration of redox homeostasis and induction of survival and proliferation 
mechanisms of cells [42]. 
 
Similarly, treatments of MCF-7 cells with 100 pg/ml estrogen for 45 minutes induced 
rapid serine phosphorylation of NRF1 (Fig 5) which were abrogated by both chemical 
and biological ROS modulators.  In addition, silencing of Akt1, the Akt isoform 
implicated in mediating cell survival and growth [65-67] likewise reduced NRF1 
phosphorylation, and anchorage independent growth of MCF-7 cells (Fig 6). These 
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findings imply that estrogen induced oxidants modulate NRF1 expressions. It also 
implies that redox activations of Akt signaling in response to estrogen exposures 
phosphorylate and tran-sactivates NRF1. The absence of Akt1 expression leads to 
reduced NRF1 phosphorylation and reduced growth of MCF-7 cells exposed to estrogen. 
 
NRF1 expression promotes in vitro proliferation and growth of estrogen responsive 
breast cancer cells 
 
In order to show that NRF1 are implicated in the mediation of growth of breast cancer 
cells in vitro, NRF1 was silenced in MCF-7 cells.  Cells were then cultured with or 
without estrogens for 21days. Colony formation, growth and viability of cells in soft agar 
assays were measured. Data reveals that estrogen increased colony formation growth in 
control knockdown groups (Null kd) comparable to the  untransfected cells (Fig 7B i-iv). 
However, estrogen fails to induce colony formation or colony growth of NRF1 silenced 
cells implying that NRF1 are essential in the mediation of estrogen induced in vitro 
growth of MCF-7 cells (Fig 7B v,vi). To test whether reduction in growth is due to cell 
death because of NRF1 knockdown, cells from soft agar plates were counted for cell 
viability per 1000 cells using trypan blue exclusion assays. We found that while there 
were differences in cell death due to NRF1 status, differences were not significant to 
account for observed lack of colony formations or growth of cells in NRF1 knockdown 
versus Null kd cells (data not shown). In addition, immunoprecipitation analysis of NRF1 
expression and phosphorylation status revealed that Null kd cells expresses increased 
NRF1 protein and exhibit increased phosphorylation in response to prolonged estrogen 
exposure (Fig 7A,B). Silencing of NRF1 however, inhibits its expression or 
phosphorylation in response to chronic exposures to estrogens (Fig 7C). To confirm that 
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NRF1 is indeed responsible for this  observation, the expression levels of mtTFA, one of 
the genes targeted by  NRF1 expression [68] was assessed. Western blot analysis of cell 
lysates from Null kd vs NRF1 knock down revealed a positive correlation between NRF1 
and mtTFA expressions; i.e. up regulation of NRF1 leads to up regulation of mtTFA and 
vice versa (Fig 7). To confirm NRF1’s role in growth regulation of MCF-7 exposed to 
estrogens, we overexpressed NRF1 (NRF1ox) or its DN-NRF1 and assessed in vitro 
proliferation and growth in response to estrogens. We observed that while over-
expressing NRF1 enhanced estrogen induced proliferation and growth of MCF-7 cells, 
over-expressing DN-NRF1 actually reduced estrogen mediated proliferation and growth 
of MCF-7 cells (Fig. 8). Interestingly however, the effects of NRF1ox alone were 
significantly greater than E2 treated control cells in both soft agar and BrdU assays.  
 
 
NRF1 over-expression modulates invasion of MCF-7 cells 
 
NRF1 has been implicated in the modulation of various protease expressions involved in 
cell migration and spreading.  Proteases include the calpains [37] whose over-expression 
is implicated  in tumorigenesis, metastasis and angiogenesis in breast cancer and other 
cancer types [69;70], GalNAc-T3 genes that function in glycosylation of mucin proteins 
in epithelial derived tumors [71] which is also plyas a central role in invasive mammary 
[72] and colorectal [73] carcinoma. In this study, in vitro invasion assay of MCF-7 cells 
overexpressing NRF1 displayed a threefold increase in invading cells compared to vector 
or non transfected (NT) group (Fig. 9A). NRF1ox cells when transfected with DN-NRF1 
or treated with ebselen showed significantly higher number of cells compared to the 
control MCF-7 cells trasnfected with vector/DN-NRF1 alone and also treated with 
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ebselen. (Fig. 9B). In addition, groups treated with estrogen also had significantly more 
invading cells and mucosal environment compared with groups treated with vehicle (Fig 
9B). These findings indicate that NRF1 participates in cell invasion in a redox dependent 
manner.  
 
DISCUSSIONS 
 
Estrogens are chemicals capable of promoting growth of breast cancer cells via ER and 
non-ER mediated pathways. Estrogens induce ROS via mitochondria biogenesiss. At 
sublethal levels, these ROS induce redox signaling that participate in growth of estrogen 
exposed breast cancer cells [27;74;75]. In this study, we provide evidence that estrogen 
induced ROS are essential for proliferation and malignant growth of estrogen responsive 
breast cancer cells. We also report that the mechanism involves redox activation and 
phosphorylation of NRF1 because over-expression of biological ROS scavengers or 
treatment of cells with chemical antioxidants inhibited NRF1 activation which in turn 
reduced estrogen mediated growth and metastasis of breast cancer cells.  
 
The role of estrogen induced oxidants in breast carcinogenesis has long been established 
[76-79]. However, the role of these oxidants in mediation of growth of cancer cell 
remainscontroversial. In this study, we observed that treatments of MCF-7 cells with a 
dose comparable to physiological level of estrogen induced intracellular ROS which 
promoted in vitro growth of breast cancer cells. Conversely pre-treatment of cells with 
chemical or biological antioxidant prior to estrogen exposure inhibited induced ROS 
formation and in vitro growth of cells. These observations implies that the growth 
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promoting properties of estrogen in breast cancer cells are mediated in part by estrogen 
induced oxidants as ROS scavengers abolished estrogen induced growth of breast cancer 
cells. These findings are in line with other reports which indicate that sublethal levels of 
oxidants induce significant mitogenic effects on a number of gynecological cancers [80-
82] including breast cancer [4;54;83]. It may also explain the aggressive nature of breast 
cancer attained after therapeutic failures because  these therapeutic agents also act as pro-
oxidant upon their prolonged use [44-47]. Nonetheless, the initial antiproliferative 
responses of these chemotherapeutic agents may be due to their antioxidant properties 
[84-87].  
 
Our group and others have reported that mitochondria is a major source of estrogen 
induced ROS [27;75] in breast cancer cells. We investigated whether altering 
mitochondria MnSOD activity would modulate estrogen induction of intracellular ROS 
and growth of breast cancer cells. We found that infection of MCF-7 cells with 
adenovirus overexpressing MnSOD at moi 50 increased intracellular ROS production, as 
well as increased proliferation and growth of MCF-7 cells. However, when cells were 
infected with adenovirus at moi 200, ROS production increased significantly compared to 
ROS from moi 50 infected cells, but cell proliferation and growth decreased significantly. 
ROS production from moi 50 infected cells correlated positively with DNA synthesis and 
growth of MCF-7 cells, however, the effects of estrogen exposure on MnSOD expressing 
cells were statistically insignificant. This implies that the mitogenicity observed in these 
cells are due entirely to mitochondria ROS and not by estrogens exposures. Therefore, 
while we were able to show a direct correlation between intracellular ROS production 
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and cell growth in response to estrogen exposure, we were unable to show any significant 
combinational effects between estrogen exposures, MnSOD overexpression and cell 
growth even though our data does indicates a correlation between MnSOD expression 
and cell proliferation.  
 
It has been reported that ROS mediates mitogenic activation of the PI3K/Akt signaling 
pathway which promotes survival and growth of exposed cells [88;89]. Estrogens has 
likewise been demonstrated to activate PI3K/Akt signaling pathway in endometrial and 
breast cancer cells, in an ER dependent and independent manner [90;91]. However, 
whether oxidants mediate estrogen induced activation of PI3K/Akt signaling in breast 
cells and whether Akt activation is linked with growth of these cells is not clear. In our 
study, we observed that estrogen induced Akt activation in breast cancer cells were 
diminished by catalase over-expression and by chemical ROS scavengers. Whether 
oxidant activation of Akt in estrogen exposed cells is associated with proliferation and 
growth regulation is not known. To investigate this possible link, we silenced Akt1, an 
Akt isoform known to be involved in regulating mammary tumorigenesis and growth of 
cancer cells [65;92]. Wefound that knocking down this gene diminished estrogen induced 
proliferation and growth of MCF-7 cells. While Akt is a global activator of a number of 
transcription factors with diverse physiological functions, our data suggest that estrogen 
activation of Akt in breast cancer cells are also ROS mediated and activation of Akt 
signaling cascades are essential in transducing signaling processes that favors survival 
and growth of breast cancer cells.  
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Activated Akt promotes cell survival and growth via a number of mechanisms. For 
example, Akt phosphorylates and deactivates pro-apoptotic factors such as BAD, 
Caspase-9, and Forkhead transcription factors (FKHR) as well as other pro-survival 
transcription factors [93]. Other targets of activated Akt in response to oxidative stress 
includes NRF1, a redox sensitive gene known to regulate transcription of genes involved 
in antioxidant responses, apoptosis, as well as regulation of mitochondrial biogenesis 
[62;94-96]. Oxidant mediated phosphorylation of NRF1 are thought to induce nuclear 
translocation and transcriptional regulation of various cellular response such as 
restoration of redox homeostasis, enhancement of cell survival and growth, as well as 
regulation of mitochondria biogenesis [97]. Prolong estrogen exposure has likewise been 
reported to up-regulate NRF1 expressions via ER alpha (ERα) mediated mechanisms in 
MCF-7 cells which leads to increased mitochondria biogenesis in these cells [26]. While 
this observation is novel, others have reported that sodium butyrate, a non estrogenic but 
pro-oxidative compound [98] also induces NRF1 expression in MCF-7 cells [71]. 
Furthermore, SERMs such as TAM, RAL and Fulvestrant which are all pro-oxidant upon 
chronic exposures [99], also increases NRF1 expression in SERM resistant MCF-7 cells 
[100]. These studies all suggest that estrogen inductions of NRF1 in estrogen responsive 
or resistant breast cancer cells are not exclusive to ER status. It implies that perhaps 
estrogen induced oxidants may also mediate NRF1 expression in breast cancer cells 
irrespective of ER status.  
 
Here, we report that exposure of MCF-7 cells to estrogen not only up-regulates NRF1 
expressions, but it also induces NRF1 phosphorylation by Akt in a redox dependent 
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manner. Treatment of cells with ROS modulators or silencing of NRF1 fail to mediate 
estrogen induced NRF1 expressions and phosphorylation, and inhibited growth of breast 
cancer cells. While ERα is believed to regulate estrogen induced NRF1 expression in 
MCF-7 cell line [26], our data indicates that estrogen induced oxidants are essential for 
NRF1 expressions and phosphorylation. Upon phosphorylation, this transcription factor 
is believed to translocate into the nucleus where they regulate mitochondria biogenesis, 
oxidative phosphorylation and mediates oxidant induced survival and growth of breast 
cancer cells, by unknown mechanism. These observation are in agreement with reports 
that have shown NRF1 is phosphorylations by oxidants in rat hepatoma cells promoting 
survival and growth of during periods of oxidative stress [62]. Our data may also explain 
the observation that despite the high oxidative environment of breast cancer cells in vivo 
[11], these cells survive, proliferate and grow as opposed to undergoing apoptosis and 
cell death. Activated NRF1 may also cause cancer cell metastasis, therapeutic failures 
and poor prognosis of breast cancer patients as oxidative stress are associated with 
metastasis and drug failures in a number of malignancies including breast cancer 
[101;102]. In addition, it has been reported that estrogen and insulin induce proliferation 
and growth of MCF-7 cells via NRF1 activation [103], but insulin, with estrogens also, 
act as pro-oxidants [104;105] and  activate Akt signaling pathways [106;107] in a variety 
of cells types. It is therefore feasible that the pro-oxidative properties of estrogen alone or 
in combination with insulin promote survival and growth of breast cancer cells through 
persistent expressions and phosphorylation of NRF1.  
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In summary, overexpression of MnSOD and Catalase or treatment with antioxidant 
ebselen selectively inhibited cell proliferation and invasion of MCF-7 cells that were 
transfected with NRF1. Also, knocking down Akt isoform in estrogen treated cells that 
has been shown to phsphorylate NRF1 reduced the rate of cell proliferation. It appears 
therefore, that the level of NRF1 expression indicates a redox state of breast cancer cells 
and activation of NRF1 via Akt pathway is a key modulator of estrogen induced breast 
cancer cell proliferation and metastasis. 
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FIGURES AND LEGENDS 
 
 
 
 
Fig. 1. Estrogen induced ROS mediates in vitro proliferation of MCF-7 breast cancer 
Cells. 3500 cells/well were seeded in 96well plate for BrdU cell proliferation assays and 
1.0x10^4cells/well for ROS production assays. Next day, cells were infected with 
Adenovirus over-expressing MnSOD or Catalase at either moi 50 or 200 in serum free 
media. Other group of cells was treated with 40μm ebselen and 1mM NAC diluted also in 
serum free media. Cells were cultured for 48hrs and assayed for ROS production or BrdU 
assays. For ROS assays, cells were pretreated for 4hrs before assay with ebselen and 
NAC after which 10μM DCF were loaded onto the cells for 20mins, then cells were 
challenged with 100pg/ml estrogen, and ROS readings were taken every 5mins on Tecan 
plate reader. For cell proliferation assays, 48hrs post infections, wells were challenged 
with 100pg/ml estrogen and allowed to incubate for additional 18hrs after which BrdU 
assay were carried out with Roche BrdU assay kit. (A) MCF-7 cells infected with 
catalase or MnSOD at moi 50, or treated chemical antioxidant, then challenged with 
estrogen. (B) MCF-7 cells infected with catalase or MnSOD at moi 200, or treated 
chemical antioxidant, then challenged with estrogen. ROS production upon E2 challenge 
was compared with DNA synthesis.  Data is expressed as standard error of mean of three 
experiments, (+/- SE). (*) indicates significant different from control group. (*#) 
indicates treatment significantly different from E2 treated group. (P<0.05) 
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Fig. 2. Differential effects of ROS production on in vitro growth of MCF-7.  MCF-7 cells 
were infected with various concentrations of MnSOD over-expressing viruses for 24hrs 
after which cells were detached and seeded for soft agar assays such that each well in 48 
well plate had 5000cells/well. Cells were incubated for 5weeks with weekly feeding. 
Colony numbers and sizes were scored using Nikon metamorph software and expressed 
as mean of five wells, +/- SD. (*) indicates significant difference from control group (null 
moi 50), (P<0.05). Representative Images were acquired with hand held Nikon camera 
over an inverted microscope with 4x objective. A) AdEmpty (Null) moi50,  B) 
AdMnSOD Moi 5, C) AdMnSOD moi 10, D) AdMnSOD moi 50, E) AdMnSOD moi 
100, F) AdMnSOD moi 200,  G) AdMnSOD moi 400, H) Mean colony and size numbers 
compared to null vector.   
 
 
Fig 3. ROS Scavengers inhibits E2 induced growth of MCF-7 cells. Cells were infected 
with biological antioxidants for 24hrs in serum free media and allowed to recover 
afterwards. 1.0x10^4 cell pellet was resuspended with 500ul 2x culture media containing 
100 pg/ml E2 or 40 µM ebselen. Cell suspensions were then mixed 1:1 with 0.5% molten 
agarose and over layered on precast bottom agarose in 48 well plate.  Cultures were 
allowed to incubate for 3-5wks with weekly feeding and images were acquired with a 
hand-held Nikon digital camera over 4x inverted microscope. Qudruplicate wells were 
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counted and expressed as mean three experiments +/- SE. (Panel A: Chemical antioxidant 
treatment group) (I) DMSO, (II) 100pg/ml E2, (III) Ebs, (IV) Ebs/E2, (V) NAC, (VI) 
NAC/E2.  (Panel B: Biological antioxidant treatment group) (I) DMSO, (II) 100pg/ml 
E2, (III) Cata, (IV) Cata/E2, (V) MnSOD, (VI) MnSOD/E2. (*) indicates significant 
difference from control group. (**) indicates significant difference from E2 treated 
group, (P<0.05). 
 
 
 
 
 
Fig. 4. Estrogen induced activation of Akt is abrogated by ROS scavengers. MCF-7 cells 
were either pre-infected with MnSOD or catalase at moi 50 and cells seeded for 
experiment, or cells were seeded and treated with 40 µM  ebselen, 10μmol/L LY294002 
(LY) and 1.0μM Rotenone for 48 hrs in starvation media.  At end of starvation periods, 
cells were harvested and lysed with RIPA buffer, and 100 ug total proteins were 
fractionated in SDS PAGE electrophoresis gel. Blots were probed for phosphorylated Akt 
(pAkt) and total Akt and band intensity were quantified with Biorad GelDoc 2000 and 
normalized to vehicle. (A) Representative Immunoblot probed for pAkt and total Akt. (B) 
Densitometry of pAkt normalized with total Akt and expressed as fold change vs. 
DMSO.  (**) indicates significant difference from control group. (*) indicates significant 
difference from E2 treated group, (P<0.05). 
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Fig. 5. Estrogen induced NRF1 activation is abrogated by ROS scavengers. To determine 
whether ROS scavengers mitigates estrogen induced activations of NRF1 in breast 
cancer, MCF-7 cells were seeded, infected with catalase or MnSOD, or with 40uM 
ebselen and estrogen as previously described. Lysate were immunoprecipitated with 
NRF1 and immunoblot probed with anti serine antibody (pNRF1) or NRF1 antibody. For 
loading control, 50 ug whole cell lysate (WCL) were fractionated and blot probed with 
beta actin (actin). Band intensity of pNRF1 was compared with NRF1, and then 
normalizes with DMSO from NT group. Representative data of 3 experiments is 
presented above. (Panel A) Non transfected group (NT) treated DMSO or E2, (Panel B, 
C) Catalase or MnSOD infected groups respectively, and then treated with DMSO or E2. 
(Panel D) Ebselen and E2 co-treated group. (E) Densitometry of pNRF1 normalized with 
total NRF1 and expressed as fold change vs. DMSO in NT group. (**) Indicates that E2 
treatment group is significantly different from control (DMSO) groups while (*) indicates 
that other treatments groups are significantly different from E2 treatment groups. Data is 
expressed as mean of 3 experiments, OD ± SE, (P<0.05). 
 
 
174 
 
 
Fig. 6. Akt phosphorylate and activate NRF1 which mediate in vitro growth of MCF-7 
cells. To determine role of Akt and NRF1 phosphorylation in estrogen induced growth of 
breast cancer cells,   MCF-7 cells were transfected with pre-designed and verified Akt1 
shRNA plasmid or its vector for 72 hrs with FuGENE 6 transfection reagent without 
change of media. Post transfection, cells were seeded for colony assay, or challenged 
with 100 pg/ml estrogen or DMSO for 30 mins. Cells were then harvested with RIPA 
buffer and 500 ug total protein was IP with NRF1, fractionated on SDS-PAGE and blots 
probed with serine antibody. 50 ug of WCL was also fractionated on SDS-PAGE gel and 
probed for total Akt, and β actin as experimental loading control. Band intensity were 
measured with Biorad versadoc 2000 software and expressed as fold change from 
DMSO. (Panels A and B)  Western blot analysis of vector and Akt1 shRNA plasmid 
transfected into MCF-7 cells then treated with DMSO or E2. (C D) Band intensity of 
NRF1 phosphoserine (pNRF1) normalized to total NRF1, and Akt normalized to actin 
respectively. (E-J) Representative pictures colonies from soft agar assay after 3 weeks 
incubation, and expressed as mean +/- SE of three experiments. (E) DMSO, (F) E2, (G) 
vector- kd/DMSO, (H) vector- kd/E2, (I)  Akt1 kd/DMSO,  (J) Akt1 kd/E2, (K) Fold 
increase of colony formation versus DMSO.  (**) Indicates that E2 treatment group is 
significantly different from control (DMSO) groups while (*) indicates that other 
treatments groups are significantly different from E2 treatment groups. Data is expressed 
as mean of 3 experiments, OD ± SE, (P<0.05). 
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Fig. 7. Silencing of NRF1 attenuates estrogen induced in vitro growth of MCF-7.  
MCF-7 cells were transfected with shRNA vector or NRF1 shRNA plasmid for 96 hrs. 
Post transfection, cells were seeded for colony assays or treated with DMSO or 100 pg 
E2 for 30mins, then harvested and lysed with RIPA buffer. 500 ug total proteins were co-
immunoprecipitated with anti NRF1 antibody, and blots probed with either anti NRF1, 
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anti phosphoserine and anti mtTFA antibodies. (Panel A) Non transfected cells (NT) 
probed with anti serine, anti NRF1, anti mtTFA and anti actin respectively. (Panel B) 
Vector transfected cells probed with anti serine, anti NRF1, anti mtTFA and anti actin 
respectively. (Panel C) NRF1 kd  cells probed with anti serine,  anti NRF1, anti mtTFA 
and anti actin. (D-F) Densitometry of NRF1 knocked on (D) phosphorylated NRF1 
compared to total NRF1, (E) total NRF1 compared to actin.  (F) mtTFA expression 
compared to actin.  (G) Representative pictures of colony assay of MCF-7 cells with 
NRF1 knockdown + estrogens treatment; (i) NT-DMSO, (ii) NT-E2, (iii) vector-DMSO, 
(iv)vector-E2, (v) NRF1-kd-DMSO, (vi) NRF1-kd-E2. (H) Fold change of colonies 
compared to NT-DMSO. (*) Indicates that E2 treatment group is significantly different 
from control (DMSO) groups while (**) indicates that other treatments groups are 
significantly different from E2 treatment groups. Data is expressed as mean of 3 
experiments, OD ± SE, (P<0.05) 
 
 
 
.
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Fig. 8. NRF1 expressions modulates estrogen induced proliferation and growth of MCF-7 
cells. MCF-7 cells were transfected with plasmid either over-expressing or under-
expressing NRF1 (NRF1-ox and NRF1-kd for 48hrs. Transfected cells were subsequently 
used for colony assay, with or without 100 pg/ml E2 treatments for 21 days. (A) Colonies 
formed by MCF-7 cells transfected with NRF1 modulating plasmid with vector control. 
(i) NT-DMSO, (ii) NT-E2, (iii) Vector-DMSO, (iv) vector-E2, (v) NRF1-ox-DMSO, (vi) 
NRF1-ox-E2, (vii) NRF1-kd-DMSO, (viii) NRF1-kd-E2. (B). Enumerated colony count 
were expressed as percentage change from NT treatment group +/- SD of three 
experiments. (*) indicates treatment significantly different from E2. (**) indicates 
treatment significantly different from control. (P<0.05) 
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Fig. 9. NRF1 over-expression modulates invasion of MCF-7 cells. MCF-7 cells were 
transfected with either Null vector (Vector) or NRF1 over-expressing vector (Ox). In a 
separate experiment, cells were also co-transfected with Ox, Ox+ vector, Ox+NRF1 
knockdown plasmids (Ox+Kd). 1.0 x 104 cells were seeded on matrigel invasion chamber 
with 8.0 µM pore size and 10% FBS media with or without 100 pg/ml estrogen were 
added to the bottom of wells as chemoattractant.  Cells were cultured for 72 hrs in CO2 
incubator. Invaded cells at bottom of wells were stained and images were acquires with 
Nikon microscope over 20x objective, and metamorph software. Data represents invaded 
cells over 5 fields, +/- SD.  (A)Invasion of NRF1ox expressing cells; i) DMSO, ii) vector, 
iii) NRF1ox. (B) Invasion of Co-transfected NRF1ox plasmid with or without estrogen as 
chemoattractant; i) Ox+DMSO, ii) Ox+E2, iii) Ox+vector+DMSO,  iv) Ox+vector+E2, 
v) Ox+ NRF1 kd+ DMSO, vi) Ox+NRF1+E2. (*) indicates treatment significantly 
different from Ox/DMSO. (**) indicates treatment significantly different from 
Ox/Null/E2. (*#) indicates treatment significantly different from Ox/Null/DMSO. 
(P<0.05) 
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CHAPTER VI 
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Victor O. Okoh, Alok Deoraj, Jai Parkash and Deodutta Roy 
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ABSTRACT 
Understanding the contribution of NRF1 activation to the susceptibility for the 
development of malignant phenotype cells by estrogen is the focus of this study. 
Consistent with the redox-sensitivity of NRF1, 4-OH-E2-induced NRF1 expression and 
its phosphorylation and acetylation were inhibited by the glutathione peroxidase mimic, 
ebselen and by overexpression of ROS modifying genes, catalase and MnSOD. NRF1 
was bound to the promoters of the cell cycle genes pcna, cyclin b1, and cdc25c, and prc1, 
confirming the prediction that these promoters contain NRF1 elements.  The exposure of 
MCF10 A cells to a carcinogenic dose of 4-OHE2 increased the binding of NRF1 to the 
promoters of these genes and that 4-OHE2-induced binding could be inhibited by 
cotreatment with ebselen (antioxidant), or over expression of catalase (H2O2 scavenger).  
These results suggest that 4-OH-E2-generated oxidants, particularly H2O2, may mediate 
NRF1 binding to these gene promoters.  Decreasing NRF1 protein levels via specific 
siRNA Knock down of NRF1, PCAF and AKT inhibited 4-OH-E2 induced generation of 
malignant phenotype. Together, these data suggest that ROS accelerate cell-cycle 
progression and anchorage-independent growth in 4-OH-E2-transformed cells by 
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controlling the expression of cell cycle genes in an NRF1-dependent manner. In 
summary, estrogen-mediated activation of a redox sensitive signaling pathway regulates 
NRF1 phosphorylation and acetylation events. These two events enhance its activating 
function by increasing its localization close to nuclear targets and its affinity for 
promoters of target genes. This, in turn, contributes to the susceptibility of normal breast 
epithelial cells to develop malignant phenotype. 
                                 
INTRODUCTION 
NRF1/α-PAL (nuclear respiratory factor-1/α-palindrome-binding protein) is a 
transcription factor (1-3). Initially, this transcription factor was mostly famous for 
controlling nuclear-mitochondrial interactions that coordinate regulation of nuclear and 
mitochondrial genes during organelle biogensis. A genome-wide analysis has revealed 
that NRF1 binding elements are present in genes involved in DNA replication, mitosis, 
and cytokinesis, suggesting that NRF1 plays an important role in cell cycle regulation 
(4,5). Interestingly, the NRF1 recognition site is one of the seven transcription factor 
binding sites which are most frequently found in the proximal promoters of ubiquitous 
genes, indicating a broader spectrum of target genes for NRF1. NRF1 overexpression has 
been observed in hepatoma, neuroblastoma and thyroid oncocytoma (6-8). In B cell 
chronic lymphocytic leukemia (CLL) patients, the mRNA expression of the 
mitochondrial biogenesis factors NRF1 and TFAM in the majority of leukemic cells is 
higher than normal lymphocytes (9). While there are more than 20 Oncomine studies 
with NRF1 over expression, the (actual) role NRF1 plays in breast cancer remains the 
least studied of all transcription factors. We have recently meta-analyzed 18 published 
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breast cancer microarray data (10). From our study, we found that: 1) NRF1 was 
significantly overexpressed in ER+ tumors compared to ER- tumors; and 2) NRF1 was 
significantly overexpressed as breast tumor’s grade increased. Investigation of the role of 
NRF1 in breast carcinogenesis is the central focus of this study. 
 
Elevated lifetime estrogen exposure is a well-known major risk factor for breast cancer, 
however the underlying mechanisms of breast susceptibility to estrogen’s carcinogenic 
effect remain elusive. In human breast cancer cells, the expression of almost 15% of the 
genes significantly affected by E2 contains the NRF1 binding element, and the NRF1 
binding signature is significantly enriched in the promoters of genes induced by estrogen 
treatment (11). Recently, Klinge’s group reported that the NRF1 promoter contains a half 
imperfect ERE, and E2 stimulates NRF1 expression (12) through the ER pathway. Motifs 
bound by ELK1, E2F, NRF1 and NFY positively correlate with malignant progression of 
breast cancer (13). From these studies, it appears that NRF1 may contribute to estrogen-
induced malignant transformation of breast epithelial cells. Therefore, we first 
investigated in this study whether NRF1 influences the susceptibility of the breast 
epithelial cells to develop tumors in response to exposure to a well known major breast 
cancer risk factor, estrogen.  4-OH-E2 is the most prevalent E2 metabolite in human 
breast tumor tissues, with tumor tissue concentrations exceeding normal tissue 
concentrations by several folds (14-16). Moreover, 4-OH-E2 is strongly carcinogenic, 
while E2 is weakly carcinogenic and the other E2 metabolite, 2-OH-E2, is non-
carcinogenic. Based on these data, 4-OH-E2 was used as the main model compound in 
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this study to produce malignant phenotype in breast epithelial cells differentially 
expressing NRF1.  
 
NRF1 is highly redox sensitive protein (17,18-22). Similar to the other transcription 
factors, the activation of NRF1 is essential for its optimal binding to the promoters of 
target genes. NRF1 can bind to DNA in the absence of its phosphorylation.  However, 
both phosphorylation and acetylation increase NRF1 DNA binding to the promoters and 
transcriptional activation (23,24). We and others have shown that estrogen exposure to 
breast cells produce reactive oxygen species (ROS) (18,25,26,27). We have shown that 
NRF1 binding to its promoter is inhibited by mitochondrial inhibitors as well as by 
antioxidants (18). Thus, estrogen-generated ROS may also regulate NRF1 expression. 
Therefore, we also examined whether a carcinogenic dose of 4-OH-E2 increases NRF1 
phosphorylation and acetylation in MCF-10A cells and that these changes are inhibited 
by antioxidants or overexpression of catalase. Our findings revealed that  activation of 
NRF1 by phosphorylation and acetylation depended on estrogen-induced ROS formation. 
This is essential for NRF1 to contribute to the susceptibility of breast epithelial cells to 
estrogen’s carcinogenic effect. We further determined whether NRF1 over-expression 
converts non-aggressive breast tumors to aggressive and invasive tumors, and a dominant 
negative suppressor of NRF1 is sufficient to prevent aggressive and invasive tumor 
formation in vivo. We confirmed our in vitro findings of the role of NRF1 in breast 
cancer invasion by in vivo.  
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MATERIALS AND METHODS 
Reagents 
17β-Estradiol (E2), 2-hydroxyestradiol (2-OH-E2), 4-hydroxyestradiol (4-OH-E2), 
Ebselen, N-acetyl-cysteine (NAC),  Dimethylsulfoxide (DMSO) were all purchased from 
Sigma (St Louis, MO, USA). All antibodies; PI3K (p110), phospho PI3K (p85), 
phospho-Akt (ser 473) and total Akt antibodies were purchased from Cell Signaling 
Technology Inc. (Boston, MA). All tissue cultures reagents were purchased from 
Invitrogen Corporation (CA) unless otherwise specified.  
 
Culture of cells and MCcells and Adenovirus Gene Transfer 
Human mammary epithelial cells (MCF-10A) and breast cancer MCF-7 and MDA-MB 
231 cells were obtained from American Type Culture Collection (ATCC). MCF-10A 
cells were routinely cultured in phenol red-free DMEM-F12 media (1:1) supplemented 
with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), epidermal growth 
factor (20 ng/ml), 100 ng/ml cholera toxin and penicillin-streptomycin (100 μg/ml each) 
and incubated at 37°C in a humidified atmosphere containing 5% CO2. Breast cancer 
cells were cultured in DMEM-F12 Media with 10% fetal calf serum. The cell culture 
media, serum, antibiotics, and growth supplements except cholera toxin (Calbiochem, La 
Jolla, CA) were purchased from Invitrogen Corp CA). For experimental purposes, culture 
media were changed to starvation media (serum free media + antibiotics) and allowed to 
incubate for 48 hrs prior to commencement of most experiments, unless otherwise 
indicated. Serum deprivation synchronizes cells in the G0/G1 phase of the cell cycle.  
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The Adenovirus-CMV (empty vector), Adenovirus-MnSOD (AdCMVMnSOD), and 
Adenovirus-Catalase (AdCMVCat) constructs were purchased from ViraQuest, Inc. 
(North Liberty, IA, USA).  The adenovirus constructs used were replication-defective, 
E1- and E3-deleted recombinant adenovirus. Inserted into the E1 region of the adenovirus 
genome was either the human MnSOD or catalase gene, both of which are driven by a 
cytomegalovirus promoter. Cells were seeded in plates at 15%-70% confluence. The 
following day, cells were infected with Adenoviruses over-expressing MnSOD or 
catalase or vector at 100 MOI in serum free media. Control cells were treated with 100 
MOI of the adenovirus-CMV construct. This viral load were determined to achieve 
greater than 50% growth arrests of MCF-10A cells without significant cell death for 
duration of experiment.  Infected cells were cultured for 48 hrs after which cells were 
used for experiments. 
 
Akt1 and NRF1 RNAi transfections  
Pre-designed and verified human shRNA for Akt1 or NRF1 and corresponding null 
vector controls were purchased from OriGene (OriGene Technologies, Inc. Rockville, 
MD). Transfections of cells were carried out in sub-confluent cell population using 
FuGENE 6 (Roche) transfection reagents according to the manufacturer's protocol. 
Briefly, MCF10A cells were seeded in 6 well plates with growth factor supplemented 
media (SM) overnight. Post seeding, cells were transfected with 2 µl of Fugene-6 
(Roche) preincubated for 20 min at room temperature with 0.5 µg plasmid RNAi or its 
null controls (sham). Forty eight hrs post transfection, media were changed to serum-free 
(starvation media) media and incubated for additional 48 hrs, after which cells were used 
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for various experiments. Transfection efficiencies ranged between 60-80% as quantified 
by decreased protein expressions levels.  
 
Cell viability assay 
CellTiter-Fluor™ Cell Viability kit was purchased from promega corporation and used 
according to manufacturer’s instructions. Briefly, cells were seeded in 96 well plate at a 
density of 1.0x104 cells/well, serum starved for 48 hrs and treated with estrogens or ROS 
modifiers. At the end of treatments procedure, substrate reagent (GF-AFC) were mixed 
with substrate buffer and dispensed into well. This assay measures protease activities in 
live cells as opposed to MTT or MTS assay kits that measure formations of formazon 
crystals by mitochondrial enzymes. Plates were read on a fluorescence plate reader at 
380–400 nm excitation and 505 nm emission and data is expressed as mean of three 
experiments +/- SD. 
 
Cell transformation 
The cell transformation was carried out by a modified protocol of Russo’s group (18). 
Briefly, MCF-10A cells were seeded at 30% density in a 10 cm dish. After 24 hrs of  
seeding, media were replaced with stavations media and allowed to culture for 48 hrs, 
and then cells were subjected to two treatment cycles with E2 or its catechol metabolites. 
A treatment cycle includes 48 hrs starvation period, 48 hrs treatment period (100 ng/ml of 
either E2, 2-OHE2, and 4-OHE2), and 48 hrs recovery period in growth media containing 
10% horse serum (HS) and no growth suppliments. At the end of two treatments cycles, 
cells that would be used for immunoprecipitation and Western blot analysis were treated 
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for additional 30 mins with estrogens, lysed with RIPA buffer, immunoprecipitated and 
processed for western analysis. For anchorage independent growth assay 5000 cells/well 
were used for colony formation assays in soft agar. 
Anchorage independent Growth 
Anchorage-independent growth, an indicator of neoplastic transformations of cells, was 
assessed soft agar assay. Briefly, base support agar were made fresh by diluting 1.0% 
molten agarose mixed with 1:1 2x culture media (2x DMEM/F12 media, 20% HS, 2x 
penstrep antibiotics and 200 pg/ml estrogens) to a final 0.5%. Molten agar was left at 42 
oC in a water bath until dispensed at 200 ul/well in 48 well plates, then allowed to 
solidify for 4 hrs at room temperature. Top agarose overlay were made fresh by mixing 
0.7% molten agarose with 2x culture media containing appropriate 5000 cells/well, then 
gently overlaid over base agar. Cells were incubated for a minimum of 21 days in 37°C 
incubator with 5% CO2.  Cultures were fed every week with top agar layer and colony 
formation was assumed when cell masses are 100 micron or greater as measured on a 
Nikon TE2000U inverted microscope (Nikon Corp., USA) with Metamorph software 
(Universal Imaging, USA), Images were acquired by using an Olympus C-5060 digital 
camera attached to the Nikon TE2000U inverted microscope with 4x objective. Four 
wells were enumerated for each groups and data expressed as mean of five wells +/- SD. 
 
Invasion Assay 
In order to determine invasiveness of cells NRF1 overexpressing, cells (5.0 x 103 
cells/ml) were seeded over 8 μm pore transwell filter insert (Transwell, Coastar 
Cambridge, MA) precoated with Matrigel (Collaborative Research, Bedford, MA). 
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Chemoattractants used were reduced growth factor supplemented media or media with 
10% FBS media positive control cells MDA MB 231. Matrix invasion were allowed for 
16 hrs at 37 °C in a CO2 incubator. The non-invaded cells inside chambers were wiped 
off with a cotton swab, and the filters were fixed, stained by Diff Quick (Sigma, St. 
Louis, MO), cut out and mounted onto glass slides. The total number of cells that crossed 
the membrane were counted under a light microscope, enumerated and expressed as fold 
increase compared to parent cell line. The experiments were repeated five times and 
results are expressed as the mean±S.E. 
 
Chemical antioxidant treatments  
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also 
removes both H2O2 and peroxynitrite) or NAC (a precursor of glutathione and scavenger 
of ROS) (31, 32) varies according to the experiments design. For all experiments, 40 μM 
ebselen and 1.0 mM NAC were used for cell treatments. For example, in DCF assays, 
antioxidants were pre-loaded onto cells for 2-4 hrs before ROS measurement commences. 
For BrdU assays, cells were cultured with the chemical antioxidants throughout the 
experimental procedure. For transformation regimen, antioxidants were applied to cells 
each time cells were treated with estrogens. For anchorage independent growth assays, 
antioxidants were added to soft agar matrix media and during weekly feeding of colonies.   
 
Immunoprecipitation and Western Blot Analysis 
After the respective treatments, cells were rinsed twice with ice cold phosphate buffered 
saline (PBS), harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% 
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Nonidet P-40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors 
(Roche). Samples were diluted to 500 µg of protein in 1 ml of lysis buffer, and pre-
cleared for 1 hr at 4 °C with 10 µl of 1:1 slurry of protein A-agarose beads (Invitrogen 
Corp) in lysis buffer. After a brief centrifugation to remove pre-cleared beads, 2 µg of 
desired capture antibodies were added to each supernatant and incubated on a rocking 
platform at 4 °C overnight and captured proteins were precipitated with 40 µl of protein 
A-agarose beads for 2 hr. The beads were washed five times with lysis buffer and 
resuspended in 40 μL sample loading buffer, subjected to electrophoresis and electro-
blotted onto a PVDF nylon membrane. Primary antibodies used for Western blots were  
diluted 1:1000 in phosphate buffered saline Tween-20, PBST  and horseradish 
peroxidase-conjugated secondary antibodies were diluted 1:50,000 in PBST. Blots were 
treated with ECL reagents (Amersham Biotech), and proteins were detected by 
autoradiography. Band intensity was quantified with Bio-Rad Gel Doc Imaging System.  
 
Immunofluorescence Labeling  
MCF-10A cells were seeded and treated in chamber slides as indicated in legends to the 
figures. Post treatments, cells were fixed with ice cold methanol for 15mins, and 
permeabilized with 0.5% Triton X-100 for 30. Cells were blocked with 1% normal goat 
sera for 1 hr after which they were probed with antibodies diluted 1:500 for Akt and 
1:500 for phospho Akt. Alexa Fluor labeled secondary antibody directed against Akt 
antibody was diluted 1:1000. The confocal fluorescence images were scanned on a Nikon 
TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1 laser 
scanning confocal microscope system (Nikon Corp., USA). The z-series scanning were 
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done at every 1 μm up to a z-depth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2 
Plan Fluor oil immersion objective. The built-in Nikon EZ-C1 software was used for 
confocal image acquisition and analyses.  
 
RESULTS 
Estrogen-induced ROS regulate NRF1 expression: Recently, Klinge’s group reported that 
the NRF1 promoter contains a half imperfect ERE, and E2 stimulates NRF1 expression 
(12) through the ER pathway. ROS is an important mediator of mitochondrial biogenesis 
by controlling the expression of the nuclear respiratory factor-1 and mitochondrial 
transcription factor A. NRF1 expression is increased by menadione, lipopolysaccharide 
(LPS), tertiary butyl hydroperoxide (t-BH), and H2O2 (19,20). Using physiologically 
achievable E2 concentration of 1 nM, which corresponds to the estrogenic menstrual 
peak, we have shown that E2 induces rapid formation of ROS in MCF-7 cells (21,22). 
Therefore, we tested the effect of carcinogenic regimen of 4-OH-E2 on the NRF1 
expression in presence of ROS modifiers. The expression of NRF1 was increased by 
several folds by 4-OH-E2 and this increase in the expression of NRF1 was inhibited by 
over-expression of catalse and MnSOD and co-treatment with Ebselen (Figures 1 and 2). 
This indicated that 4-OH-E2-induced NRF1 expression is redox sensitive.  
 
The exposure of MCF-10A cells to carcinogenic dose regimen of 4-OH-E2 increased the 
phosphorylation and acetylation of NRF1 (Figures 3-5). Both phosphorylation and 
acetylation of NRF1 by two independent signaling molecules may control NRF1 
activation. We assessed phosphorylation and acetylation of NRF1 by Western blotting 
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and confocal microscopy after treating MCF-10A cells with 4-OH-E2 in serum-free 
medium in the same condition that produces malignant phenotype. Cell lysates were 
immunoprecipitated with NRF1 antibody, resolved on an gel, transferred to a  membrane, 
and probed individually with anti-serine, anti-lysine, anti-AKT, anti-NRF1 and anti-
PCAF antibodies. In addition to increased phosphorylation and acetylation of NRF1 by 4-
OH-E2 treatment, we also detected AKT and PCAF in the NRF1 immunoprecipitates 
(Fig. 3 and 4). 4-OH-E2 exposure to MCF-10A cells induced serine phosphorylation of 
NRF1 and overexpression of catalase and MnSOD blocked 4-OH-E2-induced 
phosphorylation of serine residues on NRF1. NRF1 phosphorylation preceded P/CAF 
recruitment for acetylation, because silencing of AKT prevented acetylation of NRF1. 
 
The exposure of MCF-10A cells to a carcinogenic dose of 4-OH-E2 increased NRF1 
binding to the gene promoters for the cell cycle regulators cyclin B1, Cdc25c, and Pcna: 
MCF-10 A (5x105 cells /dish) were seeded, grown for 24 hrs, serum starved for another 
24 hrs, and transfected with NRF1, PCAF, and AKT RNAi, as well as with AdMnSOD 
(MnSOD) and Adcatalase (Cat). They were then treated with ebselen using the cell 
transformation condition as described above, and then treated with 4-OH-E2. In a 
preliminary ChIP analysis, we found that NRF1 is bound to the promoters of the cell 
cycle genes Pcna, Cyclin B1, and Cdc25c, confirming the prediction that these promoters 
contain NRF1 elements (Fig. 6). We also found that the exposure of MCF-10A cells to a 
carcinogenic dose of 4-OH-E2 increased the binding of NRF1 to the promoters of these 
genes, and that 4-OH-E2-induced binding could be inhibited by cotreatment with ebselen 
(antioxidant), by an over expression of catalase (H2O2 scavenger) and MnSOD, and by 
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RNAi of NRF1, PCAF and AKT. These results suggest that 4-OH-E2-generated oxidants, 
particularly H2O2, may mediate NRF1 binding to these gene promoters.  
 
Silencing of NRF1 and its interacting partners (PCAF or AKT) prevented 4-OH-E2-
induced anchorage-independent growth of MCF-10A cells: 4-OH-E2 treatment was able 
to induce AIG positive colony formation (Figures 2-4 and 7); and in NRF1, AKT,  or 
PCAF RNAi silenced cells, 4-OH-E2 was not able to produce any colony. The effects of 
4-OH-E2 on colony formation in cells transfected with scrambled RNAi of NRF1, PCAF, 
and AKT were similar to WT cells. This indicates that 4-OH-E2-dependent anchorage-
independent growth of MCF-10A cells is dependent on NRF1 signaling.  
 
DISCUSSIONS 
The novel finding emerged from this study are that the increased expression of NRF1 
renders support to the growth of MCF-7 cells to form tumors in vivo. Alternatively, the 
knockdown of NRF1 blocks the ability of invasive ER-MD-MBA-231 breast cancer cells 
to form aggressive tumors or prevents these cells to metastasize to other organs. 
Phosphorylation and acetylation of NRF1, which are redox sensitive, enhanced its 
binding to promoter consensus sequences of cell cycle genes and subsequently, 
transcriptional activation. Therefore, it is plausible that phosphorylation and acetylation 
of NRF1 could contribute to the growth as well as  invasiveness of the breast tumor. 
 
Recent studies show several genes with the ability to transform normal cells to malignant 
cells that are direct downstream targets of NRF1 (HP1α, SMYD3, CAPNS1) (28,29,30). 
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The overexpression of a NRF1 regulatable gene, heterochromatin protein 1 alpha (HP1α), 
involved in gene silencing produces genomic instability in cells (31-33), which is 
essential for cell transformation. Similarly, overexpression of another NRF1 transcription 
target gene, SMYD3, produces transformed phenotypes (34). Since these genes are 
overexpressed in human breast cancer tissues, we postulate that these NRF1 regulatable 
genes alone or in concert with others may contribute to the estrogen-induced malignant 
phenotype. Recently, Klinge’s group reported that the NRF1 promoter contains a half 
imperfect ERE, and E2 stimulates NRF1 expression (12) through the ER pathway in 
MCF-7 cells. Even if a small amount of ERβ present in ERα negative MCF-10A cells is 
involved in an increased synthesis of NRF1, it would not explain how increased 
localization close to nuclear targets or enhanced ability to bind to the promoters of target 
genes will be achieved upon estrogen exposure. Furthermore, ER signaling may be under 
the influence of NRF1 through its target gene, SMYD3. SMYD3 functions as a co-
activator of ERα and potentiates ERα activity in response to its ligand (35).  
 
We have shown that NRF1 binding to its promoter is inhibited by mitochondrial 
inhibitors as well as by antioxidants (18). We and others have shown that estrogen 
exposure to breast cells produce reactive oxygen species (ROS) (18,25-27).Thus, 
estrogen-generated ROS may also regulate NRF1 expression.  Both phosphorylation and 
acetylation of NRF1 protein control its activation (23,24). NRF1 has been shown to be 
phosphorylated by redox sensitive kinases p38MAPK, ERK, and AKT (19,20) and 
acetylated by P/CAF. The protein tyrosine phosphatases (PTPs) which control ERK and 
AKT phosphorylation and histone deacetylases which control histone acetyl transferase 
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(HAT) activity of P/CAF are highly sensitive to ROS (35-41). The oxidation of PTEN’s 
active site by ROS makes them inactive, which, in turn, stop dephosphorylation of PI3K 
to occur and thus result in an active AKT (PKB) (42-46). In fact, a higher activation of 
stress-activated protein kinases has been reported in E2-treated MCF-7 cells, which is 
considered to contribute to the E2-proliferative effect (47). Thus, estrogen-generated 
ROS may inactivate PTEN leading to an active phosphorylated PI3K. Subsequently, the 
active PI3K may activate AKT which will directly phosphorylate NRF1. By a similar 
mechanism histone decetylases, such as, HDAC3 and hSirT1, are inactivated by ROS 
(42-46), which in turn can allow P/CAF to acetylate NRF1. Our studies showed that a 
carcinogenic dose of 4-OH-E2 increased NRF1 phosphorylation and acetylation in MCF-
10A cells and that these changes were inhibited by antioxidants or overexpression of 
catalase. This suggests that phosphorylation and acetylation of NRF1, which are redox 
sensitive, enhance its binding to promoter consensus sequences and subsequently, 
transcriptional activation. Findings of this study further showed that NRF1 binding to the 
promoters of  cell cycle genes, PCNA, cyclin B1 and Cdc25C was inhibited by 
knockdown of NRF1, PCAF and AKT by their shRNA. Therefore, it is plausible that 
phosphorylation and acetylation of NRF1 could contribute to the aggressiveness and 
invasiveness of the breast tumor. 
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FIGURES AND LEGENDS 
 
 
 
 
 
 
Fig. 1. Redox expression of NRF1 modulates 4OHE2 induced mammary transformation. 
MCF-10A cells were seeded for 24 hrs and infected with Adenovirus overexpressing 
catalase, MnSOD, or null construct at moi 100. 24 hrs post infection, cells were subjected 
to transformation regimen with or without 100 ng/ml estrogens. For groups treated with 
chemical antioxidant, these cells were co-treated with 40 µM ebselen and estrogen for the 
duration of transformation protocol except during recovery period.  Post transformation, 
cells were either lysed with RIPA buffer, fractionated on 12% SDS-PAGE gel, then blot 
probed for NRF1 and beta actin expression, or seeded for anchorage independent growth 
on soft agar. A) Immunoblot of transformed cells normalized to Null/DMSO and band 
intensity quantified with Biorad geldoc 2000. B) Representative picture of colony count 
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per area in 24 well plate, normalized to Null/DMSO. Data expressed as mean of 3 
experiments +/- SE, (P<0.05). (I) AdNull/DMSO, (II) AdNull/4OHE2, (III) 
AdCata/DMSO, (IV) AdCata + 4-OHE2, (V) AdMnSOD/DMSO, (VI) Ad/MnSOD+ 4-
OHE2, (VII) Ebselen, (VIII) Ebselen + 4-OHE2.  
 
 
 
 
Fig. 2 NRF1 expression mediates 4OHE2 induced mammary tumorigenesis. MCF-10A 
cells were seeded at 20-30% confluency overnight and transfected with NRF1 shRNA or 
it corresponding null vector. Post transfection, cells were subjected to transformation 
regimen as previously described.  Post transfection, cells were used for western blot 
analysis probed for NRF1, TFAM and actin expressions, or anchorage independent 
growth assay.  A) Immunoblot of transformed cells normalized to non transfrected cells 
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(NT)/DMSO and band intensity quantified with Biorad geldoc 2000. (I) immunoblot of 
non transfected (NT) cells; (II) immunoblot of null transfected cells (III), immunoblot of 
NRF1 shRNA transfected cells; (IV) Fold change of NRF1 expression normalized to 
NT/DMSO; (V) Fold change of TFAM expression normalized to NT/DMSO. (B,C) 
Colonies formed after 21 days in soft agar assay were enumerated and expressed as 
numbers colonies per area. Five areas from each well was averaged over 3 plates and 
expressed as mean, +/- SE. (P<0.05).  (*) indicate significant difference from non 
transfected (NT/DMSO) group. (**) indicate significant difference from 4OHE2 
treatment group. (D) Trypan blue cell viability assessment of single cell suspension from 
colony assay at the end of 21 days culture per 1000 cells. 
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Fig. 3. Activation of Akt phosphorylate NRF1 during mammary tumorigenesis.  Cells 
were transfected with Akt shRNA or null constructs, and then subjected to transformation 
regimen as previously described. Post transformation, cells were either treated with 
estrogen for additional 30 mins and used for co-immunoprecipitation western blot 
analysis, or for used for colony assay. A) Western blot analysis of NRF1 
immunoprecipitated proteins probed with anti phosphoserine  (pNRF1) or anti NRF1 
antibodies respectively. (I) Immunoblot of null transfected cells (sham); (II) immunoblot 
of Akt1 knockdown cells (Akt1-kd); (III) phosphorylated NRF1 fold change compared to 
sham/DMSO treated group; (IV) NRF1 expression fold change compared to NRF1 
expression from sham/DMSO. Data expressed as mean of three experiments, +/- SE. 
(P<0.05).  (*) indicate significant difference from null (sham/DMSO) group. (**) indicate 
significant difference from 4OHE2 treatment group. B) Immunoflorescence label of sham 
or Akt1-kd transformed cells probed for Akt (green) or NRF1 (red) expression. Yellow is 
co-localization of Akt and NRF1 expression. C) Anchorage independent growth assay of 
transformed cells transfected with sham or Akt shRNA. 
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Fig. 4. PCAF expression participates in 4OHE2 induced mammary transformation.  Cells 
were transfected with PCAF shRNA plasmid and cells were subjected to transformation 
regimen. Post transformation, cells were either treated with estrogen for additional 30 
mins and used for western blot analysis, or seeded for colony assay formation and 
confocal immunoflorescence analysis. A) Immunoblot of sham or PCAF RNAi 
transfected cells and the fold change of PCAF expression compared to sham/DMSO 
treated group. Data expressed as mean of three experiments, +/- SE, (P<0.05).  (*) 
indicate significant difference from null (sham/DMSO) group while (**) indicate 
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significant difference from 4OHE2 treatment group. B) Immunoflorescence label of sham 
or PCAF-kd transformed cells probed for PCAF (green) or NRF1 (red) expression. 
Yellow is co-localization of PCAF and NRF1 expression. C) Anchorage independent 
growth assay of transformed cells transfected with sham or PCAF shRNA.  
 
 
 
Fig. 5. Akt Phosphorylation of NRF1 induces its Acetylation during mammary 
transformation.  MCF-10A cells were transfected with NRF1, Akt1, PCAF or null 
shRNA plasmids and the cells were subjected to transformation regimen as previously 
described. Post transformation, cells were treated with estrogen for additional 30 mins 
and lysed with RIPA buffer. 750 µg of whole cell lysate (WCL) were 
immunoprecipitated with NRF1 antibody and eluent fractionated on 12% SDS-PAGE 
gel. Blots were probed with anti serine (pNRF1), anti acetyl lysine (ANRF1), anti 
NRF1(NRF1) antibodies respectively. A) Immoblot depicting the effects various RNAi 
on NRF1’s  phosphorylation and acetylation during MCF-10A transformation with 
4OHE2. B) Densitometry of phosphorylated and acetylated NRF1 upon Akt1, PCAF and 
NRF1 knockdown. Data expressed as mean of three experiments, +/- SE, (P<0.05). 
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Fig. 6. Transactivation of NRF1 during mammary tranformation is redox dependent.  
MCF-10A cells were co-treated with estrogens and ROS modulators as previously 
described. Post transfection, cells were either seeded on chamber slide for confocal 
microscopy analysis, or treated for additional 30 mims, then harvested with RIPA buffer. 
750 µg of WCL were immunoprecipitated with NRF1 antibody and eluent were 
fractionated on 12% SDS-PAGE gel. Blots were then  probed with anti serine (pNRF1), 
anti acetyl lysine (ANRF1), anti NRF1(NRF1) antibodies respectively. 50 µg of WCL 
was also fractionated on SDS-PAGE gel and blot probed with beta actin anti body.  A) 
Immoblot depicting the effects various RNAi on NRF1’s  phosphorylation and 
acetylation during MCF-10A transformation with 4OHE2. B) Normalized band intensity 
of phosphorylated and acetylated NRF1 upon Akt1, PCAF and NRF1 knockdown 
respectively. Data normalized to vector/DMSO and expressed as mean fold change of 
three experiments, +/- SE, (P<0.05). C) Immunoflorescence label of cells co-treated with 
biological and chemical ROS modifiers, then probed for serine (green) or NRF1 (red) co-
localization (yellow).  
 
 
 
 
B 
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Fig. 7. NRF1 expression is involved in invitro growth of breast cancer cells.  A) Colonies 
formed by MCF-7 cells transfected with NRF1 modulating plasmids, with null vector 
control. (i) NT-DMSO, (ii) NT-E2, (iii) Vector-DMSO, (iv) vector-E2, (v) NRF1-ox-
DMSO, (vi) NRF1-ox-E2, (vii) NRF1-kd-DMSO, (viii) NRF1-kd-E2. (B). Enumerated 
colony count were expressed as percentage change from NT treatment group +/- SD of 
three experiments. (*) indicates treatment significantly different from E2. (**) indicates 
treatment significantly different from control.  
(P<0.05).  B) Immunoflorescence labeling of MCF7 cells treated for 45 mins with 10 nM 
estrogens, then probed for NRF1, serine, acetyl lysine antibodies respectively. NRF1 
(red), serine (blue), acetyl lysine (green), merge of NRF1/serine/acelty lysine (white). C) 
MCF-10A cells were seeded for transformation as described in methods. At end of 
transformation period, cells were treated for additional 18 hours with vehicles or 
estrogens after which they were washed with cold PBS with protease inhibitors. Cells 
were detached with trypsin and 2.0 x106 cells were counted and used for either ChIP 
assay or qRT-PCR analysis. PCR reactions with DNA or cDNA  primers for cell cycle 
regulatory genes were assembled in 25ul final volume and PCR reactions on ABI Real 
time PCR machine. Data represents mean of 3 different experiments +/-SE, (P<0.05). (I) 
CHiP analysis for NRF1 promoter occupancy of selected cell cycle regulatory gene. (II) 
Quantitative RT-PCR (qRT-PCR) for transcriptional expression of selected cell cycle 
regulatory gene.  
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